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SUMMARY 
 Human endogenous retroviruses (HERVs) are a family of viruses 
within our genome. They represent the trail of successful ancient retroviral 
infection and constitute about 8% in the human genome. Over the past few 
years, HERVs have been implicated in physiological functions and 
pathogenesis of diseases. While the role of HERVs in placental development 
has been extensively studied, the pathological role of HERVs in diseased 
states remains to be clearly defined. 
 Of interest, HERV-H, a family of the HERV families which is 
characterised by its utilisation of tRNAHis at its primer binding site, is 
selectively expressed in colon cancers but not in normal tissues. Colorectal 
cancer is the most common cancer for both men and women in Singapore over 
the past four decades. The average population risk for developing colorectal 
cancer in Singapore is among the highest in the world. This has led us to 
further investigate the role of HERV-H in colorectal carcinogenesis.  We first 
demonstrated that the HERV-H gene is not lost from the Singapore 
population. In fact, HERV-H exists at a high prevalence rate of 89.3% in the 
population sampled, providing a plausible molecular linkage to the high 
incidence rate of colorectal cancer in Singapore. 
  To investigate the role of HERV-H role in neoplastic transformation, 
we established in vitro models to demonstrate the effect of HERV-H on 
colorectal cancer cells. Our results demonstrated that HERV-H overexpression 
resulted in the augmentation of cellular proliferative activity, migratory 
capacity, ability to form cancer stem cell-like colonospheres, and expression 
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levels of cancer stem cell markers, CD133 and CD44. Furthermore, the gain 
of decreased serum dependence was most remarkable. In addition it was 
shown that knock-down of HERV-H significantly lowered cancer cell 
proliferation, substantiating the oncogenic role of HERV-H in the 
transforming process. Clearly, the oncogenic role of HERV-H was illuminated 
with reference to the hallmarks of cancer, namely, limitless replicative 
potential, tissue invasion & metastasis, self-sufficiency in growth signals and 
the deregulation of cellular energetic.  
 Using real-time PCR array, mitogen-activated protein kinase (MAPK), 
Wnt and p53 pathways were all shown to be implicated in HERV-H-mediated 
oncogenic signalling. In addition, inflammation-associated players and 
cytokines were also found to be involved in the HERV-H mediated 
transformation process. In essence, they represent the evidence that is 
consistent with the hallmarks of cancer, viz. sustaining proliferative signalling 
and tumour-promoting inflammation.  
 Together with previous clinical reports, our data demonstrates the role 
of HERV-H in colorectal cancer and highlights the molecular basis underlying 
its involvement. This provides an invaluable resource for rationalizing future 
therapeutic intervention for colorectal cancers.  
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1.1 Human and viruses 
 The human race has been continuously exposed to microbial infections 
throughout their hundreds of millions of years of evolution. Microorganisms 
like prions, viruses, bacteria, fungi and protozoa, as well as helminths and 
arthropods can infect human beings and establish a host-parasite relationship. 
On the other hand, beneficial symbiosis like commensalism and mutualism 
exist and they play a significant role in moderating the good health of the 
human digestive system. Still, parasitism remains the choice of life by many 
different types of microorganisms.  
 Viruses, for example, are notoriously known to be parasitic (Goering et 
al., 2008) and have been known to cause many infectious and debilitating 
diseases such as smallpox (Breman and Henderson, 2002), viral haemorrhagic 
fever (Paessler and Walker, 2012), poliomyelitis (Racaniello, 2006, 
Nathanson, 2008), acquired immunodeficiency syndrome (AIDS) (Moir et al., 
2011) and influenza (Belshe, 2005). However, another train of thought has 
suggested otherwise (Fox, 2004, Haig, 2012, Villarreal, 2009, Varela et al., 
2009) and put forth the idea of symbiogenetic viruses (Roossinck, 2011, Barr 
et al., 2013). 
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1.1.1 Origin of viruses 
 It has been estimated that there are some 1032 virus particles in the 
biosphere of Earth (Wommack and Colwell, 2000, Bergh et al., 1989). 
Intriguingly, the sources where these viruses come from remain to be 
elucidated. An interesting hypothesis known as the Panspermia theory 
suggested that viruses and other microorganisms originate from outer-space 
and they rain down upon Earth and bring massive contamination in the earth 
environment (Raulin-Cerceau et al., 1998). While the academic quest to 
corroborate the Panspermia theory is not lacking commentary 
(Wickramasinghe and Trevors, 2013, Demets, 2012), insightful analysis to 
falsify the theory  (Di Giulio, 2010) also exists. This creates an ongoing area 
of intense research interest in astrobiology (Smith, 2013, Carr et al., 2013).  
 Although viruses may be structurally similar due to their protein coat, 
viral genetic materials can only either be DNA or RNA. This observation has 
led to the generation of three hypotheses (Bandea, 1983). The first hypothesis 
put forward the idea that viruses were precursors of the earliest cells, 
indicating that viruses are the relics of pre-cellular life forms. The second 
hypothesis suggested that viruses were elements of cellular genomes that 
broke off from the unicellular organisms which were degenerating as a result 
of viral parasitism. Such viruses were deemed as gene robbers that pick-
pocketed the cellular genes. Analyses of viral genomes have revealed the 
diversity of these genomes and the lack of cellular homology at the sequence 
level. This has led to the realisation that it is unlikely that all viruses evolved 
from a single ancestor, the LUCA (the last universal cellular ancestor, or the 
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Last Universal Common Ancestor) (Woese, 1998, Theobald, 2010). The third 
hypothesis advocated that viruses originated from fragments of genetic 
materials that became autonomous and parasitic (Forterre, 2006). While all 
these hypotheses were interesting and debatable, the origin of viruses remains 
to be explicitly well-explained (Forterre and Prangishvili, 2009). 
 
1.1.2 Viruses 
 Viruses are metabolically inert particles that are composed of single-
stranded or double-stranded, linear or circular DNA or RNA within a capsid, 
which is made up of subunits called capsomeres. Human and animal viruses 
may also possess an additional lipid bilayer membrane or envelope wrapped 
around the nucleocapsid. Viruses are sized from 30 nm to uncommonly 400 
nm. The nomenclature and classification of viruses have been published by the 
International Committee on Taxonomy of Viruses (ICTV) (International 
Committee on Taxonomy of Viruses, 2012). To date, the ninth report of the  
ICTV defines 6 orders, 87 families, 19 subfamilies, 349 genera and 2284 virus 
and viroid species (King et al., 2011). On the other hand, the Baltimore 
classification system organises viruses into one of seven classes, based on the 
type of nucleic acid the virus contains and its mechanism of replication 
(Baltimore, 1971).  
 Viruses infect all forms of life. Virophages infect viruses; 
bacteriophages infect bacteria; mycoviruses infect fungi; plant viruses infect 
plants. In addition, viruses have also been found to infect invertebrates like 
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protozoa, worms and arthropods (Wang and Wang, 1991, Bergold, 1953, Felix 
et al., 2011). Here, the focus will be on human viruses.   
 Viral infections in humans commence with the entry of virus particles 
into the host body. The common portal modes of entry include the respiratory 
tract (via inhaled droplets or saliva), the gastrointestinal tract (in contaminated 
food or water), skin (typically either by infected insect, animal or human bites 
or parenteral exposures), genital tract, blood, transplacental and transplants. 
Following the entry into the human cell, synthesis of viral structural proteins 
and enzymes as well as replication of the viral genome must take place in 
order for a successful viral replication cycle to be initiated. Depending on the 
type of nucleic acid (DNA or RNA) a virus is carrying, synthesis of viral 
messenger RNA (mRNA) may be preceded by several routes (Table 1.1) so 
that viral structural or functional proteins can be eventually translated from the 
monocistronic mRNA and used for its biological activities. 
 The assembly of a new virus particle is facilitated by the association of 
the replicated viral genome and the capsomeres. New virus particles are 
released by budding through the plasma membrane (enveloped virus) or when 
infected cells are lysed (lytic viruses). Budding often does not damage the cell. 
Hence the infected cells continue to shed virus particles for long periods, 
leading to chronic infections that are of important epidemiological 
consideration. While viruses typically replicate in such manners, viral 
infections can manifest in an alternative pathway, namely, the lysogenic cycle, 
in which the proviral DNA becomes incorporated into the host cell 
chromosome and no progeny virus particles are produced. 
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Table 1.1.  A simplified overview of virus genome replication (Baltimore, 1971) 





ssDNA  dsDNA  mRNA  proteins   




dsDNA  mRNA  proteins  







+ssRNA  polyprotein    





ssRNA  +ssRNA  proteins  
                                   ssRNA   assembly 
segmented 
ambisense  
# ambisense RNA  +ssRNA 




dsRNA  mRNA  proteins  assembly  dsRNA 
 
 Proviral DNA continues to replicate along with the cellular DNA in 
this period of latency. Stimuli are usually needed to trigger a release from 
latency, leading to a productive infection or lytic cycle. Although the 
mechanisms regulating the reactivation of latent virus remains incompletely 
understood to date (Kobayashi et al., 2012), stimulating factors like extreme 
temperatures, physical trauma, emotional stress and immune suppression are 
commonly cited.  
 Integration of proviral DNA may also disturb the regulation of cellular 
proto-oncogenes since the integrated site may be situated right in, or close to, 
regulatory regions of the proto-oncogenes and these cellular regulatory sites 
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may be stimulated by the proviral regulatory elements. Akin to insertional 
mutagenesis, this leads to the transformation of cells that gives rise to changes 
in morphology, cellular behaviour and metabolic biochemistry. Controlled 
growth patterns and contact inhibition are lost, resulting in a state of deranged 
proliferation of cells and anchorage-independent growth. Conversely, 
synthesized viral proteins may also be oncogenic due to their interactions with 
cellular targets such as tumour suppressor protein, disrupting the normal cell 
cycling profile and facilitating carcinogenesis. 
 
1.2 Human oncogenic viruses 
 A recent study shows that approximately 16% of the global cancer 
incidence can be attributed to infections with viruses, bacteria and parasites 
(de Martel et al., 2012).  Specifically, cancer-inducing viruses, or tumour 
viruses, are the aetiological agents for about 11% of human cancers. There are 
two classes of human tumour viruses: DNA tumour viruses and RNA tumour 
viruses which are also known as retroviruses. Currently, there are six tumour 
viruses which have been classified by the International Agency for Research 
on Cancer (IARC) as “carcinogenic to humans” (Group I) (Mattock, 2012). 
These tumour viruses include Epstein–Barr virus (EBV), hepatitis B virus 
(HBV), human papillomaviruses (HPV) of several types, human T-cell 
lymphotropic virus type 1 (HTLV-1), hepatitis C virus (HCV), and Kaposi’s 
sarcoma-associated herpesvirus (KSHV), which is also known as human 
herpesvirus 8 (HHV-8). Although the human immunodeficiency virus type-1 
(HIV-1) is also listed as a group 1 cancer-causing agent, it is considered a 
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cofactor since it primarily augments the carcinogenic action of other viruses 
like KSHV, EBV and HPV through immunosuppression.  
 In general, tumour viruses employ two major mechanisms to induce 
tumours. In direct oncogenesis, the virus infects a progenitor of the clonal 
tumour cell population, and typically persists in the tumour cells. Indirect 
oncogenesis occurs when the virus exerts an indirect effect on cell and tissue 
turnover or on the immune system, predisposing the host to the development 
of tumour insidiously. The tumour progenitor cell, in this case, may not be 
invariably infected by the virus. While DNA tumour viruses target the Rb and 
p53 tumour suppressor gene products and promote cell cycle progression, 
RNA tumour viruses utilise various means to induce malignancies which 
include the introduction of viral oncogenes into a cell, the activation of a 
cellular proto-oncogene and the inactivation of a tumour suppressor gene. 
 
1.2.1 Retroviruses  
 Retroviruses are RNA viruses which have the ability to convert their 
viral RNA into a cDNA intermediary by means of a reverse transcriptase and 
integrating their proviral DNA into the host genome (Varmus, 1988, Bishop, 
1978). In general, the retrovirus virion (virus or viral particle) contains two 
copies of the RNA genome. The two strands of RNA molecules are present as 
a dimer as a result of complementary base-pairing sequences. The 
organisation of the RNA genome is depicted in Figure 1.1.  
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GAG group-specific antigen  
POL polymerase  
ENV envelope  
Proteins 
MA matrix lines envelope 
CA capsid protects the core; most 
abundant protein in virus 
particle 
NC nucleocapsid protects the genome; forms the 
core 
PR protease necessary for gag protein 
cleavage during maturation 
RT reverse transcriptase reverse transcribes the RNA 
genome 
RH ribonuclease H degrades RNA and generates 
PPT primer during reverse 
transcription 
IN integrase required for integration of 
provirus 
SU surface glycoprotein the outer envelope 
glycoprotein;  
major viral antigen 
TM transmembrane glycoprotein the inner  component of the 
mature envelope glycoprotein 
Non-coding 
sequences 
PBS primer binding site 
used by virus to initiate reverse 
transcription 
PPT polypurine tract responsible for initiating (+) 
strand synthesis during reverse 
transcription 
R repeat sequence “terminally redundant” 
U3 unique sequence at 3’ end of 
genome 
forms the 5’ end of provirus 
after reverse transcription; 
contains promoter elements 
responsible for provirus 
transcription 
U5 unique sequence at 5’ end of 
genome 
forms the 3’ end of provirus 
after reverse transcription 
(A)n polyadenylation site regulates RNA stability and 
aids in the transport of RNA 
out of nucleus during provirus 
transcription 
 
Figure 1.1. Structure of retroviral genome RNA and gene products.  RNA 
genome is capped at the 5’ end and polyadenylated at the 3’ end. The cap sequence is 
of type I, m7G5’ppp5’’GmpNp.  Both the cap and poly(A) tail are attached to the 
identical short sequences (R). Between these terminal elements are the gag, pol and 
env genes that encode the structural or functional proteins of the virion.     
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Figure 1.2. How retrovirus integrates its proviral DNA into a host cell. Retrovirus 
infects its target cell by binding to a special cell surface receptor. Following 
internalization and uncoating of the retrovirus, RNA is released from the 
nucleocapsid and is reverse-transcribed into proviral DNA.  The provirus is 
subsequently transported into the nucleus and integrated into the host chromosomal 
DNA with viral integrase.  
 
 The retroviral virion is also packed with enzymes like reverse 
transcriptase and integrase which are crucial for the replication cycle of 
retroviruses. When a retrovirus enters the cytoplasm after binding to a specific 
cell surface receptor, the process of reverse transcription takes place and a 
double-stranded DNA, termed as provirus is synthesized.  The provirus moves 
into the nucleus and integrates into the host cell genome with the aid of 
integrase (Figure 1.2). Proviral integration is permanent. With integration, the 
viral genome is replicated as an integral element of the host genome whenever 
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the infected cell divides. Thus if proviral integration is present in germ line 
cells, the provirus can be inherited and may persist as vertical transmission 
(Longo, 2010). On this note, exogenous retroviruses are considered as 
infectious while endogenous retroviruses are thought to be non-infectious 
since they remain as proviral forms. 
 Historically, exogenous retroviruses were classified under the 
categories of Types A, B, C and D. These 4 categories were formulated on the 
basis of viral morphology in negatively stained electron microscopy (Table 
1.2). As this classification does not differentiate based on genetic 
characteristics, such classification is infrequently in use today. 
 
Table 1.2. Historical classification of retroviruses. Retroviruses were once 
classified based on morphology using negatively stained electron microscopy 
(Sverdlov, 2005). 
Group Description 
A - type 
Also known as intracisternal particles. Nonenveloped, immature 
particles only seen inside cells, thought to result from endogenous 
retrovirus-like genetic elements 
B - type 
Enveloped, extracellular particles with a condensed, acentric core and 
prominent envelope spikes, e.g. Mouse mammary tumour virus 
C - type 
Same as B-type, but with a central core and barely visible spikes - e.g. 
most mammalian and avian retroviruses e.g. murine leukaemia virus, 
avian leukosis virus, human T-cell leukaemia viruses, human 
immunodeficiency virus 
D - type 
Usually slightly larger (to 120nm) and spikes less prominent, e.g. 
Mason-Pfizer monkey virus 
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 Conversely, exogenous retroviruses have also been grouped in three 
broad groups according to the general details of pathology associated with 
infection (Table 1.3). These include oncornaviruses (tumour-inducing 
viruses), lentiviruses (associated with slowly progressing, wasting disease) 
and spumaviruses (“foamy” viruses associated with persistent infection but 
without any diseases) (Weiss, 1996).  
Table 1.3. Classification of retroviruses based on pathology 






Rous sarcoma virus Contains src oncogene 
 
Mammalian C-type Abelson leukaemia virus Contains abl oncogene 
 
B-type Murine mammary tumour 
virus 
Can be endogenous or 
exogenous 
 




HTLV-BLV Human T-cell leukaemia 
virus 
Bovine leukaemia virus 
Causes T-cell lymphoma and  
neurologic disease 




HIV-1, HIV-2 Cause AIDS 




Simian foamy virus, 
human foamy virus 
Cause no known disease albeit 
display cytopathogenicity in 
vitro 
  
 Based on the differences in morphology and genome organization, the 
International Committee on Taxonomy of Viruses (ICTV) defines exogenous 
retroviruses into seven genera (Table 1.4). Under this taxonomy, exogenous 
retroviral infections usually involve the malignant transformation of an 
infected cell as well as the induction of an immunodeficiency state that leads 
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to opportunistic diseases like infections and neoplasms. While exogenous 
retroviruses mostly infect somatic cells, germ line cells can also be 
occasionally infected. In such cases, the exogenous virus must be capable of 
infecting the reproductive tissues in order to infect the germ cell progenitors. 
The survival of the infected germ cell must take place so that the progeny 
organism can survive without loss of fitness and ultimately leads to more 
progeny generations (Blikstad et al., 2008). In this way, the integrated viruses 
are hereditarily transmitted from one generation to another as stable 
Mendelian genes and are termed as human endogenous retroviruses (HERVs). 
Consequently, it is sensible to link high expression levels of HERV elements 
in reproductive tissues like ovaries, endometrium, testis and placenta 
(Forsman et al., 2005, Hu et al., 2006) to ancestral introduction and 
subsequent inheritance of exogenous retroviruses (mode of entry).  
Table 1.4. Retrovirus genera using ICTV classification 
Genus  Representative Host  HERV Class# 
Alpharetrovirus  Rous sarcoma virus  Chickens  II 
Betaretrovirus  Mouse mammary tumour virus 
(MMTV)  
Mice  II 
Gammaretrovirus  Murine leukaemia virus (MLV)  Mice  I 
Deltaretrovirus  Human T cell leukaemia virus type 1 
(HTLV-1)  
Humans   
Epsilonretrovirus  Walleye dermal sarcoma virus  Fish   
Lentivirus  HIV type  
Simian immunodeficiency virus  





Spumavirus  Simian foamy virus  Monkeys  III 
# HERV classification is not under the purview of ICTV (International Committee 
on Taxonomy of Viruses) 
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1.2.2.  Endogenous Retroviruses 
 Human endogenous retroviruses (HERVs) are a family of viruses 
within our genome and they are the remnants of ancient retroviral infections of 
the human genome. It is suggested that most HERVs integration took place at 
least 25 million years ago, before the divergence of apes and Old World 
monkeys (Shih et al., 1991). Similar to exogenous retroviruses, HERVs are 
composed of gag (group-specific antigen, core protein), pol (RNA-dependent 
DNA polymerase) and env (envelope) regions, all of which are flanked by 
long terminal repeats (LTRs) on both sides (Figure 1.3)  (Wilkinson et al., 
1994). The classification of HERVs has been convoluted since arbitrary 
nomenclatures are used by independent investigators, and a constellation of 
classification criteria like genome complexity, mechanism of replication, type 
of morphology, copy number and specificity of the tRNA primer binding site 
(PBS) exists (Urnovitz and Murphy, 1996, Gifford and Tristem, 2003, Bryant 
et al., 1978, Larsson et al., 1989, Blomberg et al., 2009). In addition, as many 
HERVs are of fragmentary sequences, there is no consensus as to how this 




Figure 1.3. Complete structural features of HERV. Arrows indicates repeat 
sequences (R) generated during integration process; LTR: Long terminal repeat; GAG 
encodes structural retroviral capsid proteins; POL encodes enzymes for viral 
replication, integration, and protein cleavage (polymerase); ENV encodes structural 
retroviral envelope proteins.  
 
GAG POL ENV LTR-3’ 5’-LTR 
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 Nevertheless, HERVs have been broadly divided into three classes on 
the basis of sequence similarity to exogenous retroviruses (Tristem, 2000). 
Class I HERVs show sequence similarity to the gamma-retroviruses 
(mammalian type C retroviruses) (Table 1.4). They are subdivided into six 
groups in which three families display homology with murine leukaemia virus 
(MuLV) and baboon endogenous virus (BaEV) in the highly conserved pol 
region and the gag and env regions. Members include HERV-H, HERV-I and 
HERV-R (ERV-9). Class II HERVs show homology to betra-retroviruses and 
alpha-retroviruses (mammalian type B and D and avian type C retroviruses). 
Class II HERVs are subdivided into 10 groups. Members include HERV-K 
and HERV-K(C4) (Dangel et al., 1995). Notably, all class II HERVs are from 
the HERV-K family, carrying the lysine tRNA specificity and could be further 
subdivided into type 1 or type 2, on the basis of the presence or absence of a 
292 bp segment at the pol-env boundary (Barbulescu et al., 1999). Class III 
HERVs show sequence similarity to the spuma-retroviruses (foamy viruses). 
Four families are included in this class, namely HERV-S, HERV-L, HERV-
U2 and HERV-U3 (Benit et al., 2001).  
 Commonly, HERVs are further classified into their families using the 
single letter amino acid code for the tRNA specificity of the primer binding 
site (PBS). For instance, the HERV-H family contains a PBS similar to 
tRNAHis. Currently, over 22 distinct families have been identified in the 
human genome (Tristem, 2000). The use of the term “family” in describing 
these HERV lineages is not used in accordance to conventional taxonomic 
rules as described by the ICTV, since the Retroviridae as a whole has been 
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assigned family status (Blomberg et al., 2009). However, this PBS designation 
has been widely used in this field (Bannert and Kurth, 2004).  
 The completion of the Human Genome Project in 2003 revealed the 
unprecedented information about the genetic make-up in human (Lander et al., 
2001). It not only determined the sequences of many genes in human DNA but 
also intriguingly uncovered the fact that the human genome is almost half 
occupied – approximately 42% – by transposable elements like  the short 
interspersed elements (SINE), the long-terminal interspersed elements (LINE), 
retrotransposons and endogenous retroviruses (Prak and Kazazian, 2000).  
 Interestingly, HERVs are the only elements that possess all the viral 
coding regions like the gag, pol and env genes that are flanked by long 
terminal repeats (LTRs), and account for up to 8% of the human genome 
(Bock and Stoye, 2000) (Figure 1.4). Approximately 400 000 HERVs have 
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Figure 1.4. Classification of transposable elements. Transposable elements, 
otherwise known as “jumping genes” are divided into elements that transpose via a 
DNA intermediate (transposons) or RNA intermediate (retroelements). Retroelements 
are further subdivided into LTR-containing elements and non-LTR- containing 
elements. The percentage of each element in the human genome is shown. LTR: long 
terminal repeat; RT: reverse transcriptase; ERV: endogenous retrovirus; SINE: short 
interspersed elements; LINE: long interspersed elements; L1: LINE-1; /+: 
minus/plus signs.  
 
1.2.3 Various HERV families 
 HERV was first discovered in 1981 when DNA from human brain 
specimens was used in Southern blot analysis (Martin et al., 1981). Since then, 
it is estimated that more than 400 000 copies of HERVs were found and these 
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that the constitution of HERVs in the human genome is complex and 
heterogeneous (Katoh and Kurata, 2013).  
 All the 3 classes of HERVs are found in the human genome. HERV-R 
(O'Connell et al., 1984, Cohen et al., 1985), HERV-E (Steele et al., 1984), 
HERV-I (Seifarth et al., 2000), HERV-H (Mager and Freeman, 1987, Mager 
and Henthorn, 1984), ERV-9 (La Mantia et al., 1991), HERV-W (Komurian-
Pradel et al., 1999), HERV-T (Werner et al., 1990), HERV-P (Harada et al., 
1987) and HERV-FRD (Seifarth et al., 1995) are Class I elements that were 
reported previously in human specimens. Similarly, Class II elements like the 
HERV-K superfamily (Andersson et al., 1999, Ono et al., 1986) that 
comprises groups of HML-1 to 10 (HML stands for human MMTV-like 
sequence), and Class III member like HERV-L (Cordonnier et al., 1995, Benit 
et al., 1999) were also demonstrated in the earlier genetic studies.  
   
1.3 HERVs in health and diseases 
 Over the past few years, HERVs have been implicated in physiological 
functions and pathogenesis of diseases (Ryan, 2004). Interestingly, similar to 
the kind of symbiogenesis as observed for mitochondria in eukaryotes and 
chloroplasts in plants, HERV-W and HERV-FRD both contribute to the 
development of the human placenta via their env gene products, syncytin 1 
(Mi et al., 2000) and syncytin 2 (Blaise et al., 2003) respectively.  Syncytins, 
which possess the cell-cell fusogenic capacity, fuse the trophoblast cells of the 
placenta and form the syncytiotrophoblasts at the maternal-fetal interface in a 
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coordinated manner with ERV-3 (also known as HERV-R) (Figure 1.5). 
Nonetheless, it appears that the role of ERV-3 in the normal physiology of 
placental development is redundant since 1% of the Caucasian population may 
have a nonsense mutation in ERV-3 and that does not seem to hinder 
pregnancy (de Parseval and Heidmann, 1998). Both syncytin-1 and syncytin-2 
have been shown to possess immunosuppressive domains. However, only 
syncytin-2 is found to be functional and pivotal in conferring maternal 












Figure 1.5. Functions of HERV-W and HERV-FRD in human placental 
development. (A) Fusion of the trophoblast cell layer into the 
syncytiotrophophoblast. (B) Expression of HERV-W and HERV-FRD env 
proteins, syncytins, mediate trophoblast cell fusion (Adapted and modified 
from (Stoye and Coffin, 2000)). 
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 Ironically, HERVs might confer some degree of antiviral protection 
against other exogenous retroviruses, for example, human immunodeficiency 
virus (HIV). Although HERVs reside in the human genome and therefore their 
encoded proteins should be regarded as self-antigens, their translated products 
are antigenic. Overall, HERV proteins are of viral origin essentially. 
Consequently, immune responses against these HERV proteins via the HERV-
specific CD8+ T-cells may help to ameliorate the pathological effects on HIV 
infected individuals (Garrison et al., 2007, SenGupta et al., 2011, Tandon et 
al., 2011), although a state of reduced immune activation prior to HIV 
infection is implicitly favorable (Songok et al., 2012). 
 Recent evidence has shown that the endogenous retrovirus activity is 
associated with the pluripotency of embryonic stem cells (Macfarlan et al., 
2012), possibly conferring the self-renewal characteristics that embryonic 
stem cells possess. In addition, demonstration of an abundance of HERV-H 
transcripts in human embryonic stem cells discloses an intricate relationship 
between the three important pluripotency transcription factors, namely 
NANOG, OCT4 and SOX2, and the HERV-H 5’ LTR (Santoni et al., 2012) . 
More studies are needed to provide the role that HERV-H plays in the intricate 
process of embryonic pluripotency. While the differential expression of 
various endogenous retroviral elements in early embryos and embryonic stem 
cells has been shown to link to histone modification machinery and DNA 
machinery (Rowe and Trono, 2011, Leung and Lorincz, 2012) , how HERV 
contributes to the development of stem cells remains to be clearly understood. 
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 The role of HERVs in diseased states has always been an interesting 
topic among many researchers. While HERV-K was frequently thought to 
play a role in the pathogenesis of diabetes via its superantigen activity (Conrad 
et al., 1997, Marguerat et al., 2004, Stauffer et al., 2001), controversial 
findings were observed as well (Badenhoop et al., 1999, Muir et al., 1999, 
Jaeckel et al., 2002).  
 HERVs have also been found to be linked with autoimmune diseases 
(Balada et al., 2010) such as multiple sclerosis (HERV-W, HERV-H) 
(Petersen et al., 2012, Garson et al., 1998) , rheumatoid arthritis (HERV-W, 
HERV-K) (Gaudin et al., 2000, Freimanis et al., 2010), systemic lupus 
erythematosus (Perl et al., 2008, Naito et al., 2003) and Sjogren syndrome 
(Hishikawa et al., 1997, Price and Venables, 1995). Proposed underlying 
mechanisms of pathogenesis include molecular mimicry, superantigen activity 
and LTR-mediated transcriptional activation, all of which putatively lead to 
the dysregulation of immune responses.  
 Recently, HERV-K (Huang et al., 2006) and especially HERV-W 
(Perron et al., 2012a, Leboyer et al., 2013) were reported to have strong 
associations with psychotic disorders like schizophrenia and bipolar disorders. 
While the  mechanisms remain to be fully elucidated, the insufficiency of 
neuronal glutamine uptake (Karlsson et al., 2004) and the latent effects of 
inflammatory neurotoxicity (Leboyer et al., 2011) were proposed. On a similar 
note, autism spectrum disorder was also found to display a higher expression 
level of HERV-H and -W (Balestrieri et al., 2012). 
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1.3.1 HERVs in cancers  
 More often than not, HERV proteins and transcripts have been 
detected in various cancerous cells which include teratocarcinoma cell lines, 
germ cell tumours, melanomas, myeloproliferative disease and cancers of 
breast, ovary, testis, prostate and colon (Dolei, 2006, Cegolon et al., 2013). 
While the definitive causal role of HERVs in carcinogenesis remains to be 
elucidated, it is evident that both Rec and Np9, two accessory viral env 
proteins of HERV-K, are able to upregulate c-myc expression by binding and 
inhibiting c-myc gene repressor promyelocytic leukaemia zinc finger protein, 
leading to a state of increased cell proliferation and reduced apoptosis (Denne 
et al., 2007). In addition, Rec protein is also found to elevate androgen 
receptor-mediated transcription, and this may drive tumour induction or 
promotion in steroid-regulated tissues (Hanke et al., 2013). Conversely, 
nuclear protein Np9 is able to interact with E3 ubiquitin ligase Ligand of 
Numb Protein-X (LNX), and this interaction may influence the differentiation-
proproliferative Notch pathway (Armbruester et al., 2004).  Recently, it has 
been found that Np9 co-activates Wnt/β‐catenin, Notch1, ERK and Akt 
signalling pathways (Chen et al., 2013) that are essential for the survival and 
proliferation of leukaemia stem/progenitor cells.  
 Studies have also pointed out that retroviral LTR may be implicated in 
carcinogenesis (Yu et al., 2013, Katoh and Kurata, 2013). A previous study 
has reported that hypomethylation of endogenous LTR (LTR of the MaLR 
family) up-regulates the CSF1R proto-oncogene expression. This in turn 
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contributes to the pathogenesis of Hodgkin's lymphoma (Lamprecht et al., 
2010a, Lamprecht et al., 2010b). 
 
1.3.2 Association between HERV-H and colorectal cancer 
 HERV-H, a family of the HERVs families, is characterised by its 
utilisation of histidine (H) tRNA at its primer binding site to initiate reverse 
transcription. Three independent clinical findings have demonstrated that 
HERV-H is selectively expressed in colon cancer but not in normal tissues 
(Liang et al., 2007b, Wentzensen et al., 2007, Alves et al., 2008). Specifically, 
different transcripts of HERV-H gag (Alves et al., 2008) and env (Wentzensen 
et al., 2004) were analysed in these studies. Although the regulatory 
mechanism of the expression of HERV mRNA remains to be elucidated, it is 
suggested that transducing agents like hormonal and environmental signals 
may induce the 5’ LTR of HERV and lead to the consequential downstream 
transcriptional activities. While it may seem that the expression of a HERV 
sequence in transformed cells could have a contributory role in the 
development of tumour, it is uncertain whether the increased expression of 
HERV-H transcripts unerringly precedes the cancer or whether it could be just 
a result of deranged gene regulation in the tumour cells. 
 The complete HERV-H sequence on chromosome X was identified 
and characterised by both Wentzensen et al (2007) and Liang QY et al (2009). 
A 17-bp sequence in the 5’ U3 region was found to possess promoter activity 
(Liang et al., 2009). Intriguingly, a missing segment on the env region of the 
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HERV-H was reported and the missing env region is similar to that of HERV-
H/env59, env60 and env62, all of which contain the immunosuppressive 
domain in vivo (Liang et al., 2009, Liang et al., 2007b).  Henceforth, should 
the putative open reading frames (ORFs) contained in this HERV-H transcript 
be productive, peptides synthesized would be immunogenic, and be able to 
elicit an immune response that is accompanied by high levels of pro-
inflammatory cytokines. Based on the ORFs of HERV-H transcripts, Alves et 
al (2008) have proposed that a gag protein of 93 amino acids (~10.3 kDa) 
would be generated, suggesting that the induction of immune response could 
be a likely event.  
 Conversely, peptides could also be functionally similar to known viral 
proteins like Rec and Np9. Rec is a 14.5-kDa protein functionally similar to 
HIV Rev and HTLV Rex, and is known to export unspliced or single spliced 
viral RNA from the nucleus to the cytoplasm. Together with Np9, a 9-kDa 
nuclear protein, they bind to the promyelocytic leukaemia zinc finger protein – 
both a tumour suppressor and transcriptional suppressor of the c-myc proto-
oncogene – abrogating transcription repression and contributing to increased 
cell proliferation and reduced apoptosis (Denne et al., 2007). 
  
1.4  Hypothesis and objectives 
1.4.1 Rationale 
 Although a unique constellation of lifestyle factors can reassure a 
markedly decreased risk of colorectal carcinogenesis (Odegaard et al., 2013), 
Chapter 1: Introduction 
 
Page | 25  
 
colorectal cancer remains as the number one cancer in Singapore (Teo and 
Soo, 2013, Wong and Eu, 2007). There is also a paucity of information 
regarding the high risk of colorectal cancer development in the local 
population (Ministry of Health, 2010, National Registry of Diseases Office, 
2010, GLOBOCAN 2012, 2012). While diet and nutrition are key modulators 
in the development of colorectal cancer (Lipkin et al., 1999) and that 
westernised dietary patterns are commonly associated with colorectal cancers 
(Randi et al., 2010), it was reported that the high colorectal cancer incidence 
in the Singapore Chinese population may be associated with insulin resistance, 
visceral adiposity and physical inactivity instead of dietary patterns (Butler et 
al., 2008). Additionally, previous studies have reported the involvement of 
activated c-myc and c-Ki-ras proto-oncogenes, as well as point mutation of the 
p53 tumour suppressor gene in the Singapore cohort of colorectal cancer 
patients (Goh et al., 1996, van Grieken et al., 2013). Nevertheless, the 
molecular pathogenesis of the high incidence rate of colorectal cancer in 
Singapore remains to be elucidated. 
 As aforementioned, HERV-H is found to be differentially expressed in 
colon cancer but not in adjacent normal tissues. It is of great interest to 
investigate how HERV-H may be involved in the development of colorectal 
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1.4.2 Hypothesis and objectives 
 Three independent clinical studies have demonstrated that the 
expression of HERV-H is selectively expressed in colon cancer but not in 
normal tissues (Liang et al., 2007b, Wentzensen et al., 2007, Alves et al., 
2008). We therefore hypothesized that HERV-H plays a contributory role in 
the complex process of colorectal carcinogenesis. According to this premise, 
my present work has the following specific objectives: 
(A)  To examine the prevalence of HERV-H in the Singapore population 
 A low distribution frequency or even non-existence of HERV-H in the 
population genetics of Singapore would sensibly negate the causal role of 
HERV-H in colorectal carcinogenesis. The existence of HERV-H in the 
human genome should therefore be verified in the very first instance. By 
engaging a cross-sectional study that involves the molecular analysis of 
genomic DNA, the prevalence of HERV-H in the local population can be 
determined.  
(B)  To study the effect of HERV-H using in vitro models  
 Using human cell lines as the model of colorectal cancer, the 
oncogenic potential of HERV-H can be investigated in vitro. Overexpression 
of HERV-H can be done via the transfection of colorectal cancer cell lines 
with expression vector containing the HERV-H construct. The effect of 
HERV-H on colorectal cancer cells can then be examined using proliferation 
assay, scratch assay, invasion assay and cytometric analysis.  A knockdown 
assay using the dicer-substrate small interfering RNA (DsiRNA) is useful in 
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observing the reversal effect of HERV-H mediating processes. Knockdown 
assay also serves to substantiate the gain-of-functions via the overexpression 
study. 
(C) To investigate the signalling pathways which are implicated in HERV-
H mediating transforming process 
 Cancer cells are known to acquire the mitogenic signalling they need 
to sustain proliferation. This is often associated with constitutive activation of 
signalling pathways. As HERV-H is thought to be involved in the 
transforming process, it would be useful to find out which cell signalling 
pathways are linked to the HERV-H mediated oncogenic process. PCR array 
technology is known to offer an efficient and reproducible approach to 
differential gene expression profiling (Arikawa et al., 2008, Ning et al., 2008). 
Use of such a technique enables the profiling of the entire transcriptome in 
HERV-H mediating transformation process.   
 An understanding of the role of HERV-H in the pathogenesis of 
colorectal cancer may provide important diagnostic and therapeutic 
information. This is useful for the identification of novel prognostic 
biomarkers in colorectal cancer and the provision of a new strategy for cancer 
prevention and intervention.   
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CHAPTER 2 
PREVALENCE OF HERV-H IN THE SINGAPORE POPULATION 
2.1 Introduction 
 Almost half of the human genome is made up of ancient transposable 
elements. Distinctively, these transposable elements are segregated into two 
major classes: DNA and RNA transposons (Finnegan, 1989). While DNA 
transposons account for about 3% of the human genome and are referred as 
Class II elements, RNA transposons constitute approximately 42% of the 
human genome and are termed as Class I elements. In another perspective, 
approximately 90% of three million transposable elements in the human 
genome are represented by RNA transposons. RNA transposons are grouped 
into those without long terminal repeats (LTR), namely the short interspersed 
elements (SINE), the long-terminal interspersed elements (LINE) and the 
processed pseudogenes, and those with LTR, viz., the retrotransposons and the 
endogenous retroviruses (ERVs) (Bannert and Kurth, 2004).  
 Both DNA and RNA transposons play a role in determining human 
genotypes and phenotypes on an evolutionary scale and at the individual level 
(Solyom and Kazazian, 2012). While Class II DNA transposons are able to 
amplify without an RNA intermediate, Class I retroelements require a reverse-
transcribed RNA intermediate to duplicate and insert into new genomic sites 
(Cordaux and Batzer, 2009). 
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2.2 Retroelements 
 Retroelements are widespread in nature. They can be found in 
vertebrate and invertebrate animals (Boulesteix and Biemont, 2005, Bannert 
and Kurth, 2004, Eickbush and Furano, 2002), plants (Finnegan, 2012) and 
fungi (Daboussi and Capy, 2003). Retroelements are organised into LTR-
retroposons and non-LTR retroposons. For non-LTR-retroposons, they are 
further grouped as SINE, LINE and processed pseudogenes. On the other 
hand, within LTR retroposons, they are further classified into infectious 
endogenous retroviruses and non-infectious retrotransposons.  
 Typically, retrotransposons are 5 – 7 kb in length and usually have two 
open reading frames (ORFs) flanked by LTR on both sides (Figure 2.1) 
(Lower et al., 1996, Finnegan, 2012). While endogenous retroviruses are 
capable of retrotransposition from cell to cell via infectious virions, 
retrotransposons are only able to retrotranspose from one site to another site 
within the genome in a cell (Finnegan, 2012). It is generally accepted that the 
differences between retrovirus and retrotransposons are the possession of 
envelope genes and genomic components needed for making a functional viral 
capsule (Deininger and Batzer, 2002, Lower et al., 1996). 
 Infectious LTR retroposons, or specifically the endogenous 
retroviruses, have long integrated into the human genome. It is estimated that 
the integration took place at least 30 million years ago (Bannert and Kurth, 
2006). In spite of the presence of ORFs, no infectious or autonomously 
retrotransposing HERVs have been demonstrated. 
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Figure 2.1. Structural features of LTR-retroelements. The LTR-
retroelements comprise two members, namely the retrotransposons and the 
endogenous retroviruses. All LTR-retroelements have a coding region that is 
flanked by LTRs at both ends. For retrotransposons, the coding region is 
usually made up of GAG and POL. Arrows indicates repeat sequences (R) 
generated during integration process. ORF: open reading frame; LTR: Long 
terminal repeat; GAG encodes structural retroviral capsid proteins; POL 
encodes enzymes for viral replication, integration, and protein cleavage 
(polymerase); ENV encodes structural retroviral envelope proteins. 
  
  It was thought that the detrimental consequences of endogenous 
retroviral activities may have induced host defensive mechanisms to suppress 
it (Gifford and Tristem, 2003). On the other hand, accumulative effects of 
mutations or deletions which can cause frame shifts or premature stop codons 
during host germ line cell division, together with hypermethylation of the 
promoter sites may have also rendered them defective.  Over the years, it was 
shown that the expression of endogenous retroviruses is actively repressed by 
the cellular machinery. In addition, the regulation of such endogenous 
retroviral silencing has been centred upon DNA methylation, histone 
modifications, and small RNAs (Maksakova et al., 2008). 
 
GAG POL ENV LTR-3’ 5’-LTR 
Endogenous retrovirus 
ORFa ORFb LTR-3’ 5’-LTR 
Retrotransposon 
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2.2.1 Human endogenous viruses  
 Human endogenous retroviruses (HERVs) are organised into 3 classes 
and further categorised into numerous families. Although HERVs account for 
about 8% of the human genome, the distribution of HERV families in human 
genome is heterogeneous (Figure 2.2). Compared to Class II ERVs, both Class 
I and III ERVs are found to have, even in each of its own class, a higher 
proportion of the human genome presence. Through analysis of the HERV 
integration sites, the estimated age of HERVs can be revealed. These findings 
have offered a likely reason for the percentage difference in human genome 
presence among the 3 HERVs classes. With reference to Class II HERVs 
which have been found to integrate within the last 5 million years, both Class I 
and III HERVs are the oldest groups and they were found to be inserted into 
the genome at least 25 million years ago (Tristem, 2000). 
 On the basis that successful integration of proviral DNA into the host 
cell’s chromosomal DNA and endogenization of retroviruses in a reproductive 
manner are the two necessary processes that must take place during the long 
period of evolution (Figure 2.3) (Hohn et al., 2013), it should be logical to 
expect that Class I and III ERVs, being the oldest groups of ERVs, are 
obviously colonising the genome at large. 
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Figure 2.2. LTR-retroelements in human genome. Only infectious LTR-
retroposons, which are otherwise known as endogenous retroviruses, is shown here.   
 
 
 The domestication or endogenization of retroviruses is a complex 
process and takes place during the course of evolution (Figure 2.3). Initially, 
exogenous retroviruses must reach and infect the germ cell progenitors 
without being removed by the host’s immune system. There are many host 
factors involved in the resistance to retroviral infection (Takeuchi and Matano, 
2008). Retroviral restriction factors like APOBEC3G, a cytidine deaminase 
which can be encapsidated and hypermutate the new negative cDNA strand  
during reverse transcription (Cullen, 2006, Yu et al., 2004), TRIM5, which 
facilitates the degradation of incoming pre-integration complex via 
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integral membrane protein that inhibits the release of fully formed progeny 
virions (Neil et al., 2008), are some antiviral means that retroviruses must 
overcome. Following successful provirus integration, the infected germ line 
progenitors must survive and develop into fertile offspring who can 
subsequently produce more fertile offspring that carries the proviral DNA. 
With time, endogenous retroviruses may become fixed in the generations.    
 
 
Figure 2.3. The retroviral endogenization process. Exogenous retrovirus is capable 
of infecting the human cells. For exogenous retrovirus to infect the germ line 
successfully, it must be able to overcome a myriad of antiretroviral restriction factors. 
If an infected germ cell containing integrated proviral DNA develops into offspring, 
the progeny must be fit enough or able to lead to more progeny generations. Thus, the 
reproductive success of these individuals brings about the transmission of the proviral 
genome vertically, a process similar to the inheritance of a host gene. During the 
course of evolution, these proviral genes can either increase in number by the 
increased frequency of the proviral elements in the population, and thereby leading to 
the ultimate fixation in the population, or become vanquished by random events or 
selective pressure against them.   
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2.2.2 HERV-H 
 As mentioned in the first chapter, HERVs are implicated in both health 
and diseases. While HERV-W element has defined its role in health, the 
causal role of HERVs in diseases remains unclear. With the intent to focus on 
disease pathology, the HERV-H family is selected and discussed. 
 HERV-H, a family of the HERVs families, is characterised by its 
utilisation of histidine (H) tRNA at its the primer binding site (PBS) to initiate 
reverse transcription. Based on genetic similarity in the pol region, HERV-H 
belongs to Class I of Gammaretrovirus-like. Several studies have shown that 
the selective expression of HERV-H in colorectal cancer but not in normal 
tissue is not an isolated event (Liang et al., 2007b, Alves et al., 2008, 
Wentzensen et al., 2007). While a distinctive pathologic link to HERV-H 
colorectal carcinogenesis remains to be delineated, there are associated 
findings that implicate HERV families in cancers like melanoma (Singh et al., 
2009), leukaemia (Depil et al., 2002), prostate cancers (Reis et al., 2013) and 
breast cancers (Wang-Johanning et al., 2008). On the contrary, it is relatively 
easy to link compelling evidence to exogenous retroviruses in human 
carcinogenesis. An association of HTLV-1 with adult T-cell 
leukaemia/lymphoma exemplifies such causal relationship (Cook et al., 2013). 
 With the premise that HERV-H plays a role in colorectal 
carcinogenesis, it is of relevance to examine the presence of HERV-H in the 
genome of an individual, since HERV elements may be present in some 
humans but not others. While the prevalence of other HERV family members 
in global populations has been documented, the distribution of HERV-H is not 
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as well documented. HERV-K113 and HERV-K115 are the two that have 
been often studied. In one study that comprised 31 genetically diverse 
humans, 29% (9/31) and 16% (5/31) of individuals tested were found to 
possess HERV-K113 and HERV-K115 respectively (Turner et al., 2001). 
Conversely, in a study that involved Asian populations in Taiwan, China and 
Japan, the average insertion frequency of HERV-K113 was 13% and that of 
HERV-K115 was 4% (Jha et al., 2009). Interestingly, the insertion frequency 
of HERV-K113 in a Singapore study (n=120) was 24% (Woo et al., 2013). 
Taken together, the prevalence of HERV families in various populations is 
highly variable. Thus, to fill the gap in knowledge about the distribution 
frequency of HERV-H, we aimed to determine the prevalence of HERV-H in 
the Singapore population and to draw investigate a plausible molecular 
linkage to the high incidence rate of colorectal cancer in Singapore.  
 
2.3  Materials and Methods 
2.3.1 Study design and subjects 
 This cross-sectional study was initiated in April 2010 to investigate the 
prevalence of HERV-H in the population of Singapore.  Between April 2010 
and Nov 2011, 808 subjects, aged 16 to 60 years, were randomly recruited 
from the residents in Singapore. The mean age at recruitment was 23.3. Of 
these, 23 subjects whose genomic materials were classified as indeterminate 
were excluded from the study, resulting in a total number of 785 subjects.  
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 The study protocol was approved by the Ethics Review Committee of 
Singapore Polytechnic. All participants gave their written informed consent, 
and genomic materials were collected after approval by the Ethics Review 
Committee. Participation in the study was voluntary, anonymous and 
confidential. 
 
2.3.2 Genotype analysis 
 Buccal cells were collected using MasterAmp™ buccal brush 
(Epicentre, Madison, WI). Genomic DNA was isolated from the buccal cells 
using the ReliaPrep gDNA Tissue Miniprep System (Promega, Madison, WI). 
Each individual’s DNA was tested for the presence of HERV-H by using 
polymerase chain reaction (PCR) amplifications previously described (Alves 
et al., 2008).  
 Briefly, PCR was conducted using the primers HERV-H: forward, 5’- 
CTT CCC TCC GTG TCT TTA CG-3’ and reverse, 5’- AAG ATT AGA 
CAC ACT CAG CAA CG-3’. The PCR mix, in volume of 50 l, contained 20 
ng of extracted genomic DNA template, 2.0 M of each primer, 200 M of 
each deoxynucleoside triphosphate, 15 mM of MgCl2, and 2.5 units of 
GoTaq® DNA DNA polymerase (Promega, Foster City, CA). PCR 
amplification was conducted with 2 min of initial denaturing at 95°C, 35 
cycles of 30 seconds at 95°C, 30 seconds at annealing temperature at 60°C, 
and 60 seconds of elongation at 72°C followed by a 10 min final extension at 
72°C.  To monitor for reagent contamination, a no template control (NTC) 
was included in every batch of PCR amplification.  A housekeeping gene, -
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actin, was used to validate the true negatives. Primers -actin: forwards, 5’-
CCT TCC TGG GCA TGG AGT CCT G-3’ and reverse, 5’-GGA GCA ATG 
ATC TTG ATC TTC-3’ were used. The PCR cycling profile of -actin 
followed exactly the same as HERV-H. Amplified PCR products were stored 
at 4°C until they were analyzed by electrophoresis on 1% agarose gel. The 
100-bp ladder (New England Biolabs, USA) was used to verify the product 
size. The strategy employed in genotype analysis is briefly summarised in 
Figure 2.4.  
 
 
Figure 2.4. Strategy used for the HERV-H genotyping analysis. 
 
 
2.3.3. Analysis of HERV-H sequence 
 To examine the magnitude of sequence homology of HERV-H, a 
specific pair of primers that flanks HERV-H on the either side of chromosome 
X was designed. The sequence of this pair of primers are: forward, 5’- TTG 
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GAA ACC TCG CTG GGC TAA AAG C-3’ and reverse, 5’-AGA ACT GAT 
TGA ACG CAA GAA GGC A-3’. A 6942bp amplicon containing the 5462-
bp HERV-H (GenBank: EF194101.1) was expected. The sequence matches 
the region from 2340319 to 2345780 on the human X chromosome (GenBank:  
NT_167197.1).  
 Long range PCR amplifications of HERV-H were carried out in 25µl 
volumes each containing 1X Phusion™ HF Buffer, 200µM of dNTPs, 0.5µM 
of each primers, 0.5 units of Phusion™ DNA Polymerase (Finnzymes, Espoo, 
Finland) and 120ng genomic DNA template. Thermal cycler PCR conditions 
were 98°C for 30 seconds followed by 30 cycles of 98°C for 10 seconds, 64°C 
for 30 seconds and 72°C for 3 minutes and 15 seconds. Final extension was 
done at 72°C for 10 minutes.  Individual reactions were combined and 
purified. Purified amplicons were subsequently sequenced using 22 set of 
sequencing primers (Table 2.1), of which were designed to bind sequentially 
with overlapping interval onto the various sites of 6942bp HERV-H 
amplicons. 22 segments were analysed with reference to human chromosome 
X (GenBank: NT_167197.1). Subsequently, these 22 segments were 
assembled to form a contiguous sequence with overlapping sequences omitted. 
The assembled contiguous sequence was analysed with reference to the 
HERV-H gene in Genbank (EF194101.1). Gene analyses were carried out 
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Table 2.1. Sequencing primers for HERV-H 
Primer Sequence Location of Binding 
(with reference to  
GenBank: NT_167197.1) 
NEA 0 GAG ATC CAC CCC TGC CCA 2345861 
NEA 1 ATC AAT CCT CCG TCC TCC TG 2345614 
NEA 2 CAG CCT TCC CTT GGT GTT TA 2345314 
NEA 3 TGT CTC TAC TCC TTC TCT GC 2345089 
NEA 4 ACC CCT TCC CTC CGT GTC TT 2344789 
NEA 5 TTA CAC ATC CGT CCC TTC CT 2344474 
NEA 6 CAC TCC TCC ACC CTG TAA TCT TTT T 2344276 
NEA 7 GCG TTT AGG CTC TTT TTC AT 2344105 
NEA 8 AAA CCC CAG CCA CAT CTC CA 2343825 
NEA 9 GAC TCC TTC CCA GAT CTT CT 2343565 
NEA 10 ATA CTC TTT TAC GCA CTC CT 2343293 
NEA 11 ATC ACC CTT ACC CCG CTC AA 2343036 
NEA 12 ATC CTC AAT ACC TCC CTC TA 2342796 
NEA 13 ATC TCC CAA ACC TCA ATC CCT TAC A 2342509 
NEA 14 ACT ATG CTC AAC TCA CTC TCT ACA 2342301 
NEA 15 GCC TAA TCG CCA CAC ACC AG 2342008 
NEA 16 CCT CCC TTC CCT ACA CAT CA 2341841 
NEA 17 GTC AAA TCA GCC AAG CAG TT 2341587 
NEA 18 TTT ACC ACT TTC CCT TCT CA 2341427 
NEA 19 TTT CTC CAA GCC ATC ACA GC 2341182 
NEA 20 GCT TCT CAA ATC ATC CAA AAC CGT A 2340972 
NEA 21 AAG AAG GCA GGA ATG TCA GG 2340711 
 
 
2.3.4 Statistical methods 
 Analyses were conducted separately for gender and ethnicity. 
Prevalence rates and 95% confidence intervals (95% CIs) were calculated 
using ProMESA software version 1.62 (EpiCentre, Massey University, New 
Zealand). Odds ratios (ORs) with 95% CIs were calculated using 
STATGRAPHICS® Centurion XVI version 16.1.05 (Statpoint Technologies, 
Inc, Virginia, USA) to estimate the association of HERV-H with the variables. 
Differences between genders were estimated by chi-square test (statistical 
significance for P <0.05) using STATGRAPHICS® Centurion XVI. All 
statistical tests were based on 2-sided probability. 
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2.4 Results 
 This study aims to examine the prevalence of HERV-H in Singapore. 
Of 808 subjects recruited, 785 were successfully analysed for HERV-H. The 
prevalence rates of HERV-H positivity are shown in Table 2.2. 89.9% 
(381/427) of females and 88.6% (320/361) of males were found to possess 
HERV-H, making a total of 89.3% HERV-H positivity. There was no 
statistical difference between males and females (P > 0.05). 
Table 2.2. HERV-H positivity in sample Singapore population 





    n Prevalence Rate (%) 95% CI# Difference (95% CI)   
Total 701 89.3 87.1 - 91.5 N.A. N.A. 
 
Gender 
      
 
Female 381 89.9 87.8 - 92.0 1.3 ( -1.76 - 4.36) 
0.583  
 
Male 320 88.6 86.4 -90.8 reference  
Race/ethnicity      
 
Chinese 438 86.1 83.7 - 88.5 reference reference 
 
 
Malay 124 95.4 93.9 - 96.9 9.3 (6.47 - 12.1) 0.0035 
 
 
Indian 121 96.8 95.6 - 98.0 10.7 (7.98 - 13.42) 0.0009 
 
  Other* 18 85.7 83.3 - 88.2 0.4 (-3.04 - 3.84) 0.9652  
          
  
 





    n Prevalence Rate (%) 95% CI# Difference (95% CI)   
Total 84 10.7 8.5 - 12.9 N.A. N.A. 
 
Gender 
      
 
Female 43 10.1 7.99 - 12.2 1.14 (0.72 - 1.79) 
0.583  
 
Male 41 11.4 9.2 - 13.6 1  
Race/ethnicity      
 
Chinese 71 13.9 11.5 - 16.3 1 reference 
 
 
Malay 6 4.6 3.13 - 6.07 3.35 (1.42 - 7.89) 0.0035 
 
 
Indian 4 3.2 1.97 -4.43 4.90 (1.76 - 13.7) 0.0009 
 
  Other* 3 14.3 11.9 -16.8 0.97 (0.28 - 3.39) 0.9652  
*Other (Burmese, Ceylonese, Eurasian, Filipino, Japanese, Javanese, Pakistani,  
Punjabi, Sikh, Vietnamese). #95% CI: 95% confidence interval; calculated based  
on Singapore Population in 2011 i.e. 5,183,700. Source: Singapore Department  
of Statistics 
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 Table 2.3 shows the degree of identity at the various sites of HERV-H 
amplicons from three subjects of different ethnic group. With reference to 
human chromosome X (GenBank: NT_167197.1), a high level of homology, 
ranging from 72% to 99% was generally observed. Similarly, when HERV-H 
sequence of individual subject was compared to the GenBank HERV-H gene 
(NCBI EF194101.1), a high range of shared identities, between 95 and 99% 
was observed (Figures 2.5 – 2.7). Table 2.4 indicates relatively good sequence 
conservation between three ethnic groups, averaging about 98%. To visualise 
the four sequences simultaneously, sequences were aligned using CLUSTAL 
Omega. Figure 2.8 reveals a high percentage of sequence identities.   
 
Table 2.3. Overview of HERV-H sequence homology in three ethnic groups. 
Sequences were aligned with NCBI BLAST program, by using GenBank-derived X 
chromosome sequence, NT_167197.1 as the query. Sequencing results that were 
doubtful due to noisy signals in Sanger sequencing are represented by “~”.  
 
 
Alignment of HERV-H Sequences to  
Human X chromosome (GenBank: NT_167197.1) 
Primer Chinese Malay Indian 
NEA 21 
2339799 – 2340701 
Identities: 899/904 
Homology: 99% 
2339799 – 2340698 
Identities: 884/885 
Homology: 99% 
~   
NEA 20 
2339814 – 2340959 
Identities: 1144/1146 
Homology: 99% 
2340336 – 2340951 
Identities: 613/618 
Homology: 99% 




2339930 – 2341161 
Identities: 1216/1232 
Homology: 99% 
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NEA 18 
2340171 – 2341412 
Identities: 1231/1242  
Homology: 99% 
2340316 – 2341412 
Identities: 1089/1093 
Homology: 99% 




2340368 – 2341570 
Identities: 1198/1203 
Homology: 99%  






2340617 – 2341821 
Identities: 1195/1206 
Homology: 99% 
2340555 – 2341829  
Identities: 1239/1267 
Homology: 97% 




2340782 – 2342000 
Identities: 1210/1219 
Homology: 99% 





2341065 – 2342292 
Identities: 1216/1228 
Homology: 99% 
2341060 – 2342292  
Identities: 1211/1235 
Homology: 98% 




2341290 – 2342501 
Identities: 1201/1212 
Homology: 99% 





2341641 – 2342781 
Identities: 1124/1142  
Homology: 98%  
2341971 – 2342773 
Identities: 793/801 
Homology: 99% 




2341796 – 2343023 
Identities: 1216/1228 
Homology: 99% 







2342259 – 2343277 
Identities: 1027/1039  
Homology: 99% 
2342026 – 2343277 
Identities: 1225/1252 
Homology: 98% 
2342026 – 2343280 
Identities: 1225/1256 
Homology: 98% 
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NEA 9 
2342433 – 2343541 
Identities: 1094/1127  
Homology: 97% 
2342282 – 2343541 
Identities: 1236/1262 
Homology: 98% 




2342566 – 2343818 
Identities: 1226/1253  
Homology: 98%  
2343043 – 2343803 
Identities: 577/768 
Homology: 75% 




2342843 – 2344096 
Identities: 1217/1254 
Homology: 97% 
2342836 – 2344097 
Identities: 985/1274 
Homology: 77% 




2343003 – 2344258 
Identities: 1240/1256  
Homology: 99% 
2342996 – 2344268 
Identities: 1037/1277 
Homology: 81% 




2343207 – 2344454 
Identities: 1237/1248 
Homology: 99% 
2343224 – 2344454 
Identities:1084/1241 
Homology: 87% 




2343521 – 2344780 
Identities: 1237/1260 
Homology: 98% 







2343836 – 2345059 
Identities: 1102/1230 
Homology: 90% 
2343846 – 2345075 
Identities: 1123/1232 
Homology: 91% 




2344046 – 2345294 
Identities: 1231/1249 
Homology: 99% 
2344042 – 2345297 
Identities: 1234/1256 
Homology: 98% 




2344334 – 2345604 
Identities: 1249/1271 
Homology: 98% 
2344330 – 2345598 
Identities: 1253/1271 
Homology: 99% 
2344340 – 2345598 
Identities: 1239/1259 
Homology: 98% 
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NEA 0 
2344913 – 2345847 
Identities: 810/941 
Homology: 86% 
2344617 – 2345847 
Identities: 563/578 
Homology: 97% 
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Figure 2.5. Definition of a HERV-H sequence from a Chinese subject.  (A) 
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Figure 2.6. Definition of a HERV-H sequence from a Malay subject. (A) 
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Figure 2.7. Definition of a HERV-H sequence from an Indian subject. (A) 







Table 2.4. Pairwise observed sequence identities (%). HERV-H sequence from 
GenBank: EF194101.1 and each of the three ethnic groups were compared with one 




Chinese Indian Malay EF194101.1 
Chinese 100 97.87 97.96 98.60 
Indian  97.87 100 98.00 99.03 
Malay 97.96 98.00 100 98.74 






Chinese     CCTTTTGATGGTAATTTTCCTTTCCTTTCCCTATATCTATTAAAAGGGCCCACCCCTATCTCCCTTTGCTGACTCTCTTTTCGGACTCAGCCCGCCTGCA  
Indian      -------------T-TTNCNTTNCCTTNCCC-TATCCTATTAAAAGGCCCCACCCCTATCTCCCTTTGCTGACTCTCTTTTCGGACTCAGCCCGCCTGCA  
Malay       CCCCTTGAAGGTAT-TTTCATTTCCTTTCCA-TAACCTATTAAAAGGcccccccccTATCTCCCTTTGCTGACTCTCTTTTCGGACTCAGCCCGCCTGCA  
EF194101.1  -------------------------------------------------------------------GCTGACTCTCTTTTCGGACTCAGCCCGCCTGCA  
Clustal Co                                                                     *********************************  
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Chinese     CCCAGGTGAAATAAACAGCCTTGTTGCTCACACAAAGCCTGTTTGGTGGTCTCTTCACATGGACGCACATGAAATTTGTTGACATTGCTCAGATTGTTAG  
Indian      CCCAGGTGAAATAAACAGCCTTGTTGCTCACACAAAGCCTGTTTGGTGGTCTCTTCACATGGACGCACATGAAATTTGTTGACATGGCTCAGATCGGGGG  
Malay       CCCAGGTGAAATAAACAGCCTTGTTGCTCACACAAAGCCTGTTTGGTGGTCTCTTCACATGGACGCACATGAAATTTGTTGACATTGCTCAGATTTTTAG  
EF194101.1  CCCAGGTGAAATAAACAGCCATGTTGCTCACACAAAGCCTGTTTGGTGGTCTCTTCACATGGACGCACATGAAATTTGGTGCCATGACTCGGATCGGGGG  
Clustal Co  ********************:********************************************************* **.*** .***.***    .*  
 
Chinese     AACTCCCTTGGGAGATTAATACTCCTTGCTCCTGCTCTATGTTccccGGGAAAAAACCCCCTACGACCTCAGGTCCTCAGACCGACGAGCCCAAGAAACA  
Indian      ACCTCCCCTGGGAGATCAATCCTCCTTGCTCCTGCTCTTTGCTTGaaaaGAA-AAATCACCTACGACCTCAGGTCCTCAGACCGACGAGCCCAAGAAACA  
Malay       AACTCCCTTGGGAAATTAATCCTCATTCCTCCTGCTCTTTGTTT--TGAGAAAAAACCACCTACGACCTCAGGTCCTCAGACCGACGAGCCCAAGAAACA  
EF194101.1  ACCTCCCTTGGGAGATCAATCCTCCGTCCTCCTGCTCTTTGCTCCCTGAGAAAGATCCACCTACGACCTCAGGTCCTCAGACCGACGAGCCCAAGAAACA  
Clustal Co  *.***** *****.** ***.***. * **********:** *      *** .*: *.*****************************************  
 
Chinese     TCTCACCAATTTCAAATCTGGTAAGCAGCCTCTTTTTACTCTCTTCTCCAACTTCCCTCACTATCCCTCAACCACTTTCTCCTTTCAATCTTGGCACTAC  
Indian      TCTCACCAATTTCAAATCTGGTAAGCAGCCTCTTTTTACTCTCTTCTCCAACTTCCCTCACTATCCCTCAACCACTTTCTCCTTTCAATCTTGGCACTAC  
Malay       TCTCACCAATTTCAAATCTGGTAAGCAGCCTCTTTTTACTCTCTTCTCCAACTTCCCTCACTATCCCTCAACCACTTTCTCCTTTCAATCTTGGCACTAC  
EF194101.1  TCTCACCAATTTCAAATCTGGTAAGCAGCCTCTTTTTACTCTCTTCTCCAACTTCCCTCACTATCCCTCAACCACTTTCTCCTTTCAATCTTGGCACTAC  
Clustal Co  ****************************************************************************************************  
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Indian      AACCTTCCATCCTCCATTCCTCCTTCTCCCTTAGCCTGTGTGCTCAAGAACTTAAAACCTCTTCAACTCACACCTGACCTAAAACCTAAATGCCTCATTT  
Malay       AACCTTCCATCCTCCATTCCTCCTTCTCCCTTAGCCTGTGTGCTCAAGAACTTAAAACCTCTTCAACTCACACCTGACCTAAAACCTAAATGCCTCATTT  
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Chinese     TCTTCTGCAACACCGCTTGGCCCCAATACAAACTTGACAATGGCTCTAAATGGCCAGAAAATGGCACTTTCGATTTCTCCATCCTACAAGACCTAAATAA  
Indian      TCTTCTGCAACACCGCTTGGCCCCAATACAAACTTGACAATGGCTCTAAATGGCCAGAAAATGGCACT-TCGATTTCTCCATCCTACAAGACCTAAATAA  
Malay       TCTTCTGCAACACCGCTTGGCCCCAATACAAACTTGACAATGGCTCTAAATGGCCAGAAAATGGCACTTTCGATTTCTCCATCCTACAAGACCTAAATAA  
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Indian      TTTTTGTCAAAAAATGGGCAAATGGTCTGAGGTGCCTGATGTCCAGGCATTCTTTTACACATCCGTCCCTTCCTAGTCTCTGTGCCCAGTGCAACTCGTC  
Malay       TTTTTGTCAAAAAATGGGCAAATGGTCTGAGGTGCCTGATGTCCAGGCATTCTTTTACACATCCGTCCCTTCCTAGTCTCTGTGCCCAGTGCAACTCGTC  
EF194101.1  TTTTTGTCAAAAAATGGGCAAATGGTCTGAGGTGCCTGATGTCCAGGCATTCTTTTACACATCCGTCCCTTCCTAGTCTCTGTGCCCAGTGCAACTCGTC  
Clustal Co  ****************************************************************************************************  
 
Chinese     CCAAATCTTCCTTCTTTCCCTCCCACCTGTCCCCTCAGTCCCAACCCCAGGCGTTGCTGAGTGTGTCTAATCTTCCTTTTCTACAAACCCATCTGACCTC  
Indian      CCAAATCTTCCTTCTTTCCCTCCCACCTGTCCCCTCAGTCCCAACCCCAGGCGTTGCTGAGTGTGTCTAATCTTCCTTTTCTACAAACCCATCTGACCTC  
Malay       CCAAATCTTCCTTCTTTCCCTCCCACCTGTCCCCTCAGTCCCAACCCCAGGCGTTGCTGAGTGTGTCTAATCTTCCTTTTCTACAAACCCATCTGACCTC  
EF194101.1  CCAAATCTTCCTTCTTTCCCTCCCACCTGTCCCCTCAGTCCCAACCCCAGGCGTTGCTGAGTGTGTCTAATCTTCCTTTTCTACAAACCCATCTGACCTC  
Clustal Co  ****************************************************************************************************  
 
Chinese     TCCCCTCCTCTCCACGCCAAGCTAGGTCCCAATTCTTCCTCAGGCTCCACTCCTCCACCCTGTAATCTTTTTATCACCTCCCCTCCTCACACCTGGTCCG  
Indian      TCCCCTCCTCTCCACGCCAAGCTAGGTCCCAATTCTTCCTCAGGCTCCACTCCTCCACCCTGTAATCTTTTTATCACCTCCCCTCCTCACACCTGGTCCG  
Malay       TCCCCTCCTCTCCACGCCAAGCTAGGTCCCAATTCTTCCTCAGGCTCCACTCCTCCACCCTGTAATCTTTTTATCACCTCCCCTCCTCACACCTGGTCCG  
EF194101.1  TCCCCTCCTCTCCACGCCAAGCTAGGTCCCAATTCTTCCTCAGGCTCCACTCCTCCACCCTGTAATCTTTTTATCACCTCCCCTCCTCACACCTGGTCCG  
Clustal Co  ****************************************************************************************************  
 
Chinese     GCTTACAGTTTCGTTCCGTGACTAGCCCTCCCCCACCTGCCCAGCAATTTACTCTTAAAAAGGTGGCTGGAGCTAAAGACATAGCCAAGGTTAAAGCTCC  
Indian      GCTTACAGTTTCGTTCCGTGACTAGCCCTCCCCCACCTGCCCAGCAATTTACTCTTAAAAAGGTGGCTGGAGCTAAAGACATAGTCAAGGTTAATGCTCC  
Malay       GCTTACAGTTTCGTTCCGTGACTAGCCCTCCCCCACCTGCCCAGCAATTTACTCTTAAAAAGGTGGCTGGAGCTAAAGACATAGTCAAGGTTAATGCTCC  
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Chinese     CTTTTCCTTATCCCAAATCAAAAACGTTTAGGCTCTTTTTCATCAAATACAACAACCCAGCCCAATTCATGGCTCGATCGGCAGCAACCTTGATACGCTT  
Indian      TTTTTCTTTATCCCAAATCAGAAGCGTTTAGGCTCTTTTTCATCAAATATAAAAACCCAGCCCAGTTCATGGCTCGTTCGGCAGCAACCCTGAGACGCTT  
Malay       TTTTTCTTTATCCCAAATCAGAAGCGTTTAGGCTCTTTTTCATCAAATATAAAAACCCAGCCCAGTTCATGGCTCGTTCGGCAGCAACCCTGAGACGCTT  
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Indian      TACAGCCCTAGACCCTAAAAGGTCAAAAGGCCGTCTTATTCTCAATA-ACATTTTATTACCCAATCTGCTCCCGATATTAAAT-AAAACTCCAAAAATTA  
Malay       TACAGCCCTAGACCCTAAAAGGTCAAAAGGCCGTCTTATTCTCAATATACATTTTATTACCCAATCTGCTCCCGATATTAAAT-AAAACTCCAAAAATTA  
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Chinese     TACAAGTGCCAGAAATCTGGCCACCAAGCCAAGAAATGCCTGCAGCCCAGGATTCCTCCTAAGCCGTGTCCCATCTGTGCGGGACCCCATTGGAAATCAG  
Indian      TACAAGTGCCAGAAATCTGGCCACCAAGCCAAGAAATGCCTGCAGCCCAGGATTCCTCCTAAGCCGTGTCCCATCTGTGCGGGACCCCATTGGAAATCAG  
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Chinese     AATGGTCAACTCACCTGGCAGCGACTCCCAAGAACCCTGGAACTCTGGCCCAAGGTTTCTTGACTGAATCCTTCCCAGATCTTCTCGGCTTAGCGGCTGA  
Indian      ACTGTTCAACTCACCTGGCAGCGACTCCCAGAGACCCTGGAACTCTGGCCCAAGGCTCTCTGACTGACTCCTTCCCAGATCTTCTCGGCTTAGCGGCTGA  
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Chinese     AGACTGACGCTGCCCAATCACCTCGGAAGCCCTGTAGACCATCACAGACACTGAGCTTTAGGTAACTCTCACAGTGGAGGGTAAGTCCGTCCCCTTCTTA  
Indian      AGACTGACGCTGCCCAATCACCTCGGAAGCCCTGTAGACCATCACAGACACTGAGCTTTAGGTAACTCTCACAGTGGAGGGTAAGTCCGTCCCCTTCTTA  
Malay       GAATGGACGCTGCCCAATCACCTCGG-AGCCCTGTAGACCATCACAGACACTGAGCTTTAGGTAACTCTCACAGTGGAGGGTAAGTCCGTCCCCTTCTTA  
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Chinese     ATCAATATGGAGGCTCCCCACTCCACATTACCTACTTTTCAAGGGCCTGTTTCCCTTGCCTCCATAACTGCTGTGGGTATTGACGGCCAGGCTTCTAAAC  
Indian      ATCAATATGGAGGCTCCCCACTCCACATTACCTACTTTTCAAGGGCCTGTTTCCCTTGCCTCCATAACTGCTGTGGGTATTGACGGCCAGGCTTCTAAAC  
Malay       ATCAATATGGAGGCTCCCCACTCCACATTACCTACTTTTCAAGGGCCTGTTTCCCTTGCCTCCATAACTGCTGTGGGTATTGACGGCCAGGCTTCTAAAC  
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Chinese     CTCTTAAAACTTCCCAACTCTAGTGCCAACTTAGACAATACTCTTTTACGCACTCCTTTTTAGTTATCCCCACCTGCCCAGTTCCCTTATTAGGCCGAGA  
Indian      CTCTTAAAACTTCCTCT----ATCGACTGCTTACACAATACACATTCACGCACTCATTCCTAGTTATCCCCCCCTGCCCAGTTC--TTATTAGGCCGAGA  
Malay       CTCTTAAAACTTCCCAACTCTAGTGCCAACTTAGACAATACTCTTTTACGCACTCCTTTTTAGTTATCCCCACCTGCCCAGTTCCCTTATTAGGCCGAGA  
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Chinese     CACTTTAACTAAATTATCTGCTTCCCTGACTACTCCTGGACTACAGCTGCATCTCATTGCCGCCCTTATTCCTAATCCAAAGCCTCCTTTGCGTCCTCCT  
Indian      CACTTTAACTAAATTATCTGCTTCCCTGACTACTCCTGGACTACAGCTGCATCTCATTGCCGCCCTTATTCCTAATCCAAAGCCTCCTTTGCGTCCTCCT  
Malay       CACTTTAACTAAATTATCTGCTTCCCTGACTACTCCTGGACTACAGCTGCATCTCATTGCCGCCCTTATTCCTAATCCAAAGCCTCCTTTGCGTCCTCCT  
EF194101.1  CACTTTAACTAAATTATCTGCTTCCCTGACTACTCCTGGACTACAGCTGCATCTCATTGCCGCCCTTATTCCTAATCCAAAGCCTCCTTTGCGTCCTCCT  
Clustal Co  ****************************************************************************************************  
 
Chinese     CTTGTATCCCCCCACCTTAACCCACAAGTATAAGATACCTCTACTCCCTCCTTGGCGACCGATCATGCACCCCTTACCATCTCATTAAAACCTAATCACC  
Indian      CTTGTATCCCCCCACCTTAACCCACAAGTATAAGATACCTCTACTCCCTCCTTGGCGACCGATCATGCACCCCTTACCATCTCATTAAAACCTAATCACC  
Malay       CTTGTATCCCCCCACCTTAACCCACAAGTATAAGATACCTCTACTCCCTCCTTGGCGACCGATCATGCACCCCTTACCATCTCATTAAAACCTAATCACC  
EF194101.1  CTTGTATCCCCCCACCTTAACCCACAAGTATAAGATACCTCTACTCCCTCCTTGGCGACCGATCATGCACCCCTTACCATCTCATTAAAACCTAATCACC  
Clustal Co  ****************************************************************************************************  
 
Chinese     CTTACCCCGCTCAATGCCAATATCTCATCCCACAGCATGCTTTGAAAGGATTAAAGCCTGTTATCACTTGCCTGCTACAGCATGGGCTCCTAAAACCTAT  
Indian      CTTACCCCGCTCAATGCCAATATCTCATCCCACAGCATGCTTTGAAAGGATTAAAGCCTGTTATCACTTGCCTGCTACAGCATGGGCTCCTAAAACCTAT  
Malay       CTTACCCCGCTCAATGCCAATATCTCATCCCACAGCATGCTTTGAAAGGATTAAAGCCTGTTATCACTTGCCTGCTACAGCATGGGCTCCTAAAACCTAT  
EF194101.1  CTTACCCCGCTCAATGCCAATATCTCATCCCACAGCATGCTTTGAAAGGATTAAAGCCTGTTATCACTTGCCTGCTACAGCATGGGCTCCTAAAACCTAT  
Clustal Co  ****************************************************************************************************  
 
Chinese     AAACTCTCCTTACCATTCCCCCATTTTACCTGTCCTAAAACCAGACAAGCCTTACAAGTTAGTTCAGAATCTGCGCCTTATCAACCAAATGTTTTGCCTA  
Indian      AAACTCTCCTTACCATTCCCCCATTTTACCTGTCCTAAAACCAGACAAGCCTTACAAGTTAGTTCAGAATCTGCGCCTTATCAACCAAATGTTTTGCCTA  
Malay       AAACTCTCCTTACCATTCCCCCATTTTACCTGTCCTAAAACCAGACAAGCCTTACAAGTTAGTTCAGAATCTGCGCCTTATCAACCAAATGTTTTGCCTA  
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Chinese     TCCACCCCGTGGTGCCAAACCCGTATACTCTTCTATCCTCAATACCTCCCTCTACTACCCATTATTCTGTTCTGGATCTCAAACATGCTTTCTTTACTAT  
Indian      TCCACCCCGTGGTGCCAAACCCGTATACTCTTCTATCCTCAATACCTCCCTCTACTACCCATTATTCTGTTCTGGATCTCAAACATGCTTTCTTTACTAT  
Malay       TCCACCCCGTGGTGCCAAACCCATATACTCTTCTATCCTCAATACCTCCCTCTACTACCCATTATTCTGTTCTGGATCTCAAACATGCTTTCTTTACTAT  
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Chinese     TCCTTTGCACCCTTCATCCCAGCCTCTCTTTGCCTTCACTTAGACTGACCCTGACACCCATTAGGCTCAGCAAATTACCTGGGCTGTACTGCCGCAAGGC  
Indian      TCCTTTGCACCCTTCATCCCAGCCTCTCTTTGCCTTCACTTAGACTGACCCTGACACCCATTAGGCTCAGCAAATTACCTGGGCTGTACTGCCGCAAGGC  
Malay       TCCTTTGCACCCTTCATCCCAGCCTCTCTTTGCCTTCACTTAGACTGACCCTGACACCCATTAGGCTCAGCAAATTACCTGGGCTGTACTGCCGCAAGGC  
EF194101.1  TCCTTTGCACCCTTCATCCCAGCCTCTCTTTGCCTTCACTTAGACTGACCCTGACACCCATTAGGCTCAGCAAATTACCTGGGCTGTACTGCCGCAAGGC  
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Chinese     TTCACAGACAGCCCCCATTACTTCAGTCAAGCCCAAATTTCATCCTCATCTGTTACCTATCTCAGCATAATTCTCATAAAAACACAGGTGCTCTCCCTGC  
Indian      TTCACAGACAGCCCCCATTACTTCAGTCAAGCCCAAATTTCATCCTCATCTGTTACCTATCTCAGCATAATTCTCATAAAAACACAGGTGCTCTCCCTGC  
Malay       TTCACAGACAGCCCCCATTACTTCAGTCAAGCCCAAATTTCATCCTCATCTGTTACCTATCTCAGCATAATTCTCATAAAAACACAGGTGCTCTCCCTGC  
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Chinese     TGATCGTGTCCGATTAATCTCCCAAACCTCAATCCCTTACAAAAGAACAACTCCTTTCCTTCCTAGGCATGGTTAGTGTGGTCAGAATTCTTACACAAGA  
Indian      TGATCGTGTCCGATTAATCTCCCAAACCTCAATCCCTTACAAAAGAACAACTCCTTTCCTTCCTAGGCATGGTTAGTGTGGTCAGAATTCTTACACAAGA  
Malay       TGATCGTGTCCGATTAATCTCCCAAACCTCAATCCCTTACAAAAGAACAACTCCTTTCCTTCCTAGGCATGGTTAGTGTGGTCAGAATTCTTACACAAGA  
EF194101.1  TGATCGTGTCCGATTAATCTCCCAAACCTCAATCCCTTACAAAAGAACAACTCCTTTCCTTCCTAGGCATGGTTAGTGTGGTCAGAATTCTTACACAAGA  
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Chinese     GCCAGGACTGCACCCTGTAGCCTTTCTGTCCAAACAACTTGACCTTCCTGTTTTAGCCTAGCCATCATGTCTGTGTGCAGCCGCTGCCGCTGCTTTAATA  
Indian      GCCAGGACTGCACCCTGTAGCCTTTCTGTCCAAACAACTTGACCTTCCTGTTTTAGCCTAGCCATCATGTCTGTGTGCAGCCGCTGCCGCTGCTTTAATA  
Malay       GCCAGGACTGCACCCTGTAGCCTTTCTGTCCAAACAACTTGACCTTCCTGTTTTAGCCTAGCCATCATGTCTGTGTGCAGCCGCTGCCGCTGCTTTAATA  
EF194101.1  GCCAGGACTGCACCCTGTAGCCTTTCTGTCCAAACAACTTGACCTTCCTGTTTTAGCCTAGCCATCATGTCTGTGTGCAGCCGCTGCCGCTGCTTTAATA  
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Chinese     CTGTTAGAGGCCCTCAAAATCACAAACTATGCTCAACTCACTCTCTACATTTCTCATAACTTCCAAAATCTATTTTCTTCCTCATACCTGACGCATATAC  
Indian      CTGTTAGAGGCCCTCAAAATCACAAACTATGCTCAACTCACTCTCTACATTTCTCATAACTTCCAAAATCTATTTTCTTCCTCATACCTGACGCATATAC  
Malay       CTGTTAGAGGCCCTCAAAATCACAAACTATGCTCAACTCACTCTCTACATTTCTCATAACTTCCAAAATCTATTTTCTTCCTCATACCTGACGCATATAC  
EF194101.1  CTGTTAGAGGCCCTCAAAATCACAAACTATGCTCAACTCACTCTCTACATTTCTCATAACTTCCAAAATCTATTTTCTTCCTCATACCTGACGCATATAC  
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Chinese     TTTCTGCTCCCCGGCTCCTTCAGCTGTACTCACACTTTCTTAAGTCCCACAATTACCATTGTTCCTGGCCTGGACTTCAATCTGGCCTCCCACATTATTC  
Indian      TTTCTGCTCCCCGGCTCCTTCAGCTGTACTCACACTTTCTTAAGTCCCACAATTACCATTGTTCCTGGCCTGGACTTCAATCTGGCCTCCCACATTATTC  
Malay       TTTCTGCTCCCCGGCTCCTTCAGCTGTACTCACACTTTCTTAAGTCCCACAATTACCATTGTTCCTGGCCTGGACTTCAATCTGGCCTCCCACATTATTC  
EF194101.1  TTTCTGCTCCCCGGCTCCTTCAGCTGTACTCACACTTTCTTAAGTCCCACAATTACCATTGTTCCTGGCCTGGACTTCAATCTGGCCTCCCACATTATTC  
Clustal Co  ****************************************************************************************************  
 
Chinese     CTGATACCACACCTGACCTCCATGACTGTATCTCTCTGATCCACCTGATATTCACCCCATATTTCCTTCTTTCCTGTTCCTCACCCTGATCACGCTTGAT  
Indian      CTGATACCACACCTGACCTCCATGACTGTATCTCTCTGATCCACCTGATATTCACCCCATATTTCCTTCTTTCCTGTTCCTCACCCTGATCACGCTTGAT  
Malay       CTGATACCACACCTGACCTCCATGACTGTATCTCTCTGATCCACCTGATATTCACCCCATATTTCCTTCTTTCCTGTTCCTCACCCTGATCACGCTTGAT  
EF194101.1  CTGATACCACACCTGACCTCCATGACTGTATCTCTCTGATCCACCTGATATTCACCCCATATTTCCTTCTTTCCTGTTCCTCACCCTGATCACGCTTGAT  










Chinese     TTATTGATGGAAGTTCCACCAGGCCTAATCGCCACACACCAGCAAAGGCAGGTTATGCTATAGTACAAGCCACTAGCCCACCTCTCAGAACCTCTCATTT  
Indian      TTATTGATGGAAGTTCCACCAGGCCTAATCGCCACACACCAGCAAAGGCAGGTTATGCTATAGTACAAGCCACTAGCCCACCTCTCAGAACCTCTCATTT  
Malay       TTATTGATGGAAGTTCCACCAGGCCTAATCGCCACACACCAGCAAAGGCAGGTTATGCTATAGTACAAGCCACTAGCCCACCTCTCAGAACCTCTCATTT  
EF194101.1  TTATTGATGGAAGTTCCACCAGGCCTAATCGCCACACACCAGCAAAGGCAGGTTATGCTATAGTACAAGCCACTAGCCCACCTCTCAGAACCTCTCATTT  
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Indian      CCTTTCCATCGTGGAAATCTATCCTCAAGGAAATAACTTCTCAGTGTTCCATCTGCTATTCTACTACTCCTCAGGGATTATTCAGGCCCCCTCCCTTCCC  
Malay       CCTTTCCATCGTGGAAATCTATCCTCAAGGAAATAACTTCTCAGTGTTCCATCTGCTATTCTACTACTCCTCAGGGATTATTCAGGCCCCCTCCCTTCCC  
EF194101.1  CCTTTCCATCGTGGAAATCTATCCTCAAGGAAATAACTTCTCAGTGTTCCATCTGCTATTCTACTACTCCTCAGGGATTATTCAGGCCCCCTCCCTTCCC  
Clustal Co  ****************************************************************************************************  
 
Chinese     TACACATCAGGCTGGAGGATTTGCCCCACCCAGGACTGGCAAATTACCTTTACTCAACATGCCCTGATTCAGGAAACTAAAATACCTCTTAGTCTAAATA  
Indian      TACACATCAGGCTGGAGGATTTGCCCCACCCAGGACTGGCAAATTACCTTTACTCAACATGCCCTGATTCAGGAAACTAAAATACCTCTTAGTCTAAATA  
Malay       TACACATCAGGCTGGAGGATTTGCCCCACCCAGGACTGGCAAATTACCTTTACTCAACATGTCCTGAGTCAGGAAACTAAAATACCTCTTAGTCTAAATA  
EF194101.1  TACACATCAGGCTGGAGGATTTGCCCCACCCAGGACTGGCAAATTACCTTTACTCAACATGCCCTGATTCAGGAAACTAAAATACCTCTTAGTCTAAATA  
Clustal Co  ************************************************************* ***** ********************************  
Chinese     GACACTTTCACTGAATAAAGTAAAGGCCTTTCCTACAGGGTCTGAGAAGGCCACCACAGTCATTTCTTCCCTTCTGTCAGACACAATTCCTCAGTTTAGC  
Indian      GACACTTTCACTGAATAAAGTAAAGGCCTTTCCTACAGGGTCTGAGAAGGCCACCACAGTCATTTCTTCCCTTCTGTCAGACACAATTCCTCAGTTTAGC  
Malay       GACACTTTCACTGAATAAAGTAAAGGCCTTTCCTACAGGGTCTGAGAAGGCCACCACAGTCATTTCTTCCCTTCTGTCAGACACAATTCCTCAGTTTAGC  
EF194101.1  GACACTTTCACTGAATAAAGTAAAGGCCTTTCCTACAGGGTCTGAGAAGGCCACCACAGTCATTTCTTCCCTTCTGTCAGACACAATTCCTCAGTTTAGC  
Clustal Co  ****************************************************************************************************  
 
Chinese     CTTCCCACCTCTATACAGTCTGATAACAGACCAGCCTTTATTAGTCAAATCAGCCAAGCAGTTTTTCAGGCTCTTAGTATTCAGTGAAACCTTTATATCC  
Indian      CTTCCCACCTCTATACAGTCTGATAACAGACCAGCCTTTATTAGTCAAATCAGCCAAGCAGTTTTTCAGGCTCTTAGTATTCAGTGAAACCTTTATATCC  
Malay       CTTCCCACCTCTATACAGTCTGATAACAGACCAGCCTTTATTAGTCAAATCAGCCAAGCAGTTTTTCAGGCTCTTAGTATTCAGTGAAACCTTTATATCC  
EF194101.1  CTTCCCACCTCTATACAGTCTGATAACAGACCAGCCTTTATTAGTCAAATCAGCCAAGCAGTTTTTCAGGCTCTTAGTATTCAGTGAAACCTTTATATCC  
Clustal Co  ****************************************************************************************************  
 
Chinese     CTTACGGTCCTCCTTCTTCAAGAAAAGTAGAACGGACTAAAGGTCTTTTAAAAACACACCTCACCAAGCTCAGCCACCAGCTTAAAAAGGACTGGACAAT  
Indian      CTTACGGTCCTCCTTCTTCAAGAAAAGTAGAACGGACTAAAGGTCTTTTAAAAACACACCTCACCAAGCTCAGCCACCAGCTTAAAAAGGACTGGACAAT  
Malay       CTTACGGTCCTCCTTCTTCAAGAAAAGTAGAACGGACTAAAGGTCTTTTAAAAACACACCTCACCAAGCTCAGCCACCAGCTTAAAAAGGACTGGACAAT  
EF194101.1  CTTACGGTCCTCCTTCTTCAAGAAAAGTAGAACGGACTAAAGGTCTTTTAAAAACACACCTCACCAAGCTCAGCCACCAGCTTAAAAAGGACTGGACAAT  
Clustal Co  ****************************************************************************************************  
 
Chinese     ACTTTTACCACTTTCCCTTCTCAGAAATCAGGCCTGTCCTCAGAATGCTACAAGGTACATCCCATTTAAGCTCCTGTATAGACGCTCCTTTTTATTAGGC  
Indian      ACTTTTACCACTTTCCCTTCTCAGAAATCAGGCCTGTCCTCAGAATGCTACAAGGTACATCCCATTTAAGCTCCTGTATAGACGCTCCTTTTTATTAGGC  
Malay       ACTTTTACCACTTTCCCTTCTCAGAAATCAGGCCTGTCCTCAGAATGCTACAAGGTACATCCCATTTAAGCTCCTGTATAGACGCTCCTTTTTATTAGGC  
EF194101.1  ACTTTTACCACTTTCCCTTCTCAGAAATCAGGCCTGTCCTCAGAATGCTACAAGGTACATCCCATTTAAGCTCCTGTATAGACGCTCCTTTTTATTAGGC  
Clustal Co  ****************************************************************************************************  
 
Chinese     CCCAGTCTCATTCCAGACACCAGACCAACTTAGACTGTGCCCCAAAAAACTTGTCATCCCTACTATCTTCTGTCTAGTCATACTCCTATTCACCGTTCTC  
Indian      CCCAGTCTCATTCCAGACACCAGACCAACTTAGACTGTGCCCCAAAAANCNTGTCATCCCTACTATCTTCTGTCTAGTCATACTCCTATTCACCGTTCTC  
Malay       CCCAGTCTCATTCCAGACACCAGACCAACTTAGACTGTGCCCCAAAAAACTTGTCATCCCTACTATCTTCTGTCTAGTCATACTCCTATTCACCGTTCTC  
EF194101.1  CCCAGTCTCATTCCAGACACCAGACCAACTTAGACTGTGCCCCAAAAAACTTGTCATCCCTACTATCTTCTGTCTAGTCATACTCCTATTCACCGTTCTC  
Clustal Co  ************************************************ *.*************************************************  
 
Chinese     AACTACTCATACATGCCCTGCTCTTGTTTACACTGCCGGTTTACACTGTTTCTCCAAGCCATCACAGCTGATATCTCCTGGTGCTATCC-CAAACTGCCA  
Indian      AACTACTCATACATGCCCTGCTCTTGTTTACACTGCCGGTTTACACTGTTTCTCCAAGCCATCACAGCTGATATCTCCTGGTGCTATCCCCAAACTGCCA  
Malay       AACTACTCATACATGCCCTGCTCTTGTTTACACTGCCGGTTTACACTGTTTCTCCAAGCCATCACAGCTGATATCTCCTGGTGCTATCCCCAAACTGCCA  
EF194101.1  AACTACTCATACATGCCCTGCTCTTGTTTACACTGCCGGTTTACACTGTTTCTCCAAGCCATCACAGCTGATATCTCCTGGTGCTATCCCCAAACTGCCA  
Clustal Co  ***************************************************************************************** **********  
 
Chinese     CTCTTAACTCTTGAAGTAAATAATCTTTGCTGGCAGGACTATGCTGAATCTCCTTAGGCACTCTCTAATCAGATGTCCTAGGTCCTCCCAATTCTTAGAC  
Indian      CTCTTAACTCTTGAAGTAAATAATCTTTGCTGGCAGGACTATGCTGAATCTCCTTAGGCACTCTCTAATCAGATGTCCTAGGTCCTCCCAATTCTTAGAC  
Malay       CTCTTAACTCTTGAAGTAAATAATCTTTGCTGGCAGGACTATGCTGAATCTCCTTAGGCACTCTCTAATCAGATGTCCTAGGTCCTCCCAATTCTTAGAC  
EF194101.1  CTCTTAACTCTTGAAGTAAATAATCTTTGCTGGCAGGACTATGCTGAATCTCCTTAGGCACTCTCTAATCAGATGTCCTAGGTCCTCCCAATTCTTAGAC  
Clustal Co  ****************************************************************************************************  
 
Chinese     ATTTAATACCCATTTTTCTCCTCCTTTTATTCGGACCTTGTATCTTCCATTTAGCTTCTCAAATCATCCAAAACCGTATCCAGGCCATCACCAATCATTC  
Indian      ATTTAATACCCATTTTTCTCCTCCTTTTATTCGGACCTTGTATCTTCCATTTAGCTTCTCAAATCATCCAATACCGNATCCAGGCCATCACCAATCCTTC  
Malay       ATTTAATACCCATTTTTCTCCTCCTTTTATTCGGACCTTGTATCTTCCATTTAGCTTCTCAAATCATCCAAAACCGTATCCAGGCCATCACCAATCATTC  
EF194101.1  ATTTAATACCCATTTTTCTCCTCCTTTTATTCGGACCTTGTATCTTCCATTTAGCTTCTCAAATCATCCAAAACCGTATCCAGGCCATCACCAATCATTC  
Clustal Co  ***********************************************************************:****.*******************.***  
 
Chinese     TATACGACAAATGTTTCTTCTAACATCCCCATGATATCACCCCTTACCACAAGACCTCCCTTCAGCTTAATCTCTCCCACTCTAGGCTCCCACGCCGCCC  
Indian      TATACGANANATGTTTCTTCTAACATCCCCATGATATCACCCCTTACCACAAGACCTCCCTTCANCTTAATCTCTCCCACTCTAGGCTCCCACGCCGCCC  
Malay       TATACGACAAATGTTTCTTCTAACATCCCCATGATATCACCCCTTACCACAAGACCTCCCTTCAGCTTAATCTCTCCCACTCTAGGCTCCCACGCCGCCC  
EF194101.1  TATACGACAAATGTTTCTTCTAACATCCCCATGATATCACCCCTTACCACAAGACCTCCCTTCAGCTTAATCTCTCCCACTCTAGGCTCCCACGCCGCCC  
Clustal Co  ******* * ****************************************************** ***********************************  
 
Chinese     CTAATCCCGCTTGAAGCAGCCCTGAGAAACATCGCCCATTATCTCTCCATACCACCCCCCAAAAATTTTCGCTGCCCCAACACTTCAACACTATTTTGTT  
Indian      CTAATCCCGCTTGAAGCAGCCCTGAGAAACATCGCCCATTATCTCTCCATACCACCCCCCAAAAATTTTCGCTGCCCCAACACTTCAACACTATTTTGTT  
Malay       CTAATCCCGCTTGAAGCAGCCCTGAGAAACATCGCCCATTATCTCTCCATACCACCCCCCAAAAATTTTCGCTGCCCCAACACTTCAACACTATTTTGTT  
EF194101.1  CTAATCCCGCTTGAAGCAGCCCTGAGAAACATCGCCCATTATCTCTCCATACCACCCCCCAAAAATTTTCGCTGCCCCAACACTTCAACACTATTTTGTT  
Clustal Co  ****************************************************************************************************  
 
Chinese     TTATTTGTCTTATTAATATAAGAAGGCAGGAATGTCAGGCCTCTGAGCCCAGGCCAGGCCATCGCATCCCCTGTGACTTGCACGTATACATCCAGATGGC  
Indian      TTATTTGTCTTATTAATATAAGAAGGCAGGAATGTCAGGCCTCTGAGCCCAGGCCAGGCCATCGCATCCCCTGTGACTTGCACGTATACATCCAGATGGC  
Malay       TTATTTGTCTTATTAATATAAGAAGGCAGGAATGTCAGGCCTCTGAGCCCAGGCCAGGCCATCGCATCCCCTGTGACTTGCACGTATACATCCAGATGGC  
EF194101.1  TTATTTGTCTTATTAATATAAGAAGGCAGGAATGTCAGGCCTCTGAGCCCAGGCCAGGCCATCGCATCCCCTGTGACTTGCACGTATACATCCAGATGGC  
Clustal Co  ****************************************************************************************************  
 
Chinese     CTAAAGTAACTGAAGATCCACAAAAGAAGTAAAAACAGCCTTAACTGATGACATTCCAACATTGTGATTTGTTCCTGCCCCACCCTAACTGATAAATGTA  
Indian      CTAAAGTAACTGAAGATCCACAAAAGAAGTAAAAACAGCCTTAACTGATGACATTCCAACATTGTGATTTGTTCCTGCCCCACCCTAACTGATAAATGTA  
Malay       CTAAAGTAACTGAAGATCCACAAAAGAAGTAAAAACAGCCTTAACTGATGACATTCCAACATTGTGATTTGTTCCTGCCCCACCCTAACTGATAAATGTA  
EF194101.1  CTAAAGTAACTGAAGATCCACAAAAGAAGTAAAAACAGCCTTAACTGATGACATTCCAACATTGTGATTTGTTCCTGCCCCACCCTAACTGATAAATGTA  
Clustal Co  ****************************************************************************************************  
 
Chinese     CTTTGTAATCTCCCCCACCCTTAAGAAGGTCCTTTGTAATTCTCCCCACCCTTGAGAGTGTACTTTGTGAGATCCACACCTGCCCACCAGAGAACAAACC  
Indian      CTTTGTAATCTCCCCCACCCTTAAGAAGGTCCTTTGTAATTCTCCCCACCCTTGAGAGTGTACTTNGTGAGATCCACACCTGCCCACCAGAGAACAAACC  
Malay       CTTTGTAATCTCCCCCACCCTTAAGAAGGTCCTTTGTAATTCTCCCCACCCTTGAGAGTGTACTTTGTGAGATCCACACCTGCCCACCAGAGAACAAACC  
EF194101.1  CTTTGTAATCTCCCCCACCCTTAAGAAGGTCCTTTGTAATTCTCCCCACCCTTGAGAGTGTACTTTGTGAGATCCACACCTGCCCACCAGAGAACAAACC  
Clustal Co  *****************************************************************.**********************************  
 
Chinese     CCCTTTGACTGTAATTTTCCATTACCTTCCCTAATCCTATAAAACGGCCCCACCCCATCTCCCTTTGCTGACTCTCTTTTCGGACTCAGCCCGCCTGCAC  
Indian      CCCTTTGACTGTAATTTTCCNTTACCTTCCCT--------------------------------------------------------------------  
Malay       CCCTTTGACTGTAATTTTCCATTACCTTCCCTAATCCTATAAAACGGCCCCACCCCATCTCCCTTTGCTGACTCTCTTTTCGGACTCAGCCCGCCTGCAC  
EF194101.1  CCCTTTGACTGTAATTTTCCATTACCTTCCCTAATCCTATAAAACGGCCCCACCCCATCTCCCTTTGCTGACTCTCTTTTCGGACTCAGCCCGCCTGCAC  
Clustal Co  ******************** ***********                                                                      
 
Chinese     CCAGGTGAAATAAACAGCCTTGTTGCTCACACAAAGCCTGTTTGGTGGTCTCTTCACACGGACGCGCGTGAAAGTCATTAACAATGTTCAGTATTTTAAA  
Indian      ----------------------------------------------------------------------------------------------------  
Malay       CCAGGTGAAATAAACAGCCTTGTTGCTCACACAAAGCCTGTTTGGTGGTCTCTTCACACGGACGCGCGTGAAAGTCATTAACAATGTTCAGTATTTTAAA  
EF194101.1  CCAGGTGAAATAAACAGCCTTGTTGCTCACA---------------------------------------------------------------------  
Clustal Co                                                                                                        
 
Chinese     GAGTTCCCTCAATAAATAATACTCATTGAACCAACTCGATTTTTGaaaaaaaaaGGAAGAGTCCACTGATCGTGAAAACCTCCCTTGACTTTCTTGTCTA  
Indian      ----------------------------------------------------------------------------------------------------  
Malay       GAGTTCCCTCAATAAATAATACTCATTGAACCAACTCGATTTTTGaaaaaaaaaGGAAGAGTCCACTGATCGTGAAAACCTCCCTTGACTTTCTTGTCTA  
EF194101.1  ----------------------------------------------------------------------------------------------------  












Chinese     AAAACTTTTCAGATAGACTAGAACAAAGTTCTACAGCTAAAATGAACATAAAATCACCTGACCTATTTGCTTAACCTGCAACCACCCAAGGGGTTCACCT  
Indian      ----------------------------------------------------------------------------------------------------  
Malay       AAAACTTTTCAGATAGACTAGAACAAAGTTCTACAGCTAAAATGAACATAAAATCACCTGACCTATTTGCTTAACCTGCAACCACCCAAGGGGTTCACCT  
EF194101.1  ----------------------------------------------------------------------------------------------------  
Clustal Co                                                                                                        
 
Chinese     TGCCTGCTACCTAGACAGAGCCGATTCATTAAGACGGGAATTGCAATAGAGAAAGAGTAATTCGTGCAGAGCTGGCTGTGCGGGAGATCCGAGTTTTATT  
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Indian      ----------------------------------------------------------------------------------------------------  
Malay       TGCCTGCTACCTAGACAGAGCCGATTCATTAAGACGGGAATTGCAATAGAGAAAGAGTAATTCGTGCAGAGCTGGCTGTGCGGGAGATCCGAGTTTTATT  
EF194101.1  ----------------------------------------------------------------------------------------------------  
Clustal Co                                                                                                        
 
Chinese     ATTACTCAAATCAGTCTCCCCGAGCATTCAGGGAGCAGAGCTGTTAAGGATAACTTGGTGGGTCGGGAGAAGCCAGTGAGTCAGGAGTGCTGATTGGTCA  
Indian      ----------------------------------------------------------------------------------------------------  
Malay       ATTACTCAAATCAGTCTCCCCGAGCATTCAGGGAGCAGAGCTGTTAAGGATAACTTGGTGGGTCGGGAGAAGCCAGTGAGTCAGGAGTGCTGATTGGTCA  
EF194101.1  ----------------------------------------------------------------------------------------------------  
Clustal Co                                                                                                        
 
Chinese     GAGATGAAATCATAGGGAGTCAGAGCTGCCTTCTTGCG-TCAATCCAGTTCT  
Indian      ----------------------------------------------------  
Malay       GAGATGAAATCATAGGGAGTCAGAGCTGCCTTCTTGCGTTCAATTCAGTTCT  
EF194101.1  ----------------------------------------------------  
Clustal Co                                                        
 
 
Figure 2.8. Comparison of HERV-H sequence. Result of pairwise alignment of 
HERV-H sequences from three different ethnic groups, namely, Chinese, Indian and 
Malay together with GenBank HERV-H (NCBI: EF194101.1) are shown. Clustal 
consensus sequence (Clustal Co) is also shown. Black background indicates sequence 





2.5  Discussion 
 HERVs represent the trail of successful ancient retroviral infection of 
the human germ line. As a consequence of the persistence of vertical 
transmission, about 8% of the human genome is occupied by HERVs (Lander 
et al., 2001). Their existence, through millions years of evolution, implies that 
HERVs have overcome the stringent evolutionary selection and successfully 
domesticated into the host genomes although the accumulation of mutations, 
deletions, frame shifts or premature stop codons as well as hypermethylation 
of the promoter sites may have rendered them defective or inactive (Blikstad 
et al., 2008). While retroelements like Alu (in SINE) has been known to link 
to breast cancer and X-linked agammaglobulinemia, and L1 (in LINE) to 
haemophilia A and B, and Duchenne muscular dystrophy, as well as SVA to 
Fukuyama muscular dystrophy and neutral lipid storage disease with 
myopathy (Solyom and Kazazian, 2012, Cardelli and Marchegiani, 2012), the 
role  of HERVs contributing to carcinogenesis remains unclear and 
perplexing.  
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 To the author’s knowledge, this is the first study presenting the 
prevalence of HERV-H in a Southeast Asian population. HERV-H was 
present in 89.3% of the sample Singapore population. Of late, one study 
involving 20 Western Asian subjects has reported that up to 87% of HERV-H 
insertional polymorphism was observed in all their subjects  (Guliyev et al., 
2013). These findings corroborate with the report that HERV-H, a Class I 
ERVs that is considered one of the oldest classes of ERVs (Class I and III), is 
occupying a relatively higher proportion in the human genome (Hohn et al., 
2013).  
 
 Nevertheless, the differential prevalence rates of HERV-K elements in 
different human races (Woo et al., 2013, Jha et al., 2009, Turner et al., 2001) 
imply that the domestication process of retroviruses may not necessarily lead 
to the fixation of proviral DNA in the human genome. Although there may be 
times when the replicative activity of retrovirus is high and this can lead to the 
outbreaks of integration (Belshaw et al., 2005), the processes of evolution are 
capable of modulating genetic diversity.  To elaborate, both selective forces 
and random genetic drift are capable of either fixing or losing the retroviral 
elements. In addition, population bottlenecks may also contribute to a lesser 
extent of genetic variation. It is noteworthy to find that “jumping genes” like 
retrotransposons are subjected to fixation or extinction in the human 
population during the course of evolution (Figure 2.3). Akin to gene knockout 
experiment in vitro, the insertional polymorphisms, fixed or loss of 
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endogenous retroviral elements in the genome, might provide the means of 
examining the role of HERV in diseases (Moyes et al., 2007).  
 
 A recent debate about the presence of HERV-K found in the genome 
sequences of archaic Neanderthal and Denisovan fossils (both ~40,000 years 
old), are indeed found in the genomes of modern humans reveals the process 
of integration is not completely fixed. To elaborate, HERV-K elements that 
were found in Neanderthals and Denisovans, were initially reported to be 
absent in modern human reference genome. With more analyses performed on 
many new genome sequences of modern-day humans, it is realised that these 
HERV-K elements are indeed present in these modern-day humans. This 
demonstrates that the HERV-K elements are present in the genome at 
fluctuating frequencies, a result of the effects of genetic drift over the years 
(Marchi et al., 2013, Agoni et al., 2012). On the same note, the loss of HERV-
H gene could occur over many generations as evidenced in human evolution 
(Mager and Freeman, 1995). Taken together, the high prevalence rate of 
HERV-H in the sample Singapore population provides a logical basis to 
conduct further studies on the role of HERV-H in colorectal carcinogenesis. 
To put it in another way, a low distribution frequency or even extinction of 
HERV-H in the population genetics of Singapore would sensibly negate the 
needs to further investigate the causal role of HERV-H in oncogenesis. 
 
 Knowing that HERV-H is highly prevalent in the sample local 
population, a further close examination of the three contiguous sequences 
from 3 different ethnic groups was performed and revealed a high level of 
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conservation, up to 99%. Generally, highly conserved sequences are regarded 
as functional and biologically important. However, it is unclear why these 
proviral sequences remain undisturbed and well-fixed over long periods of 
evolutionary history. A thorough evaluation of the biological significance of 
this evolutionarily conserved region is beyond the current scope of this study, 
but this observation obviously warrants further investigations. On this note, 
putative coding regions were analysed and expression of such a putative 
peptide has led to some interesting findings with regard to HERV-H in 
carcinogenesis. These findings will be discussed in the following chapter. 
 
 In summary, there is a high prevalence of HERV-H in the sample 
Singapore population and this high distribution frequency is independent of 
factors like gender. Additionally, the percentage of sequence identities for 
HERV-H between different ethnic groups is generally very high, suggesting 
that the HERV-H region is well conserved.   The findings of this study could 
therefore be the basis for future HERV-H molecular and population genetic 
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CHAPTER 3 
ROLE OF HERV-H IN COLORECTAL CARCINOGENESIS 
3.1 Introduction 
 Cancer is a devastating disease and incurs an immerse toll on those 
afflicted everywhere (Bray et al., 2013). It is a leading cause of death in most 
countries and the escalating healthcare expenses associated with cancer 
treatment (Mariotto et al., 2011, Warren et al., 2008) exact huge financial 
burdens on patients and their families. The substantial amounts of money 
spent on cancer research (Eckhouse et al., 2008) has not abated as healthcare 
administrators continue to support the search for new drugs and better 
treatment options for cancer patients. In Singapore, cancer was among the 
leading causes of death in 2006 – 2011 (Teo and Soo, 2013). Hence, the 
burden of cancer presents a major public health problem that requires 
continuous governmental support to combat the scourge of cancer, especially 
when the multifactorial pathogenesis of carcinogenesis is always evolving 
(Hanahan and Weinberg, 2011).  
  
3.2 Colorectal cancer 
 According to GLOBOCAN 2008, a database created under the 
auspices of the International Agency for Research on Cancer, World Health 
Organization, colorectal cancer, cancer of the large bowel (colon and rectum), 
is the third most common cancer in men and the second in women (Ferlay et 
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al., 2010). Approximately 60% of the cases occur in developed countries. 
Incidence rates vary considerably in both sexes worldwide, the highest rates 
being in Australia/New Zealand and Western Europe, the lowest in Africa 
(except Southern Africa) and South-Central Asia, and intermediate in Latin 
America. Incidence rates are substantially higher in men than in women 
(overall ratio 1.4:1). It accounts for 8% of all cancer deaths, making it the 
fourth most common cause of death from cancer. 
 Over the past four decades, Singapore has shown a dramatic increase 
in the incidence rate of colorectal cancer. With an annual increasing average 
rate of approximately 2.6% and 2.35% for men and women respectively, 
colorectal cancer is now the most frequent cancer when both genders are 
combined (Wong and Eu, 2007, Ministry of Health, 2010, Teo and Soo, 
2013). 
 The development of colorectal cancer is associated with many 
contributing risk factors. An overview of these risk factors is summarised in 
Table 3.1. The classic description of colorectal carcinogenesis is the adenoma-
carcinoma sequence and multistep tumorigenesis, together with various 
genetic alterations and several biological pathways (Fearon and Vogelstein, 
1990, Markowitz and Bertagnolli, 2009, Cappell, 2008). An overview of these 
hereditary genetic alterations is represented in Table 3.2. It is noteworthy that 
the majority of colorectal cancers (up to 85%) do not develop in association 
with hereditary genetic variations. In fact, these sporadic colorectal cancers 
involves the accumulation of sequential mutations of several key signalling 
pathways, mediating the transitional phase of normal mucosa-to-benign 
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adenoma-to-severe dysplasia-to-frank carcinoma. APC mutations, K-ras 
mutations, loss of 18q (including DCC, SMAD2 and SMAD4) and deletion of 
17p (TP53), together with DNA methylation and malfunction of the mismatch 
repair genes, are the molecular events associated with sporadic colorectal 
cancers (Cunningham et al., 2010). 
 
Table 3.1. Risk factors for colorectal cancer (Cappell, 2008, Centers for Disease 
Control and Prevention, 2011, American Cancer Society, 2012) 
 
Parameters Proposed mechanism 
Epidemiology 
Old age Acquired colonocyte mutations accumulate with 
age 
Living in highly industrialised nations, 
e.g. US 
Dietary and environmental carcinogens 
Diet 
Low fruit and vegetable Anticarcinogenic substances in fruits and 
vegetables 
 (e.g., folic acid) 
Obesity Carcinogens in an unhealthy diet or possible role 
of abnormal insulin levels in carcinogenesis 
Social habits 
Smoking cigarettes Carcinogens present in tobacco; associated with 
MSI 
Alcohol May promote cell proliferation, inhibit DNA 
repair, contribute  abnormal DNA methylation; 
suppress tumour immune surveillance, alter 
composition of bile 
acids, induce cytochrome p450 enzymes to 
activate 
carcinogens or low levels of folic acid 
Genetics/family history 
FAP (familial adenomatous polyposis) Develops hundreds of adenomatous colonic 
polyps. Inevitably develops colon cancer 
resulting from small but significant risk for 
malignant transformation in each adenoma 
Gardner’s syndrome Variant of FAP 
HNPCC (Lynch syndrome)  
 
Mutant mismatch repair gene leads to 
accumulation of genetic mutations, including 
mutations of tumour suppressor genes 
Peutz-Jeghers syndrome  
 
Syndromic hamartomatous polyps occasionally 
may transform to adenomas 
Juvenile polyposis Syndromic juvenile polyps can transform to  
adenomas and then cancers over time 
Family history of nonsyndromic colon 
cancer 
Postulated shared genetic factors leading to mild 
susceptibility to colon cancer and possibly 
shared environmental factors 
Hyperplastic polyposis Genetic mutation in hyperplastic polyposis 
seems to predispose to colon cancer 
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Inflammatory bowel disease 
Chronic ulcerative colitis Dysplasia and genetic mutations associated with 
mucosal injury and repair 
Chronic Crohn’s colitis Dysplasia and genetic mutations associated with 
cell injury and repair 
 
History of prior neoplasia 
Colonic adenomatous polyps Precursor lesions of colon cancer 
Prior colon cancer Genetic predisposition or environmental factors 
Other 
Pelvic radiation Carcinogenic effects resulting from radiation-
induced 
mutations 
Streptococcus bovis bacteraemia May promote colonocyte proliferation 
Ureterosigmoidostomy Carcinogens excreted in urine or colonic 
mucosal proliferation during repair after urine-
induced mucosal injury 
Acromegaly Growth hormone promotes proliferation of 
preexisting colonic adenomas and cancers 
Diabetes mellitus Insulin may modulate colonocyte proliferation 
Prior cholecystectomy Continuous colonic exposure to potentially 
carcinogenic bile acids after cholecystectomy 
Lifestyle factors 
Physical inactivity Physical activity may stimulate 
immunosurveillance 
and stimulate intestinal peristalsis to decrease 
mucosal contact with faecal carcinogens 
Low calcium  
 
Calcium binds to bile acids that otherwise are 
potentially colonotoxic 
High fat Various theories (e.g., increased bile secretion to 
induce cell proliferation) 
High red meat  Animal fat in red meat or carcinogens (e.g., 
nitrosamines) 
Low selenium Selenium can help neutralize toxic free radicals 
due to antioxidant effects 
Low folate  Folate needed for DNA synthesis and repair 
Low carotenoid diet  Carotenoids can help neutralize free radicals 
resulting from antioxidant effects 
Low fiber diet  Dilution of carcinogens in stool due to increased 
stool bulk and stool water with a high fibre diet 
 
 
Table 3.2. Inherited colorectal cancer syndromes (Cheah, 2009, Gryfe, 2009) 
Syndrome Associated genes 
Hereditary non-polyposis colorectal 
cancer (HNPCC) or Lynch syndrome 
MSH2, MLH1, MSH3, MSH6, PSM1, 
PSM2 
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Familial adenomatous polyposis (FAP) 
and Variants:  
- Gardner 
- Turcot 
- Attenuated FAP 
APC 
Hamartomatous polyposis syndromes 
 Juvenile polyposis syndrome (JPS) SMAD4, BMPR1A 
 Peutz-Jeghers syndrome (PJS) LKB1 
 Cowden syndrome PTEN 






Hyperplastic/serrated polyposis syndrome Yet to be elucidated 
 
3.3 Oncogenic viruses 
 Viral infections have been reported as aetiological agents in various 
diseases. In recent years, many researchers have put forward the notion that 
infectious agents are capable of transforming the normal cells, and directing 
the infected host to malignancy. Oncogenic viruses like Epstein–Barr virus 
(EBV), hepatitis B virus(HBV), human papillomaviruses (HPV), human T-
cell lymphotropic virus type 1 (HTLV-1), hepatitis C virus (HCV), and 
Kaposi’s sarcoma-associated herpesvirus (KSHV) are the 6 viruses classified 
by the International Agency for Research on Cancer as being “carcinogenic to 
humans”. To this end, approximately 11% of cancers are attributable to 
exogenous viruses (Parkin et al., 1999).  
 Human endogenous retroviruses have been associated with the 
pathogenesis of cancer. Retrovirus-related elements have been reported to be 
detected in cancers like seminomas, testicular teratocarcinomas and 
choriocarcinomas as well as certain breast cancers, small-cell lung 
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carcinomas, renal cancers and leukaemias (Ryan, 2004). However, the role of 
these transcripts remains poorly defined. On the other hand, studies have 
indicated that immune responses to the human endogenous retroviral proteins 
are closely associated with the progression or the prognosis of cancer. These 
include the HERV-K gag protein in prostate cancer (Reis et al., 2013) and the 
HERV-K env protein in breast cancer (Zhao et al., 2011). 
 
3.4 Human endogenous retroviruses 
 The human endogenous retroviruses were first reported in 1981 
(Martin et al., 1981). Approximately 8% of the human genome is occupied by 
HERVs (Bannert and Kurth, 2004, Lander et al., 2001)  and this was thought 
to be the result of retroviral proviruses inserting themselves into the germline 
of human ancestors 40 million years ago (Barbulescu et al., 1999). Obviously, 
the initial infection of the germline must have overcome several factors which 
include the host immune system (Baumann, 2006) that encompasses innate 
antiretroviral protein activity like TRIM 5 (Towers, 2005), APOBEC3G 
(Cullen, 2006) and siRNA (Blikstad et al., 2008). In the course of evolution, 
the accumulation of mutations, truncations, frame shifts or premature stop 
codons as well as hypermethylation of the promoter sites may have rendered 
the retroelements to be defective or inactive (Blikstad et al., 2008). However, 
there remains a potential that these retroelements may affect the stability of 
the genome through illegimate recombination or hypomethylation (Schulz et 
al., 2006).  
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 While the studies of retroviruses have enhanced our understanding on 
the molecular biology of cancer, development, differentiation and gene 
regulation, research on endogenous retroviruses is just beginning. Notably, 
studies on the association of cancers with HERVs have focused on the 
expression of retroelements. The discovery of Rec and Np9 of HERV-K has 
shed some light on tumorigenesis. Both Np9 and the Rev-like regulatory 
protein, Rec, interact with the promyelocytic leukaemia zinc finger protein 
PLZF (Boese et al., 2000), resulting in an abrogation of transcriptional 
repression of the c-myc gene. As a consequence, increased cell proliferation 
and cell survival ensue. 
 
3.4.1 HERV-H in colorectal cancer 
 Recent clinical findings reported that HERV-H is selectively expressed 
in colon cancers but not in normal tissues (Alves et al., 2008, Liang et al., 
2009, Liang et al., 2007b, Wentzensen et al., 2004, Wentzensen et al., 2007). 
Specifically, different transcripts of HERV-H, namely, gag (Alves et al., 
2008) and env (Wentzensen et al., 2004) were observed in these studies 
involving patient samples (Table 3.3). Concordance between the findings of 
these four clinical studies performed at different geographical locations with 
divergent populations involved strongly suggests that HERV-H may play a 
role in colorectal carcinogenesis. The findings from these studies also revealed 
HERV-H was expressed in at least 50% of colorectal cancers. In fact, the 
study by Liang and colleagues reported 95% of their tumour cases were 
associated with HERV-H expression (Liang et al., 2009). Additionally, about 
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22% of colorectal adenomas were found to demonstrate HERV-H 
transcriptional activity.  
 
Table 3.3. Clinical findings of HERV-H expression in colorectal cancers. 
Sample size HERV-H up-regulation Transcript Reference 
21 tumour-normal 
tissue matched pairs 
16/21 (76%) env 
(Wentzensen et al., 
2004) 
14 tumour-normal 
tissue matched pairs 
 
34 tumour-normal 
tissue matched pairs 
 
36 tumour-normal 
















(Wentzensen et al., 
2007) 
25 tumour samples 
11/18 (60%) 







gag (Alves et al., 2008) 
20 tumour-normal 
tissue matched pairs 
19/20 (95%) gag (Liang et al., 2009) 
  
 
 Although the regulatory mechanism of the expression of HERV 
mRNA remains poorly understood, it is postulated that transducing agents like 
hormonal and environmental signals may activate the 5’ long terminal repeat 
(LTR) of HERV and lead to consequential downstream transcriptional 
activities (Wentzensen et al., 2007). Based on the ORFs of HERV-H 
transcripts, a putative gag protein of 93 amino acids would be generated, but it 
is not known how this putative protein would contribute to tumour 
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progression. Interestingly, a recent finding has demonstrated that the 
expression of HERV-K transmembrane envelope proteins inhibits immune 
cell activation and modulates IL-10 release. This suggests that the 
transmembrane protein may suppress the immune system and thereby prevent 
the rejection of tumour cells and facilitate the process of carcinogenesis 
(Morozov et al., 2013). 
 Nevertheless, the role of HERV-H in colorectal carcinogenesis 
remains to be elucidated. To investigate how HERV-H is involved in 
tumorigenesis, we examined the effect of HERV-H overexpression on human 
colorectal cancer cell lines. Specifically, the ability to proliferate, migrate and 
invade was studied as these characteristics demonstrate important aspects of in 
vivo tumour biology. A knockdown assay was also conducted to study the 
effect of reduced HERV-H expression on colorectal cancer cells. In addition, 
the expression levels of CD133 and CD44, the widely-used cell surface 
markers for colon cancer stem cells (O'Brien et al., 2007, Dalerba et al., 2007), 
were also examined. These studies sought to characterise the mechanisms by 
which HERV-H contributes to colorectal carcinogenesis.  
 
3.5 Materials and Methods 
3.5.1 Cell lines and culture conditions 
 HT29, a human colon adenocarcinoma cell line from a 44-year-old 
Caucasian female (Fogh, 1975) and LS174T, a human colon adenocarcinoma 
cell line from a 58-year-old Caucasian female (Tom et al., 1976) were 
obtained from the NUH-NUS Tissue Repository at the National University 
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Hospital. HT29 cells and LS174T cells were routinely cultured in McCoy’s 
5A Medium supplemented with 10% fetal bovine serum (FBS) and in 
Minimum Essential Medium (MEM) α supplemented with 10% fetal bovine 
serum, respectively. Both cell lines were maintained in a humidified 
atmosphere of 5% CO2 in air at 37˚С and used when in the log phase of 
growth. 
 
3.5.2 Plasmid generation 
 The plasmid pEGFP-N2 (Clontech, Palo Alto, California, United 
States) was a kind gift from Dr Wang Cheng, Duke-NUS Graduate Medical 
School Singapore.  pEGFP-N2:HERV-H  was constructed by amplification of 
HERV-H  with the primer pair A (5′- ctc AAG CTT atg ggc aac ctt cca tcc t -
3′) and B (5′- cgt GGA TCC cgg aag gga cgg atg tgt aa -3′) to provide HindIII 
and BamHI restriction sites without the stop codon, respectively. The 
restriction sites for the primer pair are represented by uppercase letters. The 
amplified fragment was digested with HindIII and BamHI and inserted into 
the HindIII and BamHI sites of the pEGFP-N2 vector. The inserted fragment 
of the construct was sequenced and verified. The resulting pEGFP-N2:HERV-
H encoded a 93 amino acid-HERV-H tagged with a green fluorescent protein 




Chapter 3: Role of HERV-H in colorectal carcinogenesis 
 
Page | 69  
 
(B) 
Atgggcaacc ttccatcctc cattcctcct tctcccttag cctgtgtgct caagaactta 
aaacctcttc aactcacacc tgacctaaaa cctaaatgcc tcattttctt ctgcaacacc 
gcttggcccc aatacaaact tgacaatggc tctaaatggc cagaaaatgg cactttcgat 
ttctccatcc tacaagacct aaataatttt tgtcaaaaaa tgggcaaatg gtctgaggtg 
cctgatgtcc aggcattctt ttacacatcc gtcccttccG ggatccaccg gccggtcgcc 
accatggtga gcaagggcga ggagctgttc accggggtgg tgcccatcct ggtcgagctg 
gacggcgacg taaacggcca caagttcagc gtgtccggcg agggcgaggg cgatgccacc  
tacggcaagc tgaccctgaa gttcatctgc accaccggca agctgcccgt gccctggccc 
accctcgtga ccaccctgac ctacggcgtg cagtgcttca gccgctaccc cgaccacatg 
aagcagcacg acttcttcaa gtccgccatg cccgaaggct acgtccagga gcgcaccatc 
ttcttcaagg acgacggcaa ctacaagacc cgcgccgagg tgaagttcga gggcgacacc 
ctggtgaacc gcatcgagct gaagggcatc gacttcaagg aggacggcaa catcctgggg 
cacaagctgg agtacaacta caacagccac aacgtctata tcatggccga caagcagaag 
aacggcatca aggtgaactt caagatccgc cacaacatcg aggacggcag cgtgcagctc 
gccgaccact accagcagaa cacccccatc ggcgacggcc ccgtgctgct gcccgacaac 
cactacctga gcacccagtc cgccctgagc aaagacccca acgagaagcg cgatcacatg 
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Figure 3.1. The pEGFP-N2:HERV-H expression construct. (A) Schematic 
drawing of pEGFP-N2:HERV-H plasmid map. The amplified 298bp-HERV-H is 
inserted into the multiple cloning site of the pEGFP-N2 vector. With CMV early 
promoter, HERV-H is synthesized as a fusion protein, tagging on to the N terminus 
of EGFP. A neomycin resistance cassette (Neor), consisting of the SV40 early 
promoter, the kanamycin/neomycin resistance gene of Tn5, and polyadenylation 
signals from the Herpes simplex virus thymidine kinase gene, allows stably 
transfected eukaryotic cells to be selected using G418. Plasmid map was generated 
using PlasMapper Version 2.0 (Dong et al., 2004) (B) The sequence of fusion HERV-
H:GFP in plasmid. Blue highlight: Start/stop codon; Grey highlight: HERV-H; Green 
highlight: GFP. (C) NCBI Nucleotide BLAST analysis of actual sequencing result of 
fusion HERV-H:GFP (http://blast.ncbi.nlm.nih.gov/Blast.cgi) is shown. 
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3.5.3 Transfection and stably transfected cell lines generation 
 Transfection of HT29 and LS174T cells was carried out in serum-free 
McCoy’s 5A and MEMα respectively, using Lipofectamine 2000 CD 
(Invitrogen, USA) in a 6-well plate according to the manufacturer’s 
instructions. Stably transfected HT29 and LS174T cells were generated by 
selecting the successfully integrated neo gene using the antibiotic G418 at the 
concentration of 800 g/mL. Selection took place in a 6-well plate, where it 
took approximately 3-4 weeks for foci of G418-resistant colonies to appear. 
Thereafter, the resistant foci were clonally expanded over an additional 2–3 
weeks. Colonies were then picked and expanded on a 6-well plate, followed 
by growth in a T25 tissue culture flask.  
 After 3–4 weeks, adherent transfected cells were trypsinized into 
single-cell suspensions and sorted by flow cytometry (DB FACSVantage 
SE™). To facilitate the recovery of large numbers of transfected cells, pre-
sorting triggered by fluorescence was carried out. Using forward scatter as a 
triggering signal, the final sort was grouped into GFP-positive and GFP-
negative populations. The resulting GFP positive cells were resuspended in 
complete medium with G418 and cultured in a humidified atmosphere of 5% 
CO2 in air at 37˚С and used when in the log phase of growth. 
 
3.5.4 Subcellular localization 
 For subcellular localization assays, transfected cells were grown to 
about 30% density on glass coverslips and fix in 1% paraformaldehyde in 
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phosphate-buffered saline (PBS) for 20 minutes at room temperature. 
Following 1X PBS wash, the cells were stained with Hoechst 33342 at a final 
concentration of 5g/mL for 15 minutes in the dark. Stained cells were 
imaged under the Olympus IX71 fluorescent microscope, equipped with 
cellSens Standard 1.5 software (Olympus). 
 
3.5.5 Proliferation assay 
 Cell proliferation assays were carried out by seeding cells at a density 
of 2×105 viable cells to each well of a 6-well plate. At the indicated time 
points, the cells were trypsinized and counted using a Luna™ automated cell 
counter (Logos Biosystems, Korea) after trypan blue staining. All results were 
presented as means ± standard deviation from triplicate wells. 
 
3.5.6 Invasion assay 
 Invasion assays were performed in 24-well plate transwell chambers 
with 8m-pore polycarbonate filter inserts (the CHEMICON cell invasion 
kit). Briefly, a total of 1.25 x 105 cells were seeded on the ECM-coated inserts 
in 50 L of serum-free medium inserts for invasion assays. The lower 
chambers were filled with 500 L of 10% FBS-supplemented McCoy’s 5A or 
MEMα medium. After 24 hours, cells on the upper side of the filter were 
removed by aspiration and the cells on the lower surface of the insert were 
dislodged by cell detachment solution. Detached cells were subsequently lysed 
and stained with CyQuant GR Dye. An aliquot of the lysis/dye mixture was 
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transferred to a 96-well plate for fluorometric reading using 485/535 nm filter 
set. The RFU value represents the invasive ability. Assays were performed in 
triplicates. Data were presented as mean RFU values ± standard deviation 
from triplicate wells.  
 
3.5.7 Scratch assay 
 HT29 cells transfected with HERV-H:GFP or with GFP (2 x 105) were 
seeded in triplicate in a 6-well tissue culture plate and cultured in McCoy’s 5A 
containing 10% fetal bovine serum, to form confluent cell monlayers. A single 
scratch was then made with a 10L pipette tip across the cell layer and rinsed 
twice with PBS to remove non-adherent cells. The wounded monolayers were 
subsequently cultured in medium containing 10% fetal bovine serum at 37°C.  
The repopulation of the denuded area was monitored by capturing images 
every 24 hours for 72 hours at fixed positions. All cell cultures were analysed 
in parallel and triplicate measurements were taken. Cell migration was 
assayed by evaluating closure of a linear wound over these 72 hours. Areas 
were quantified by image analysis using Wimasis image analysis software 
(ibidi GmbH, Germany). The percentage of wound (scratch area) at 0 h 
(control) was arbitrarily assigned as 100%.  
 
3.5.8 Sphere-forming ability of LS174:HERV-H_GFP  
 Adherent colorectal cells were trypsinized into single-cell suspensions 
and were plated into 6-well plates with a density of 2 x 105 cells per well. 
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Cells were grown and complete medium was refreshed every 3 days. Sphere 
formation was monitored at 3, 6, 9 and 12 days. At day 12, pictures were 
taken with an inverted microscope (IX70 Olympus). The diameter of the 
spheres in all wells was measured using DP2-BSW software (Olympus) from 
saved images captured at 10x magnification. An analysis of large sphere 
(>100 m) formation ability was analysed. 
 
3.5.9 Revival of HERV-H_GFP- and GFP-transfected LS174T and 
HT29 cells after 30 days of serum deprivation 
 Adherent colorectal cells were trypsinized into single-cell suspensions 
and were plated onto 6-well plates with a density of 2 x 105 cells per well. 
Cells were allowed to attach for 24 hours in medium supplemented with 10% 
fetal bovine serum. Thereafter, cells were grown in medium without fetal 
bovine serum. Medium was refreshed at every 5-day intervals for 25 days. At 
day 30, the remaining adherent cells in the 6-well plates were refreshed with 
medium supplemented with 10% fetal bovine serum.  This day was designated 
as post-famine day 0. Cell growth was monitored at 0, 2, 4 or 6 days post-
famine and the colonies were photographed in two randomly chosen 
microscopic fields per well, using the IX70 inverted microscope (Olympus). 
The diameter of the colonies in all wells was measured using DP2-BSW 
software (Olympus) from saved images captured at 10x magnification. 
Experiments were done in triplicates.  
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3.5.10 Detection of CD44 and CD133 expression by flow cytometry 
 Adherent colorectal cells were trypsinized into single-cell suspensions 
and rinsed once with PBS. Dissociated cells were stained with PE-conjugated 
anti-CD44 antibody or anti-CD133 antibody (Miltenyi Biotech, USA) and 
incubated for 30 minutes in the dark at 4°C. Mouse IgG1-PE (Miltenyi 
Biotech, USA) was the isotype control antibody.  After incubation, the cells 
were washed once in PBS and resuspended in 500 L cold PBS with 10% 
FBS for flow cytometry analysis within 1 hour.  The flow cytometry analysis 
of cells was carried out using the FACSCalibur flow cytometry system 
(Decton Dickinson, USA) with 50,000 events being counted for each case. 
 
3.5.11 Knockdown of HERV-H by Dicer-Substrate small interfering 
RNA (DsiRNA) 
3.5.11.1 DsiRNA Design 
 A total of three DsiRNA targeted against HERV-H mRNA were 
designed (Integrated DNA Technology, Coralville, IA, USA). The sequences 
of the three DsiRNAs are as follows: 
 
(1) WH 1: 
Sense sequence 5’ – CCU CCU UCU CCC UUA GCC UGU GUG C – 3’ 
Antisense sequence 5’ –GCA CAC AGG CUA AGG GAG AAG GAG GAA– 
3’ 
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(2) WH 2: 
Sense sequence 5’ – CUC CAU CCU ACA AGA CCU AAA UAA T– 3’ 
Antisense sequence 5’ – AUU AUU UAG GUC UUG UAG GAU GGA 
GAA– 3’  
 
(3) WH 3: 
Sense sequence 5’ – CAA AUG GUC UGA GGU GCC UGA UGT C– 3’ 
Antisense sequence 5’ – GAC AUC AGG CAC CUC AGA CCA UUU GCC– 
3’. 
 
A validated negative control duplex (scrambled DNA) with the following 
sequences was used: 
Sense sequence 5’ –CGU UAA UCG CGU AUA AUA CGC GUA T– 3’ 
Antisense sequence 5’ –AUA CGC GUA UUA UAC GCG AUU AAC GAC– 
3’ 
 
3.5.11.2 DsiRNA Transfection 
 The day before transfection, cells were trypsinized, diluted with fresh 
medium and transferred to 6-well plates (2 x 105cells/well). 2nM or 10nM 
DsiRNAs were transfected using transfection reagent (Lipofectamine 
RNAiMax) according to manufacturer’s protocol (Invitrogen, USA). 
Routinely, transfection was carried out at about 10–20% cell confluency as 
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3.5.11.3 Effect of HERV-H targeting DsiRNA at the mRNA level 
 At 72 hours after DsiRNA transfection, cells were harvested and total 
RNA was prepared by RNeasy® mini kit (Qiagen, Germany). Harvested total 
RNA was quantitated using Nanodrop 100 spectrophotometer 
(ThermoScientific, USA) and 1g of the total RNA was then reverse 
transcript using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
USA) in accordance to the manufacturer’s instructions. Briefly, 1g of the 
extracted RNA was mixed with enzyme reverse transcriptase and buffer to a 
final volume of 20L and subjected to thermal profile of 25ºC for 5 minutes, 
42ºC for 30 minutes followed by 85ºC for 5 minutes, in accordance to the 
manufacturer’s instructions. 
 The primers used for the house-keeping gene  actin were the forward 
primer: 5′- ACC AAC TGG GAC GAC ATG GAG AAA-3′ and the reverse 
primer 5′-TAG CAC AGC CTG GAT AGC AAC GTA-3′. 
 The primers used for HERV-H were the forward primer: 5’- CTT CCC 
TCC GTG TCT TTA CG-3’ and the reverse primer: 5’- AAG ATT AGA 
CAC ACT CAG CAA CG-3’. 
 The quantitative real time polymerase chain reaction (qRT-PCR) was 
performed using the iTaq™ Universal SYBR® Green Supermix (Bio-Rad 
Laboratories, USA) on the BioRad CFX96TM Real-Time PCR system (Bio-
Rad Laboratories, USA). Briefly, 1µL of cDNA and 0.5µL of the forward and 
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the reverse primers were added to iTaq™ Universal SYBR® Green Supermix. 
The reaction mix was then subjected to thermal profile of denaturation at 95ºC 
for 30 seconds, followed by amplification and quantification in 40 cycles at 
95ºC for 5 seconds  followed by 60ºC for 30 seconds. At the end of 
amplification cycles, melting temperature analysis was performed by the 
BioRad CFX96TM Real-Time PCR system (Bio-Rad Laboratories, USA). 
Relative gene expression was quantified based on 2-∆∆CT method (Livak and 
Schmittgen, 2001). 
 
3.5.11.4 Effect of DsiRNA constructs on cell proliferation 
 At 72 hours after DsiRNA transfection, the effect of WH1, WH2 and 
WH3 DsiRNA on cell viability was determined by trypan blue assay using a 
Luna™ automated cell counter (Logos Biosystems, Korea). 
 
3.5.12 Statistical methods 
 Values are expressed as mean plus or minus standard deviation (SD) 
for 3 experiments. Unless specified, data differences were subject to statistical 
analysis by paired student’s t-test using STATGRAPHICS® Centurion XVI 
version 16.1.05 (Statpoint Technologies, USA). P values of <0.05 were 
considered statistically significant. All statistical tests were based on 2-sided 
probability. 
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3.6 Results 
3.6.1 Subcellular localization of HERV-H 
 To examine the subcellular localization of HERV-H, a fusion construct 
of enhanced green fluorescent protein (GFP) linked to the N terminus of 93-
amino-acid HERV-H was generated. The colocalization of fusion construct 
HERV-H:GFP was studied and it was found that HERV-H:GFP fusion protein 
demonstrated cytoplasmic staining (Figure 3.3). Previous studies have also 
shown that retroviral gag proteins are predominantly in the cytosol (Yu et al., 
1995, Resh, 2005). For the control, free GFP was observed to be expressed 
throughout the cell including nuclei (Figure 3.2). 



















Figure 3.2.  Intracellular localization of GFP. HT29 cells were transfected with 
plasmid pEGFP-N2 producing the indicated free GFP. (A) Phase contrast image of 
transfected HT29. (B) Nuclei of transfected HT29 were stained with Hoechst 33342. 
(C) Transfected HT29 analyzed for GFP fluorescence. (D) The merged image shows 
colocalization of nuclei and GFP. 
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Figure 3.3.  Intracellular localization of HERV-H. HT29 cells were transfected 
with plasmid pEGFP:HERV-H  producing the fusion protein HERV-H tagged with 
GFP. Cytoplasmic HERV-H:GFP is stable in transfected cells. (A,E) Phase contrast 
image of transfected HT29. (B,F) Nuclei of transfected HT29 were stained with 
Hoechst 33342 (C,G) Transfected HT29 analyzed for HERV-H:GFP fusion protein 
fluorescence. (D,H) The merged image shows colocalization of nuclei and HERV-
H:GFP fusion protein. 
 
3.6.2 Proliferation assay 
 To investigate the effect of HERV-H overexpression on the rate of 
proliferation, HT29 and LS174T cells were transfected with pEGFP-
N2:HERV-H to upregulate the HERV-H expression levels. Compared to the 
control group which is the respective cell line transfected with empty plasmid 
pEGFP-N2, HERV-H overexpression enhances the proliferative potency of 
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Figure 3.4. Effect of HERV-H overexpression on the rate of proliferation of 
HT29 and LS174T cells. (A) HT29 cells were transfected with plasmid pEGFP-
N2:HERV-H or empty plasmid pEGFP-N2. (B) LS174T cells were transfected with 
plasmid pEGFP-N2:HERV-H or empty plasmid pEGFP-N2. At the indicated time 
points, the cells were trypsinized and counted using a Luna™ automated cell counter 
(Logos Biosystems, Korea) after Trypan blue staining. Experiments were done in 
triplicates. ***, P <0.001; *, P < 0.05.   
 
 
3.6.3 Invasion assay 
 Cell invasion through the extracellular matrix (ECM) is an important 
process during tumour metastasis. Tumour cells initiate invasion by adhering 
to and spreading along the blood vessel wall. The invasion capability of cells 
is revealed by their ability to penetrate into the ECM-coated filter membrane 
in the transwell invasion chamber assay. The invasion potential of the HERV-
H transfected colorectal cancer cells was examined and the results obtained 
revealed there was no observable difference in the invasiveness potential of 
the HERV-H transfected HT29 and LS174T cells and the respective control 
cells which were transfected with empty plasmid pEGFP-N2 (Figure 3.5). 
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Figure 3.5. HERV-H does not promote colorectal cancer cell invasion. Cells were 
allowed to invade towards 10% FBS for 24 h. Fluorescence measurements were taken 
as described. Data were presented as mean RFU values ± standard deviation from 
triplicate wells.  (A) HT29 cells were transfected with plasmid pEGFP-N2:HERV-H 
or empty plasmid pEGFP-N2. (B) LS174T cells were transfected with plasmid 
pEGFP-N2:HERV-H or empty plasmid pEGFP-N2. There is no significant difference 
in RFU values for both transfected cell lines. 
 
Chapter 3: Role of HERV-H in colorectal carcinogenesis 
 
Page | 84  
 
3.6.4 Scratch assay 
 The contributory role of HERV-H in cell migration was examined 
using the in vitro scratch assay. The in vitro scratch assay is widely regarded 
as a straightforward method to study cell migration (Rodriguez et al., 2005, 
Lampugnani, 1999). With basic steps like the creation of a “scratch”, a gap 
made on a confluent monolayer, and meticulous examination of the 
microphotographs taken during the closing of the scratch, the rate of cell 
migration can be measured to indicate cell motility (Liang et al., 2007a). The 
inherent cell morphology of LS174T cells is clumpy rather than uniform. 
Hence, it is unlikely to obtain a confluent monolayer of LS174T cells without 
gaps. In view of this technical limitation, only HT29 cells were subjected to 
scratch assay.  
 The percentage of migration area covered after 72 h was 78 ± 7% for 
HERV-H expressing HT29 cells and 40 ± 13% for control cells (Figure 3.6). 
The percentage of migration area of the HERV-H expressing HT29 cells was 
significantly higher than that of the control cells (P < 0.05). The results 
revealed the HERV-H plays a role in the cell migration properties of 









Chapter 3: Role of HERV-H in colorectal carcinogenesis 
 
Page | 85  
 
(A) 
0hr 24 hr 48 hr 72 hr 














     
    
    









    
    




Chapter 3: Role of HERV-H in colorectal carcinogenesis 
 





Figure 3.6. Cell migration of HT29 cells over a 72-h period in a wound scratch 
assay. (A) Representative images of cells migrating into the wounded area at 0, 24 h, 
48 h and 72 h. (B) Graph showing the percentage of wound in control (HT29:GFP) 
and transfected cells (HT29:HERV-H_GFP) after 72-hour. The percentage of wound 
(scratch area) at 0 h (control) was arbitrarily assigned as 100%. Quantitative analysis 
was done using the WimScratch software (Wimasis GmbH, Munich, Germany). 
Results are presented as mean ± SD of three independent experiments. *P <0.05 




3.6.5 HERV-H induces large sphere forming ability in LS174T cells 
 The ability to form a sphere is an indicator of a cancer stem-like 
phenotype (Lobo et al., 2007). To examine the ability of HERV-H to induce 
sphere-forming ability in colorectal cells, HERV-H expressing LS174T cells 
were cultured and refreshed at 3-day interval. It was found that when 
compared to the control group, HERV-H expressing LS174T cells notably 
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possess the ability to form large spheres (>100 m). Using the Mann-
Whitney-Wilcoxon test, the large-sphere forming ability of LS174T:HERV-
H_GFP is significantly higher when compared to that of LS174T:GFP (P < 






  137.62 m 266.78 m 
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Comparison of Medians 
Median of sample 1: 125.0 
Median of sample 2: 139.0 
 
Mann-Whitney (Wilcoxon) W-test to compare medians 
 Null hypothesis: median1 = median2 
 Alt. hypothesis: median1 NE median2 
 
 Average rank of sample 1: 17.2174 
 Average rank of sample 2: 29.7826 
 
 W = 409.0   P-value = 0.00155082 
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Figure 3.7.  Sphere-forming ability of LS174T:HERV-H_GFP. (A) 
Representative images of large sphere (>100 m) are shown. Actual diameter  in 
m is shown.   Photomicrographs (X15 magnification) were taken by IX70 
microscope (Olympus) equipped with DP2-BSW software (Olympus) (B) Box-and-
Whisker plot showing 25th, 50th and 75th percentiles (horizontal lines) of spheres that 
are >100 m. The plus sign (+) indicates the location of the sample mean. (C) Dot 
plot showing the spread of spheroid sizes. Mann-Whitney W-test indicates the ability 
of LS174T:HERV-H_GFP to form large sphere is significantly different (P < 0.01) 




3.6.6 Revival of HERV-H_GFP- and GFP-transfected LS174T and 
HT29 cells after 30 days of serum deprivation 
 To investigate the effect of HERV-H overexpression on the 
dependence of serum for growth, the survival rate of HERV-H overexpressing 
LS174T and HT29 cells after 30 days of serum deprivation was tested (Figure 
3.8). Interestingly, HERV-H overexpressing LS174T and HT29 cells survived 
and were able to form large colonies following serum replacement (Figures 
3.9 and 3.11). Using the Mann-Whitney-Wilcoxon test, the colony-forming 
ability of LS174T:HERV-H_GFP is significantly higher when compared to 
that of LS174T:GFP (P < 0.01) (Figure 3.9). Similarly, the colony-forming 
ability of HT29:HERV-H_GFP is significantly higher when compared to that 
of HT29:GFP (P < 0.05) (Figure 3.11). 
 When compared to control cells, the growth rate of HERV-H 
overexpressing LS174T and HT29 cells was significantly higher after serum 
replacement (P <0.001) (Figures 3.10 and 3.12).  
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Day 4 or 6
Seed cells at 2 x 105 cells per well
Allow for cell attachment in 10% fetal bovine serum 
Replace medium without fetal bovine serum 
supplementation
Replace medium without fetal bovine serum 
supplementation
Replace medium without fetal bovine serum 
supplementation
Replace medium without fetal bovine serum 
supplementation
Replace medium without fetal bovine serum 
supplementation
Replace medium without fetal bovine serum 
supplementation
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Comparison of Medians 
Median of sample 1: 112.0 
Median of sample 2: 167.0 
 
Mann-Whitney (Wilcoxon) W-test to compare medians 
Null hypothesis: median1 = median2 
Alt. hypothesis: median1 NE median2 
 
Average rank of sample 1: 16.6667 
Average rank of sample 2: 28.5517 
 
W = 393.0   P-value = 0.00399311 




Figure 3.9. Survival of transfected LS174T cells following 30-day of serum 
deprivation.  (A) Representative images of respective transfected LS174T cells at 
indicated time points are shown. Photomicrographs (X10 magnification) were taken 
by IX70 microscope (Olympus) equipped with DP2-BSW software (Olympus). (B) 
Box-and-Whisker plot showing 25th, 50th and 75th percentiles (horizontal lines) of 
various sizes of colonies.  The plus sign (+) indicates the location of the sample 
mean. (C) Dot plot showing the spread of colony sizes. Mann-Whitney W-test 
indicates the ability of LS174T:HERV-H_GFP to form numerous large colonies is 

























Chapter 3: Role of HERV-H in colorectal carcinogenesis 
 
Page | 93  
 
   
 
 
Figure 3.10. Proliferation rate of transfected LS174T cells following 30-day of 






 HT29:GFP HT29:HERV-H_GFP 
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Comparison of Medians 
Median of sample 1: 78.5 
Median of sample 2: 141.0 
 
Mann-Whitney (Wilcoxon) W-test to compare medians 
Null hypothesis: median1 = median2 
Alt. hypothesis: median1 NE median2 
 
Average rank of sample 1: 12.125 
Average rank of sample 2: 24.2571 
  
W = 219.0   P-value = 0.0142807 
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Figure 3.11. Survival of transfected HT29 cells following 30-day of serum 
deprivation.  Representative images of respective transfected HT29 at indicated time 
points are shown. Photomicrographs (X10 magnification) were taken by IX70 
microscope (Olympus) equipped with DP2-BSW software (Olympus).  (B) Box-and-
Whisker plot showing 25th, 50th and 75th percentiles (horizontal lines) of various sizes 
of colonies. The plus sign (+) indicates the location of the sample mean. (C) Dot plot 
showing the spread of colony sizes. Mann-Whitney W-test indicates the ability of 
HT29:HERV-H_GFP to form numerous large colonies is significantly different (P < 






Figure 3.12.  Proliferation rate of transfected HT29 cells following 30-day of 
serum deprivation. Experiments were done in triplicates. **, P <0.01; ***, P 
<0.001.   
 
 
3.6.7 CD133 and CD44 expression in HERV-H transfected HT29 and 
LS174T cells.  
 
 CD133 (Ricci-Vitiani et al., 2007) and CD44 (Dalerba et al., 2007) are 
widely used as markers of cancer stem cells. To examine the effect of HERV-
H on the expression of these cancer stem cell markers, cytometric analysis 
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was performed to analyse the expression profiles of these CD markers in the 
transfected HT29 and LS174T cell lines. The relative percentages of cells 
expressing CD133 and CD44 in transfected HT29 are presented in Figure 3.14 
and 3.15 respectively. Similarly, the relative percentages of cells expressing 
CD133 and CD44 in transfected LS174T cells are presented in Figure 3.17 
and 3.18 respectively. Generally, up-regulation of HERV-H expression 
augments the expression levels of CD133 and CD44 in both cell lines, and all 





Figure 3.13.  Cytometric analysis of HT29 cells. The red histogram indicates 
untreated HT29 cells, green and black lines indicate HT29:HERV-H_GFP and 
HT29:GFP cells respectively 
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Isotype control PE-CD133 
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Figure 3.14. Cytometric analysis of CD133 on HT29 cells. (A)  Isotypic controls 
were used to establish the right gating. The top portion (left upper quadrant and right 
upper quadrant) is CD133 positive. (B) Percentage of CD133 positive and negative 
cells in transfected HT29 cells. (C) Graph showing the significant difference in 
CD133 expression levels (P = 0.035).  Independent triplicate experiments are shown. 
*, P <0.05. 
Setting 
HT29:GFP HT29:HERV-H_GFP 
CD133 + CD133 – CD133 + CD133 – 
Expt A 7.5 92.5 25.1 74.9 
Expt B 7.1 92.9 22.3 77.7 
Expt C 5.1 94.9 13.8 86.2 
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(A) Isotype control PE-CD44 
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Figure 3.15. Cytometric analysis of CD44 on HT29 cells. (A)  Isotypic controls 
were used to establish the right gating. The top portion (left upper quadrant and right 
upper quadrant) is CD44 positive. (B) Percentage of CD44 positive and negative cells 
in transfected HT29 cells. (C) Graph showing the significant difference in CD44 






CD44 + CD44 – CD44 + CD44 – 
Expt H1 91.1 8.9 98.9 1.1 
Expt H2 87.8 12.2 97.8 2.2 
Expt H3 86.4 13.6 98.6 1.4 
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Figure 3.16.  Cytometric analysis of LS174T cells. The red histogram indicates 
untreated LS174T cells, green and blue lines indicate LS174:HERV-H_GFP and 
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(A) Isotype control PE-CD133 
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CD133 + CD133 – CD133 + CD133 – 
Expt A 1.96 98.04 2.29 97.71 
Expt B 2.48 97.52 2.81 97.19 









Figure 3.17. Cytometric analysis of CD133 on LS174T cells. (A)  Isotypic controls 
were used to establish the right gating. The top portion (left upper quadrant and right 
upper quadrant) is CD133 positive. (B) Percentage of CD133 positive and negative 
cells in transfected LS174T cells. (C) Graph showing the significant difference in 
CD133 expression levels (P = 0.017).  Independent triplicate experiments are shown. 
*, P <0.05. 
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(A) Isotype control PE-CD44 
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CD44 + CD44 – CD44 + CD44 – 
Expt A 35.9 64.1 54.9 45.1 
Expt B 38.1 61.9 55.9 44.1 







Figure 3.18. Cytometric analysis of CD44 on LS174T cells. (A)  Isotypic controls 
were used to establish the right gating. The top portion (left upper quadrant and right 
upper quadrant) is CD44 positive. (B) Percentage of CD44 positive and negative cells 
in transfected LS174T cells. (C) Graph showing the significant difference in CD44 
expression levels (P = 0.018). Independent triplicate experiments are shown. *, P 
<0.05. 
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3.6.8 Inhibition of HERV-H gene expression and cell proliferation by 
DsiRNA 
 
 To address the reversal effect of DsiRNA on increased proliferation 
rate of cells transfected with HERV-H, cells transfected with pEGFP-
N2:HERV-H or pEGFP-N2 were selected for knockdown experiments. Equal 
numbers (2 × 105) of LS174T:HERV-H_GFP and LS174T:GFP cells were 
transfected with DsiRNA directed against HERV-H. Quantitative RT-PCR 
was performed to determine the effect of HERV-H targeting DsiRNA on the 
expression of HERV-H in transfected LS174T cells. The results obtained 
showed a significant (60%) down-regulation of HERV-H expression in cells 
treated with HERV-H:DsiRNA when compared to cell treated with scrambled 
DsiRNA (Figure 3.19). Further examination on the effect of DsiRNA on cell 
viability was conducted after 72 hours of DsiRNA treatment. The results in 
Figure 3.20 clearly indicated that the knockdown of HERV-H had resulted in 
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Figure 3.19. Reduction of HERV-H expression in LS174T cells by DsiRNA. After 
72 hours of DsiRNA treatment, RNA was extracted and the levels of HERV-H 
mRNA were determined by quantitative RT-PCR. LS174T:GFP cells were used as 
the control. The rate of HERV-H expression was normalized to the expression of -
actin.  Scrambled DsiRNA refers to the negative control group and HervH DsiRNA 
refers to the HERV-H silencing group. Relative gene expression was quantified based 
on 2-∆∆CT method (Livak and Schmittgen, 2001).  (A) LS174T:GFP cells (B) 
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Figure 3.20.  Effect of DsiRNA on cell proliferation of LS174T:HERV-H_GFP. 
Seventy two hours after DsiRNA transfection, the effect of various DsiRNA (WH1, 
WH2 and WH3) at 2nM and 10 nM on cell proliferation was determined by trypan 
blue assay. Cells treated with NC1, scrambled DsiRNA, served as the negative 
control. WH1, WH2 & WH3 refer to DsiRNAs targeting at HERV-H and these were 
the HERV-H silencing experiment groups. Experiments were done in triplicates. (A) 
Effect of NC1, WH1 and WH2 (B) Effect of NC1 and WH3. **, P <0.01; ***, P 
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Figure 3.21.  Effect of DsiRNA on cell proliferation of LS174T:GFP cells. 
Seventy two hours after DsiRNA transfection, the effect of various DsiRNA (WH1, 
WH2 and WH3) at 2nM and 10 nM on cell proliferation was determined by trypan 
blue assay. Cells treated with NC1, scrambled DsiRNA, served as the negative 
control. WH1, WH2 & WH3 refer to DsiRNAs targeting at HERV-H and these were 
the HERV-H silencing experiment groups. Experiments were done in triplicates. (A) 
Effect of NC1, WH1 and WH2 (B) Effect of NC1 and WH3. 
 
3.7 Discussion 
 To date, little is known about the role of endogenous retroviruses in 
cancer development.  Although many studies have shown correlation of the 
transcriptional activities of endogenous retroviral elements with tumour 
specimens, the precise molecular pathogenesis is still poorly understood.  
  
 Nevertheless, endogenous retroviruses have generated much interest in 
the clinical research fields. The involvement of endogenous retroviral 
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elements in the study of multiple sclerosis is progressing with interesting 
clinical data (Nissen et al., 2013). These include the strong association of 
HERV-K18.3 haplotype (de la Hera et al., 2013, Tai et al., 2008) or HERV-
Fc1 (Nexo et al., 2011) with multiple sclerosis susceptibility, and a gender 
difference in HERV-W copy numbers in multiple sclerosis patients (Garcia-
Montojo et al., 2013). Review articles summarizing the advances and 
controversial issues on neuropathogenesis (Hon et al., 2013, Christensen, 
2010, Antony et al., 2011) are also available. Conversely, endogenous 
retroviruses have also been implicated in autism spectrum disorders 
(Balestrieri et al., 2012) as well as severe psychiatric disorders like 
schizophrenia and bipolar disorder (Perron et al., 2012b, Perron et al., 2008, 
Frank et al., 2005, Karlsson et al., 2001).     
 
 Similarly, there is an increasing interest in the study of HERVs as 
causal factors in cancer biology (Lower et al., 1993, Herbst et al., 1996, 
Wang-Johanning et al., 2003).  Activation of HERV-K is found to be 
necessary for the malignant progression of melanoma (Serafino et al., 2009). 
The expression of HERV-K gag antigen and the presence of anti-HERV-K-
gag antibodies have been demonstrated to be correlated to prostate cancer 
progression (Reis et al., 2013). Still, the quest for the aetiopathogenic role of 
endogenous retroviral elements in human tumours is ongoing. A simple reason 
for this is that their mechanistic role in disease development is still not clearly 
defined.     
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 The six hallmarks of cancer have been proposed by Douglas Hanahan 
and Robert A. Weinberg in 2000. These six acquired capabilities are depicted 
in Figure 3.22 (Colotta et al., 2009). This widely regarded conceptual 
framework forms the basis of cancer biology and sets the tone of findings 
discussion in this study.     
 
3.7.1 Proliferation: Heightened replicative potential observed  
 In a series of experiments conducted, our results have demonstrated 
the oncogenic potential of a 93-amino acid HERV-H peptide. HERV-H 
overexpressing cells were proliferating at a higher rate. This corroborates one 
of the six hallmarks of cancer – limitless replicative potential. Although 
arguably the replicative activity of colorectal cancer cells should have already 
been developed in the established cell lines, it is the increased rate of 
proliferation that set the underlying mechanism for expansive tumour growth 
(Cho et al., 2006, Csibi et al., 2013). 
 
 In the experiments in which HERV-H was knocked down by dicer-
substrate small interfering RNA the cells were observed to decrease their 
growth rate with concomitant decrease in HERV-H expression. These data 
therefore illustrate a central role of HERV-H in the replicative potential of 
cells and clearly demonstrate that HERV-H expression is associated with the 
phenotypic transformation of colorectal cancer. 
Chapter 3: Role of HERV-H in colorectal carcinogenesis 
 
Page | 112  
 
  
Figure 3.22. The six hallmarks of cancer proposed by Hanahan and Weinberg in 
2000.  The hallmarks of cancer consist of six biological capabilities acquired during 
the transformation of normal cells to cancer cells. The hallmarks underlie an 
organizing principle for rationalizing the complexities of neoplastic disease. The 
hallmarks are (1) sustaining proliferative signalling, (2) evading growth suppressors, 
(3) resisting cell death, (4) enabling replicative immortality, (5) inducing 
angiogenesis, and (6) activating invasion and metastasis. 
 
 
3.7.2 Migration: Initial step for tissue invasion & metastasis engaged 
 Cell motility or the migration process of adherent cells from one 
location to another is the initial phase of the complex metastasis process. Cell 
migration can take place either as single cells or in small groups, thereby 
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locations. In order for the cell to migrate, it must acquire an invasive 
phenotype that is characterized by both the loss of cell-cell interactions and 
increased cell motility (Palmer et al., 2011). In our study, HERV-H 
overexpressing cells were able to migrate at a higher rate. The engagement of 
the initial process of invasion and metastasis is therefore demonstrated. 
However the invasive property is not demonstrated. While the discordant 
effects of HERV-H on the invasion and metastasis is not clearly understood, it 
may be associated with the rise in CD133/CD44 expression, which will be 
explained later. 
 
3.7.3 Sphere-forming ability: stem cell potential evaluated  
 In 2011, Douglas Hanahan and Robert A. Weinberg put forward four 
more hallmarks of cancer, namely, (1) deregulation of cellular energetic, (2) 
avoidance of immune destruction, (3) genome instability and mutation, and (4) 
tumour promoting inflammation (Figure 3.23). Interestingly, it is in this new 
proposal that the role of cancer stem cells found in the tumour 
microenvironment was discussed (Hanahan and Weinberg, 2011). Undeniably, 
it is the presence of cancer stem cells that may account for the sudden 
termination of tumour dormancy. On the other hand, it is regarded that the 
sphere-forming assay evaluate the potential of a cell to behave as a stem cell 
(Pastrana et al., 2011). With these notions in mind, the large sphere-forming 
ability gained by the HERV-H overexpressing LS174T cells provided the 
capability of initiating and sustaining tumour growth by forming a population 
of cancer stem cells and descendant cells. Obviously, this presents a poor 
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clinical prognosis and offers limited effective therapeutic modalities (Kleffel 




Figure 3.23. The next-generation hallmarks of cancer proposed by Hanahan and 
Weinberg in 2011. The progress in cancer research over the past decade has 
provided many interesting developments in the field. Consequently, four new 
hallmarks (shaded circles), viz. deregulation of cellular energetic, avoidance of 
immune destruction, genome instability and mutation, and tumour promoting 
inflammation were added. Along with these new hallmarks, the concept of “tumour 
environment” was introduced, and the signalling networks in the tumour 
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 The sphere-forming ability of colon cancer cells have also been 
correlated with the expression of CD133 (Ricci-Vitiani et al., 2007) and CD44 
(Su et al., 2011). Several studies stipulated the experimental conditions for 
generating cancer-stem-cells-like sphere cells from colorectal cancer cells 
(Todaro et al., 2007, Kanwar et al., 2010, Fan et al., 2011, Hwang et al., 
2011), which include the use of stem cell medium or serum-free medium 
supplemented with various mix of B27, epidermal growth factor, fibroblast 
growth factor and insulin. Our study revealed the swift gain of sphere-forming 
ability in HERV-H transfected LS174T cells, without the need of special 
experimental conditions as previously stated. This suggests that the HERV-H 
element might act, to some extent, as a molecular switch/link to a myriad of 
stem cell potency factors, resulting in the quick formation of cancer-stem-cell-
like sphere cells. 
 
3.7.4 Stem cell phenotype:  CD133 and CD44 highly expressed 
 CD133, a five-transmembrane glycoprotein of 120 kDa molecular 
weight, was first demonstrated in haematopoietic stem and progenitor cells 
(Yin et al., 1997, Miraglia et al., 1997).  When tumour initiating characteristic 
was found to be common in CD133-positive cells isolated from many 
neoplasms (Yin et al., 1997, Singh et al., 2004, Collins et al., 2005, Suetsugu 
et al., 2006, Hermann et al., 2007, Ferrandina et al., 2008, O'Brien et al., 
2007), it was subsequently widely used to identify and isolate stem cells and 
cancer stem cells. CD44, a transmembrane glycoprotein which functions in 
cell adhesion, migration, homing, proliferation, survival and apoptosis, is 
regarded as a cancer stem cell marker for many neoplasms (Zoller, 2011, Du 
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et al., 2008). As CD133 and CD44 are widely used markers of cancer stem 
cells, their clinical relevance in prognostication is slowly gaining its traction 
through clinical studies (Horst et al., 2009b, Du et al., 2008, Galizia et al., 
2012).  
 
 Our study has demonstrated that overexpression of HERV-H has 
augmented the expression of CD133 and CD44 in both HT29 and LS174T 
cells significantly (P < 0.05). In addition, HERV-H overexpressing colorectal 
cells were able to proliferate faster. This is consistent with the previous study 
(Ieta et al., 2008) in which the tumour-forming ability and higher proliferative 
capacity of CD133+ cells in colon cancer cell lines was demonstrated.  
 
 As previously mentioned, HERV-H overexpressing colorectal cells 
were unable to display the characteristics of cell invasiveness.The increased 
levels of CD133 in both transfected HT29 and LS174T cells did not associate 
with a higher degree of cell invasiveness. Previously, CD133+ HT29 cells 
have been shown to possess higher invasive abilities when compared with 
CD133– HT29 cells (Ieta et al., 2008). Similarly, CD133 was demonstrated to 
play an important role in HCT116 colon cancer cell invasion (Zhang et al., 
2013a). On the other hand, controversial findings have reported that CD133 is 
unlikely to contribute functionally to the metastatic phenotype of colon cancer 
cells (Horst et al., 2009c, Shmelkov et al., 2008). With these discordant 
findings, it may appear that CD133 may possess a dualistic nature.  
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 Similarly, greater cell invasiveness is not observed in CD44-positive 
HERV-H overexpressed HT29 and LS174T cells.  While CD44-
overexpressing SW480 cells colon cancer cells have been shown to exhibit a 
2.5-fold increase in cell invasion (Cho et al., 2012), CD44 overexpression has 
also been demonstrated to inhibit invasion in vitro for prostate cancer (Yang et 
al., 2010). While this may arguably be taken as the metastatic role of CD44 is 
tissue-specific, previous studies have reported that a reduced expression of 
CD44 was found in colon cancer metastases (Weg-Remers et al., 1998, 
Harada et al., 2001). Of interest, a recent study has shown that the expression 
of CD44 by LS174T colon carcinoma cells functions as a tumour suppressor 
(Dallas et al., 2012) and that the knockdown of CD44 exhibits a large increase 
in metastatic potential. Taken together, CD44 may be regarded as the mediator 
for decreased cell invasiveness.  
 
3.7.5 Serum independence: Self-sufficiency in growth signals met and 
possible reprogrammed cellular energetics 
 Normal cells need mitogenic growth signals to proliferate. In other 
words, growth promoting signals are required to direct the cells through cycles 
of cell growth and division. On the other hand, cancer cells are able to acquire 
the mitogenic signalling they need to sustain proliferation. This may take 
place in an autocrine manner, leading to overexpression of growth receptors or 
constitutive activation of signalling pathways (Hanahan and Weinberg, 2000, 
Hanahan and Weinberg, 2011).  
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 One of the most interesting findings in this study is the increased 
revival rate of HERV-H-overexpressing LS174T and HT29 cells after 30 days 
of serum deprivation. Fetal bovine serum contains high levels of growth 
stimulatory factors. Hence, supplementation of fetal bovine serum in the 
culture medium always helps in the optimisation of in vitro cell culture (Zheng 
et al., 2006). With prolonged serum deprivation, growth of normal cells is 
very unlikely. Although an insufficient supply in serum nutrients may not 
have an overt effect on cancer cell viability, starved cancer cells are sensitive 
to apoptosis (Braun et al., 2011). Nevertheless, the alteration of cellular 
metabolism to suit changes in nutrient availability suggests cancer cells have 
successfully adapted their metabolism to ensure survival. It is reported that 
such metabolic alteration in cancer cells is modulated at the epigenetic level 
(Yun et al., 2012). Interestingly, the Warburg effect (Warburg, 1956) has been 
found to play a role in this phenomenon via “aerobic glycolysis” and 
glutamine can be used to support the synthesis of cellular building blocks like 
amino acids, ribonucleotides and lipids (Dang, 2009). With growth media 
containing GlutaMAX, a more stable source of glutamine, the Warburg 
effect may be the factor for cancer cells survival.   
 
 Here we show for the first time that HERV-H expressing LS174T and 
HT29 cells possess the advantage of surviving through long period of serum 
deprivation. The ability to pull through such a long period of serum 
deprivation may be associated with the increased expression of CD133. 
Population of CD133+ cells was shown to be capable of growing as 
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undifferentiated colon-spheres in a serum-free media  supplemented with EGF 
and FGF-2 (Ricci-Vitiani et al., 2007). While the sphere-forming ability, 
higher proliferative capacity and survival of long period of serum-free 
cultivation may be attributed to the increase in CD133 expression, it should be 
realised that it is after all, the up-regulation of HERV-H expression that 
initiated the whole process.    
 
3.7.6 Concluding remarks  
 Taken together, overexpression of HERV-H promoted colorectal 
cancer cell proliferation, motility, and sphere formation and reduced serum 
dependence via increased expression of CD133 and CD44. Specifically, the 
expression of HERV-H is conferred by the 93-aa Gag protein, which is one of 
the ORFs in the HERV-H sequence. As such, this study represents part of the 
determination of the roles of HERV-H in colorectal carcinogenesis. It is 
unknown if HERV-H up-regulation in colorectal cancer biopsies is a 
bystander effect, but results presented in this chapter appear to suggest 
otherwise, given that HERV-H directly regulates various hallmarks of cancer. 
In the next chapter, the involvement of various signalling pathways and key 
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CHAPTER 4 
ROLE OF HERV-H IN VIRAL MEDIATED SIGNALLING 
4.1 Introduction 
 In 2000, the six hallmarks of cancer described by Douglas Hanahan 
and Robert Weinberg provided a new paradigm of cancer development 
framework (Hanahan and Weinberg, 2000). Later in 2011, both Hanahan D 
and Weinberg R put forward another 4 new hallmarks to account for the 
advances in cancer research in the field (Hanahan and Weinberg, 2011). The 
notion of a multistep process of human tumour pathogenesis, which entails the 
accumulation of multiple independent mutations that lead to the deregulation 
of cell signalling pathways coupled with uncontrolled cell growth, has always 
been the central dogma of cancer biology.  
 
4.2  Viral-mediated cancers 
 About 20% of the human cancers are linked to infectious agents, of 
which 15% are associated with viruses (zur Hausen, 1991, Parkin, 2006, Zur 
Hausen, 2009). While viruses are notorious for devastating diseases, for 
example, cancers, it should be appreciated poignantly that viral carcinogenesis 
has contributed much to the molecular study of cancer development and the 
fundamentals of cell signalling pathways. Nevertheless, tumour-initiating 
viruses were initially known to cause malignant diseases in animals. These 
include Rous sarcoma virus (RSV) that causes sarcoma in chickens, Harvey 
sarcoma virus that causes sarcoma in rats, myeloproliferative leukaemia virus 
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that causes acute leukaemia in mice, AKT8 virus that causes leukaemia in 
mice and avian  leukosis virus that causes leukaemia in chickens (Rosenberg, 
1997).  
 Although most oncogenes, which encode proteins that control cell 
proliferation, differentiation and apoptosis, were first recognized in 
retroviruses, it must be bear in mind that oncogenes from DNA viruses also 
play a crucial role in the development of cancer in which the cell cycle process 
is modulated via the retinoblastoma protein (pRb), or constitutive expression 
of signalling receptors (Vogt, 2012, Croce, 2008).  
 On the other hand, it must also be realised that not all retroviruses 
carry an oncogene in their genome. Retroviruses that lack an oncogene and are 
still able to induce tumours are collectively known as cis-acting retroviruses. 
The mechanism by which these retroviruses causes malignancy is mediated 
through a process known as insertional mutagenesis (Hayward et al., 1981, 
Mikkers and Berns, 2003, Maksakova et al., 2006). It is in this process where 
provirus integrates in the vicinity of a cellular oncogene and is able to function 
as a transcriptional regulator. This enhances or disrupts the transcriptional 
activities of the cellular gene, bringing upon the oncogenic potential of the 
cellular gene (Uren et al., 2005, Cavazza et al., 2013, Fan and Johnson, 2011). 
To date, there are approximately seventy proto-oncogenes activated by 
proviral insertion of a non-transforming retrovirus (Rosenberg, 1997), but 
these have been limited to non-human carcinogenesis (McLaughlin-Drubin 
and Munger, 2008).  
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4.2.1 Retroviral oncogenes 
 Oncogenes were first discovered in cancer-causing retroviruses 
(Kalland et al., 2009). To date, there are approximately 30 retroviral 
oncogenes of which most are associated with avian and rodent viruses (Table 
4.1). The first oncogene, v-src, was discovered in 1911 by Peyton Rous, who 
identified a transforming agent, now known as Rous sarcoma virus (RSV), in 
a cell-free filtrate that was capable of inducing sarcomas in injected chickens 
(Rous, 1911, Rous, 1983). This has led to many studies of oncogenic 
retroviruses (Martin, 2004) with chickens and the discovery of c-myc from 
avian myelocytomatosis virus MC29 (Duesberg et al., 1977) and erbB from 
avian erythroblastosis virus (Bister and Duesberg, 1979, Lai et al., 1979). 
Nevertheless the studies of oncogenic retroviruses had been extended to 
mammals like mice, and this had subsequently led to the discovery of ras from 
Harvey and Kirsten sarcoma viruses (Shih and Weeks, 1984, Shih et al., 
1979).  
 
Table 4.1. Oncogenic viruses and associated oncogenes  
Product Oncogene Virus 
platelet-derived growth factor-β Sis Simian sarcoma virus 
EGFR ErbB Avian erythroblastosis virus  
thyroid hormone receptor-α. ErbA Avian erythroblastosis virus 
GTPase Ha-ras Harvey sarcoma virus 
GTPase  Ki-ras Kirsten sarcoma virus 
a modular signalling link Crk  CT10 avian sarcoma virus 
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a signalling protein kinase Src Rous sarcoma virus  
a signalling protein kinase Abl Abelson murine leukemia 
a signalling protein kinase Akt Akt8 murine thymoma virus 
a signalling protein kinase Mos Moloney murine sarcoma virus 
a component of the AP1 complex Jun Avian sarcoma virus 17  
a component of the AP1 complex Fos 
Finkel–Biskis–Jinkins murine 
sarcoma virus 
a transcription factor Myc 
Avian myelocytomatosis virus 
MC29 
lipid kinase Pi3k Avian sarcoma virus 16 
 
  
4.3 Viral-mediated signalling pathways 
 One of the hallmarks of cancer – self-sufficiency in growth signals 
proposed by Hanahan and Weinberg, indicates that cancer cells are able to 
acquire the mitogenic signalling they need to sustain proliferation. Whereas 
this may take place via an autocrine manner, overexpression of growth 
receptors or simply constitutive activation of signalling pathways (Hanahan 
and Weinberg, 2000, Hanahan and Weinberg, 2011), growth signalling 
pathways may be deregulated or even reprogrammed to regulate the deranged 
cancer cells. The intracellular circuitry of signalling networks is both complex 
and intricate. Seven signalling pathways have been implicated in cancer and 
embryonic stem cells. These are: (1) the JAK/STAT pathway, (2) the NOTCH 
signalling pathway, (3) the MAP-Kinase/ERK pathway, (4) the PI3K/AKT 
pathway, (5) the NFkB pathway, (6) the Wnt pathway and (7) the TGFβ 
pathways (Dreesen and Brivanlou, 2007). Interestingly, viral-mediated 
signalling pathways involve several more pathways. These include: the p53 
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signalling pathway, the B cell receptor signalling pathway, the JAK/STAT 
signalling pathway and the chemokine signalling pathway (Saha et al., 2010). 
 In the preceding chapter, our study has demonstrated the oncogenic 
potential of HERV-H in a series of experiments. However, little is known 
about the signalling pathways that HERV-H is involved in during the 
transforming process. Thus, in this study, we focused on examining the 
pathways that HERV-H is involved in by using PCR array technology and 
Western blotting technique. 
 
4.4 Materials and Methods 
4.4.1 Cell lines and culture conditions 
 The human colorectal cancer cell lines LS174T were transfected with 
pEGFP-N2 or pEGFP-N2:HERV-H as previously described in Chapter 3 
(Section 3.5.1). Transfected colorectal cells were routinely cultured in 
Minimum Essential Medium (MEM) α supplemented with 10% fetal bovine 
serum and 800 g/ml of G418. Both cell lines were maintained in a 
humidified atmosphere of 5% CO2 in air at 37˚С and used when in the log 
phase of growth. 
 
4.4.2 PCR array 
4.4.2.1  PCR array panels 
 The TaqMan® OpenArray® Human Signal Transduction Panel, 
QuantStudio™ 12K Flex  (P/N 4475392) and TaqMan® OpenArray® Human 
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Inflammation Panel, QuantStudio™ 12K Flex (P/N 4475389) were obtained 
from Life Technologies Corporation, Singapore. 
 The TaqMan® OpenArray® Human Signal Transduction Panel was 
developed to identify differentially expressed genes involved in major 
signaling pathways. This gene signature panel contained 573 TaqMan® assays 
specific to signal transduction-related genes plus 24 endogenous controls. The 
format of the OpenArray® plate allowed for 1 to 4 replicates to be run in 
parallel per plate. In this real-time PCR assay panel, genes encoding the JAK-
STAT, NFκB, Akt, GPCR, cAMP, and MAP kinase pathways were well 
represented. The full lengths of these pathways were covered, from ligand to 
receptor to kinase to transcription factor. In addition, there are 18 endogenous 
control genes against which the assays can be normalized.  
 The TaqMan® OpenArray® Human Inflammation Panel is designed 
for quantitative gene expression analysis of inflammation genes important in 
drug discovery. The panel covered 586 genes that have been studied as targets 
for a range of inflammatory diseases, plus 21 endogenous control genes, 
which the assays can be normalized.  
 
4.4.2.2  PCR array analysis 
 Total RNA was extracted from the transfected colorectal cells using 
the RNeasy® mini kit (Qiagen, Germany). Harvested total RNA was 
quantitated using the Nanodrop 100 spectrophotometer (ThermoScientific, 
Waltham, USA). Reverse transcription was performed using Super-Script 
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VILO cDNA synthesis kit (Invitrogen, USA) in accordance to the 
manufacturer’s instructions. For PCR array, Human Signal Transduction Panel 
and Human Inflammation Panel (Life Technologies, USA) were used and 
PCR was performed on the QuantStudio™ 12K Flex Real-Time PCR System 
(Life Technologies, USA), according to the manufacturer’s instruction (Figure 
4.1). Analyses of the raw data were done through the Gene Set Enrichment 
Analysis Web Portal (Broad Institute of MIT and Harvard) and through the 










Isolation of RNA from transfected colorectal cell lines
Preparation of cDNA from isolated RNA samples
Aliquoting cDNA-containing Master Mix to each well of 
the same PCR Array plate containing the predispensed 
gene-specific primer sets
Performance of thermal cycling
Analysis of gene expression in terms of fold changes  
using the ΔΔCt method
Chapter 4: Role of HERV-H in viral mediated signalling 
 
Page | 128  
 
4.4.3 Western Blot Analysis 
 Cells cultivated to 80% confluence were lysed with M-PER 
Mammalian Protein Extraction Reagent (Thermo Scientific, USA) containing 
protease inhibitors (Complete Mini, Roche).  Protein concentrations were 
estimated using a Bradford assay (Bio-Rad, CA, USA) and optical density 
(OD) was measured with UV-VIS double beam spectrophotometer 
(Shimadzu, Japan). Aliquots of extracted protein were preserved at −80°C 
until further use. Samples were mixed with 4x loading buffer (Amresco, 
Solon, USA), denatured at 99°C for 5 minutes and loaded onto Any kD™ 
Mini-PROTEAN® TGX™ Precast Gel (BioRad) before electrophoresis. An 
amount of 40 µg/lane/protein lysate was run. The proteins were transferred to 
a methanol-activated polyvinylidenedifluoride (PVDF) membrane using an 
iBlot semi-dry blotting system (Invitrogen, USA) at 10 V for 7 minutes. The 
membrane was subsequently blocked, probed and washed with reagents 
provided by the WesternBreeze® kit (Invitrogen, USA). Reagents were used 
as recommended by the manufacturer.   
 Primary antibodies (anti-phospho p44/42 MAP Kinase, anti-phospho-
SAPK/JNK, anti-phospho- p38 MAPK;  1:1000, Cell Signaling Technology, 
USA) and secondary antibodies (anti-rabbit HRP-linked IgG, 1:1000, Cell 
Signaling Technology, USA) were used. Mouse -tubulin antibody (1:1000; 
Santa Cruz Biotechnology, USA) was used as a housekeeping protein control. 
Detection was performed using the Super Signal West Pico Chemiluminescent 
Substrate kit (Pierce, Thermo Scientific, USA) and chemiluminescent signals 
were captured by the C-DiGit Blot scanner (Li-Cor Biosciences, USA ).  
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 Membranes were stripped using a Restore PLUS Western Blotting 
Stripping buffer (Pierce, Thermo Scientific, USA) at room temperature for 30 
minutes and reprobed with another antibody immediately. All subsequent 
reprobing procedures started with a blocking step as described above. 
 
4.5 Results 
4.5.1 PCR array analysis of colorectal cancer cells expressing HERV-H 
using GSEA 
 The gene expression profiles of colorectal cancer cells transfected with 
(i) an empty vector (pEGFP-N2) and (ii) a vector containing HERV-H 
(pEGFP-N2:HERV-H ) were analysed using a high-throughput PCR array 
containing 573 primer/probe sets for signal transduction-related genes and 586 
primer/probe sets for inflammation-associated genes. These were mapped into 
the Gene Set Enrichment Analysis (GSEA) software and were filtered 
according to the manufacturer’s instructions. Specifically, bioinformatics 
analysis revealed the differentially regulated genes were associated with host 
cellular pathways that are involved in cell 
cycle/mitosis/proliferation/apoptosis.  
 The top 20 upregulated (>1.5 fold) signalling transduction pathways 
identified from 27 signal transduction-related genes in LS174T:HERV-
H_GFP were shown in Table 4.2. The upregulated pathways included those 
involved in cytokine signalling, -catenin signalling, Wnt-mediated signalling, 
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G-protein  signalling, PI3K signalling, p53 downstream effectors signalling, 
Stem cell factor receptor-mediated signalling and MAPK signalling.  
 Among the genes that were involved in these top 20 identified 
pathways were gamma interleukin 2 receptor (IL2RG),  interleukin 1 (IL1B), 
wingless-type MMTV integration site family member 11 (Wnt11), MAP4K1 
and nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 
(NFATC4) (Figure 4.2).  
 The heat map of differentially expressed genes using LS174T:HERV-
H_GFP and LS174T:GFP cells is shown in Figure 4.3. Heat map analysis 
indicated that early growth response 1 (EGR1), dickkopf WNT signaling 
pathway inhibitor 1 (DKK1), caspase 1 (CASP1), interleukin 1  (IL1B), 
NFATC4 and Wnt11 were differentially upregulated whereas myocyte 
enhancer factor 2C (MEF2C), paired-like homeodomain transcription factor 2 
(PITX2) and mitogen-activated protein kinase kinase kinase kinase 1 
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Table 4.2. Top 20 signal transduction pathways. The pathways were identified 
from 27 genes with CT>1.5 fold in LS174T:HERV-H_GFP. FDR: false discovery 
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Figure 4.2. The distribution of each signal transduction-related gene in the top 
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Figure 4.3. Differential expression of signal transduction-related genes in 
transfected LS174T colorectal cancer cells. Heat map, and gene expression 
increased (red) and decreased (green) in a comparison of colorectal cells expressing 
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 The top 20 upregulated (>1.5 fold) inflammatory diseases associated 
pathways identified from 28 inflammation-related genes in LS174T:HERV-
H_GFP are shown in Table 4.3.  
 Among the upregulated pathways were the interleukin 2-mediated 
signalling pathway, the interleukin 1-mediated signalling pathway, the JAK-
STAT signalling pathway, the interleukin 10 anti-inflammatory signalling 
pathway and the Wnt signalling pathway.  
 Among the genes that were involved in the top 20 identified pathways 
were  interleukin 1 (IL1B), type I interleukin 1 receptor (IL1R1), v-kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), TP53,  
NFATC4 and Wnt 16 (Figure 4.4).  
 Heat map analysis indicated that NFATC4, interleukin 16 (IL16), 
caspase 1 (CASP1) and interleukin 1  (IL1B) were differentially upregulated 
whereas cell death-inducing p53 target 1 (C16orf5), tumour protein p53 
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Table 4.3. Top 20 inflammation associated pathways. The pathways were 
identified from 28 genes with CT>1.5 fold in LS174T:HERV-H_GFP. FDR: 
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Figure 4.4. The distribution of each inflammatory diseases-related gene in the 
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Figure 4.5. Differential expression of inflammatory diseases associated genes in 
transfected LS174T colorectal cancer cells. Heat map, and gene expression 
increased (red) and decreased (green) in a comparison of colorectal cells expressing 
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4.5.2 PCR array analysis of colorectal cancer cells expressing HERV-H 
using IPA 
 Using the ingenuity pathway analysis (IPA) application, the cellular 
pathways that were affected by HERV-H mediated transforming process were 
identified. With the use of Human Signal Transduction Panel, the top scoring 
network (Score = 31) associated with HERV-H transduction include genes 
involved in cell death and survival, inflammatory response and cancer (Table 
4.4). In addition, cancer was the top disease implicated. There were four top 
molecular and cellular functions significantly associated with HERV-H 
transduction. These four functions were associated with cell death and 
survival, cellular growth and proliferation, cellular development and cell cycle 
(Table 4.4).  
 With the canonical pathway analysis, the top pathway that was 
identified to be significantly associated with HERV-H transduction was the 
TGF- signalling in colorectal cancer cells (Table 4.4). Signalling network 
showing various canonical pathways following HERV-H transduction is 
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Table 4.4. IPA analysis of implicated network/pathway in human signal 
transduction panel after HERV-H transduction. 
Associated Network Score 
Cell death and survival, Inflammatory response, Cancer 31 
   
Diseases and Disorders P value Molecules involved 
Cancer 1.3210-07 - 6.5910-03 25 
   
Molecular and Cellular Functions P value Molecules involved 
Cell Death and Survival 6.2210-07 - 6.6010-03 15 
Cellular Growth and Proliferation 8.6610-07 - 4.9810-03 15 
Cellular Development 2.4310-06 - 5.1310-03 15 
Cell Cycle 2.6310-06 - 4.9510-03 5 
   
Top Canonical Pathways P value Ratio 
TGF- signalling 1.210-05 4/93 (0.043) 
Role of Osteoblasts, Osteoclasts and 
Chondrocytes in Rheumatoid Arthritis 
2.410-05 5/225 (0.022) 
IPA employs Fisher’s exact test to determine the relationship between the input dataset and 






Chapter 4: Role of HERV-H in viral mediated signalling 
 










Chapter 4: Role of HERV-H in viral mediated signalling 
 






























Chapter 4: Role of HERV-H in viral mediated signalling 
 




Figure 4.6. Connectivity of differentially expressed signal transduction-related 
genes in colorectal cancer cells following HERV-H transduction. (A) Signalling 
network showing all involved genes.  (B) Signalling network showing canonical 
pathway of molecular mechanisms of cancer. (C) Signalling network showing 
canonical pathway of colorectal cancer metastasis signalling. (D) Signalling network 
showing canonical pathway of TGF- signalling. (E) Signalling network showing 
canonical pathway of ERK/MAPK signalling. (F) Signalling network showing 
canonical pathway of SAPK/JNK signalling.  Geometric figures in bold letters denote 
genes involvement in the study. Solid interconnecting lines shows the genes that are 
directly connected and the dotted lines signify indirect connection between the genes 
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 On the other hand, using the Human Inflammation Panel, the top 
scoring network (score = 43) associated with HERV-H transduction include 
genes involved in cellular movement, haematological system development and 
function and immune cell trafficking (Table 4.5). Moreover, both 
inflammatory disease and response were the top ranking disease and disorder 
(Table 4.5).  
 Cellular development, cellular growth and proliferation, cell-to-cell 
signalling and interaction, cell death and survival, and cellular movement were 
the predominant biological functions associated with the top five molecular 
and cellular functions (Table 4.5).  
 With the canonical pathway analysis, the top pathway that was 
identified to be significantly associated with HERV-H transduction was 
intriguingly involving the role of macrophages, fibroblasts and endothelial 
cells in rheumatoid arthritis (Table 4.5). Signalling network showing various 
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Table 4.5. IPA analysis of implicated network/pathway in human 
inflammation panel after HERV-H transduction. 
Associated Network Score 
Cellular Movement, Haematological System Development and Function, 
Immune Cell Trafficking 
43 
Cancer, Cellular Development, Cellular Growth and Proliferation 6 
   
Diseases and Disorders P value Molecules involved 
Inflammatory Disease 9.0110-11 - 3.4310-03 19 
Inflammatory Response 1.1310-07 - 3.4310-03 17 
   
Molecular and Cellular Functions P value Molecules involved 
Cellular Development 1.4310-09 - 3.4310-03 18 
Cellular Growth and Proliferation 1.4310-09 - 3.4310-03 18 
Cell-To-Cell Signaling and Interaction 5.4310-09 - 3.4310-03 18 
Cell Death and Survival 3.4210-08 - 3.4310-03 16 
Cellular Movement 6.6910-07 - 3.4310-03 12 
   
Top Canonical Pathways P value Ratio 
Role of Macrophages, Fibroblasts and Endothelial 
Cells in Rheumatoid Arthritis 
4.2410-07 7/311 (0.023) 
Role of Osteoblasts, Osteoclasts and Chondrocytes 
in Rheumatoid Arthritis 
1.4310-06 6/225 (0.027) 
TREM1 Signalling 2.2210-06 4/57 (0.07) 
IPA employs Fisher’s exact test to determine the relationship between the input dataset and 
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Figure 4.7. Connectivity of differentially expressed inflammatory diseases 
associated genes in colorectal cancer cells following HERV-H transduction. (A) 
Signalling network showing all involved genes.  (B) Signalling network showing 
canonical pathway of molecular mechanisms of cancer. (C) Signalling network 
showing canonical pathway of colorectal cancer metastasis signalling (D) Signalling 
network showing canonical pathway of ERK/MAPK signalling. (E) Signalling 
network showing canonical pathway of SAPK/JNK signalling. (F) Signalling 
network showing canonical pathway of apoptosis signalling. Geometric figures in 
bold letters denote genes involvement in the study. Solid interconnecting lines shows 
the genes that are directly connected and the dotted lines signify indirect connection 
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4.5.3 Western blot analysis of MAPK pathway 
 Based on the PCR array analysis, the protein levels of specific MAP 
kinases were examined. Western blot analysis using LS174T:HERV-H_GFP, 
LS174:GFP, HT29:HERV-H_GFP and HT29:GFP demonstrated that 
phosphor-p42/44 MAPK and phosphor-SAPK/JNK expressions were 











Figure 4.8. Western blot showing phosphor-MAP kinases in transfected 
colorectal cells. Left panel: LS174T cells transfected with GFP:HERV-H or GFP, 
right panel: HT29 cells transfected with GFP:HERV-H or GFP. Cells at 80% 
confluence were harvested and the protein concentrations of cell lysates were 
measured by Bradford assay. 40 g of the cell lysate were loaded into each lane and 
subjected to immunoblotting. Immunoreactive bands for phosphor-p38 MAPK, 
phosphor-p42/44 MAPK, phosphor-SAPK/JNK and tubulin (housekeeping protein 
control) are shown. Band intensity was quantified using the Image Studio software 
(version 3.1.4) for C-DiGit Blot scanner (Li-Cor Biosciences, USA). The relative 
levels of phosphor-p38 MAPK, phosphor-p42/44 MAPK and phosphor-SAPK/JNK 
were normalised to their respective tubulin levels, and are shown.  
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 All cells possess the dynamic ability to coordinate their activities with 
environmental changes. In all multicellular organisms, such coordination 
depends on an elaborate network of communication that regulates the growth, 
differentiation, and metabolism of distinctive tissue types and organs. The 
basis of such communications is the engagement of signalling molecules, 
which can be used in either intercellular signalling or intracellular signalling 
(Krauss, 2008). The need to communicate and respond appropriately with the 
environment, neighbouring cells, as well as between intracellular 
compartments, is therefore a survival requirement (Sideman, 2005). 
 
 Interestingly, the very nature of embryonic development has engaged 
Hedgehog, Wnt (wingless related), transforming growth factor-β, receptor 
tyrosine kinase (RTK), Notch, Janus kinas (JAK) / signal transducer and 
activator of transcription (STAT)  and nuclear hormone pathways for the tight 
spatial and temporal regulation of cell proliferation and differential (Pires-
daSilva and Sommer, 2003). As such, cells are continuously exposed to and 
responding to a myriad of extracellular molecular signals and hence are tightly 
regulated in their lifetime. On this aspect, imbalances in signalling can lead to 
altered cell growth, differentiation and apoptosis (Dranoff, 2004). 
 
 In the preceding chapter, our study has demonstrated HERV-H endows 
colorectal cells with higher proliferative capacity, migratory ability and 
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reduced serum dependence. While the phenotypes were observable, the 
signalling pathways that HERV-H are involved in remains to be elucidated. 
Here, PCR array analysis, together with Western blot findings, revealed the 
implicated pathways when HERV-H-transfected colorectal cancer cells were 
compared with its own transfected control group of cells, GFP-transfected 
colorectal cancer cells.  
 
 Using GSEA and IPA application, PCR array analyses clearly 
indicated that there was a difference in the differential expression of genes and 
a probable mode of action underlying the disease and disorder development. 
While signalling pathway involving Wnt, PI3K-Akt and TGF- were 
previously described in colorectal carcinogenesis (Fearon and Vogelstein, 
1990, Takayama et al., 2006, Worthley et al., 2007, Markowitz and 
Bertagnolli, 2009, Ogino and Goel, 2008) , our study revealed the 
involvement of Wnt and MAPK (p42/44 or ERK1/2 and SAPK/JNK) when 
HERV-H is mediating the transforming process. Nevertheless, abrogation of 
p53 functions was consistently detected in both instances of colorectal cancer. 
 
 In the pathway analysis, IPA intriguingly associated the role of 
macrophages, fibroblasts and endothelial cells in rheumatoid arthritis (Table 
4.5), a condition that could not be easily reconciled with carcinogenesis, in our 
study. A further examination revealed the up-regulation of various signalling 
pathways in the pathogenesis of rheumatoid arthritis. These pathways are the 
ERK/MAPK pathway, the NF-B pathway, the Wnt pathway and the JAK-
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STAT pathway. Activation of these pathways enhances the state of chronic 
inflammation with pro-inflammatory cytokines and growth factors, of which 
support the notion of cancer-related inflammation. Furthermore, macrophage 
migration inhibitory factor (MIF), which released from 
monocytes/macrophages, fibroblasts and endothelial cells (Babu et al., 2012, 
Calandra and Roger, 2003), is also found to play a role in colorectal 
carcinogenesis (He et al., 2009, Wilson et al., 2005, Conroy et al., 2010).  
 
 In the following sections, relevance of the uncovered signalling 
pathways to carcinogenesis will be discussed. These include the Wnt 
signalling pathway, the MAP kinase pathway, the p53 signalling pathway and 
the cytokines signalling pathways.  
 
4.6.1 The Wnt signalling pathway 
 Wnt signalling plays a central role in embryonic development, 
differentiation, cell motility, cell proliferation, and adult tissue homeostasis. 
Wnt proteins or ligands are evolutionarily conserved, secreted cysteine-rich 
glycoproteins that transmit signals from outside a cell through cell surface 
receptors to the inside of the cell (Kikuchi et al., 2011). In humans, 19 
members of the Wnt family are known (Papkoff et al., 1987). 
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Figure 4.9. Wnt signalling pathways. Wnt regulates at least three major 
intracellular signalling pathways: the -catenin-dependent pathway, the planar cell 
polarity (PCP) pathway and the Wnt-calcium pathway. PCP signalling triggers 
activation of the small GTPases RhoA and Rac1, which in turn activate Rho kinase 
(ROCK) and Jun-N-terminal kinase (JNK) respectively, resulting in actin 
polymerization and microtubule stabilization.  This pathway is heavily involved in 
the regulation of cell polarity, cell motility and morphogenetic processes.  In the -
catenin pathway, interaction of Wnt with Frizzled and LRP5 or LRP6 recruits and 
inactivates destruction complex that consists of glycogen synthase kinase 3 (GSK3), 
casein kinase 1 (CK1), Axin and adenomatosis polyposis coli (APC). This allows 
-catenin to accumulate and translocate to the nucleus, where it activates the 
transcription of target genes under the control of T cell factor (TCF). The Wnt-
calcium pathway involves the activation of calcium- and calmodulin-dependent 
kinase (CAMKII), protein kinase C (PKC) and calcineurin. Calcineurin activates 
nuclear factor of activated T cells (NFAT), which modulates the gene transcription of 
cell fate and cell migration. CDC42: small GTPase; DAAM: DVL-associated 
activator of morphogenesis; DVL: Dishevelled; LRP: low-density lipoprotein 
receptor-related protein; PLC: phospholipase C; ROR: receptor tyrosine kinase-like 
orphan receptor; RYK: receptor tyrosine kinase. (Adapted from (Niehrs, 2012)) 
 
 
Chapter 4: Role of HERV-H in viral mediated signalling 
 
Page | 153  
 
 Based on conventional grouping, Wnt signalling pathways have been 
classified into canonical (-catenin/CTNNB1-dependent) or non canonical (-
catenin/CTNNB1-independent) signalling pathways (Niehrs, 2012). Non 
canonical signalling pathways are further grouped as planar cell polarity 
(PCP) pathway and Wnt/Calcium pathway (Figure 4.9). Briefly, canonical 
Wnt signalling, mediated by Wnt ligands, regulates the destruction complex 
(comprising GSK3, CKI, Axin and APC) to stabilise and translocate -
catenin to the nucleus where it regulates gene expression. In contrast to 
canonical Wnt signalling, non-canonical Wnt signalling, also mediated by 
Wnt ligands, regulates gene expression via the c-JUN-N-terminal kinase 
(JNK) or the calcium-dependent kinases, CAMKII and PKC.  
  
 It has been reported that Wnt1, Wnt3, and Wnt8 activate the canonical 
Wnt signalling, whereas Wnt5a and Wnt11 are thought to act mainly through 
the non-canonical Wnt pathway (Cohen et al., 2008). In addition, ten members 
of the frizzled family of G‑protein-coupled receptors, as well as the receptor 
tyrosine kinases (RTK) ROR1 and ROR2 and the RTK-like protein RYK, are 
known to be involved (Angers and Moon, 2009, Wang et al., 2006, Kohn and 
Moon, 2005). 
 
 The longstanding implication of the Wnt signalling pathway in 
carcinogenesis stems from the discovery of mouse proto-oncogene, int1, 
which is now known as Wnt1 (Nusse and Varmus, 1982). Chronic activation 
of the Wnt signalling pathway has been associated with many human 
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malignancies including colorectal carcinomas and hepatocellular carcinomas 
(Logan and Nusse, 2004, Burgess et al., 2011). 
 
 Interestingly, recent studies have implicated tumour viruses are 
capable of modulating Wnt signalling and directing the dysregulated 
activation of Wnt pathway towards human cancer development. -catenin, the 
central modulator of the canonical Wnt pathway, was found to be elevated in 
Epstein Barr virus-associated nasopharyngeal carcinoma (Hayward et al., 
2006); nuclear accumulation of -catenin in human papillomavirus infected 
cervical and oropharyneal cancer cells can also activate the Wnt pathway via 
its E6/E7 viral oncoproteins expression (Rampias et al., 2010). 
 
4.6.1.1  Possible involvement of Wnt in HERV-H mediated 
transformation process 
 PCR array analyses revealed unique differential gene expression 
profiles that involved the signalling pathways and inflammation-association 
genes. Of interest, relatively higher expression of Wnt11, NFATC4 and 
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4.6.1.1.1 Wnt 11 
 Wnt11 is well established for its ability to trigger non canonical Wnt 
signalling (Pandur et al., 2002, Cha et al., 2008, Zhang et al., 2012). 
Specifically, Wnt11 signalling has been shown to promote intestinal cell 
proliferation, transformation and migration (Ouko et al., 2004) and that Wnt11 
is upregulated in primary colorectal cancer (Nishioka et al., 2013). A recent 
study also revealed a higher Wnt11 mRNA expression in primary colorectal 
cancer tissues when compared to adjacent non-tumour tissues. In the same 
study, Wnt11 transfectants demonstrated increased phosphorylation of JNK 
and c-jun as well as increased proliferation and migration/invasion activities 
(Nishioka et al., 2013). The result of our study is consistent with this finding, 
suggesting that Wnt11/JNK signalling pathway is, at least partly, involved in 
the tumorigenesis process. 
 
4.6.1.1.2 NFATC4 
 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 
4 (NFATC4) is a member of the NFAT family consisting of NFATC1, 
NFATC2, NFATC3, NFATC4 and NFATC5, of all are activated via the 
control of calcineurin, a calcium dependent phosphatise. NFAT signalling, 
which is controlled by both negative and positive feedback (Crabtree and 
Olson, 2002), regulates the differentiation and development of the 
cardiovascular system and the musculoskeletal system as well as keratinocytes 
and adipocytes. Furthermore, NFAT signalling also plays  a role in cell 
adaptation which aids cells like pancreatic cells, epidermal cells, and cardiac, 
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skeletal and smooth muscle cells to respond to the environmental changes 
(Horsley and Pavlath, 2002). NFAT has been closely linked with Wnt 
pathway (Wang et al., 2013, Niehrs, 2012, Sugimura et al., 2012, Sugimura 
and Li, 2010, Gregory et al., 2010). To date, numerous studies have implicated 
NFAT and Wnt signalling in colon cancers (Werneck et al., 2012, Slattery et 
al., 2011, Duque et al., 2005, Hong et al., 2007, Jauliac et al., 2002), including 
a few investigations that identifies NFATC2 as the critical player in colorectal 
carcinogenesis (Daniel et al., 2013, Gerlach et al., 2012). The increased 
expression of NFATC4 in LS174T:HERV-H_GFP cells compared to 
LS174T:GFP cells is consistent with these previous findings. 
 
4.6.1.1.3 DKK1 
 While the introduction of HERV-H may perturb the signalling 
pathways in an upregulated manner, it is important to realise that a living cell 
is after all apt at homeostatic regulation, for instance, be programmed with 
negative feedback mechanisms. Thus, despite of the upregulation of genes 
involving proliferative activity after oncogenic Herv-H transduction, some 
genes are down-regulated. 
 
 As DKK1 is a potent Wnt signalling inhibitor (Glinka et al., 1998), by 
binding to LRP with high affinity and itself being as a target gene for 
signalling pathway (Bafico et al., 2001, Mao et al., 2001, Semenov et al., 
2001) , DKK1 plays a role in modulating the Wnt pathway by establishing a 
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negative-feedback loop (Niida et al., 2004). Thus, a high DKK1 expression in 
our study indicates that the aberrantly upregulated Wnt signalling has resulted 
a corresponded increase in DKK1 expression. 
 
4.6.2 The MAP Kinase pathway 
 The mitogen-activated protein kinase (MAPK) signalling pathway 
mediates a wide range of cellular activities which include cell proliferation, 
differentiation, cell survival, neuronal function and the immune response 
(Krishna and Narang, 2008). This large family of serine/threonine kinases, 
which can translocate into the nucleus, phosphorylates proteins like 
transcription factors, co-activators and co-repressors, is capable of regulating 
cellular transcriptional activities. 
 
 MAPK pathways are made up of a three-tier kinase module in which a 
MAPK is activated when phosphorylated by a mitogen-activated protein 
kinase kinase (MAPKK), which in turn is activated upon phosphorylation by a 
MAPKKK (Dhillon et al., 2007). The MAPK pathway is regarded as one of 
the most important pathways for cell proliferation since it entails major cell-
proliferation signalling pathways from the cell surface to the nucleus  (Fang 
and Richardson, 2005). In mammalian cells, the MAP kinases are classified 
into three main families, which include the ERKs (extracellular-signal-
regulated kinases, ERK 1/2; also known as p42/44 MAP kinase), the JNKs 
(Jun amino-terminal kinases)/SAPKs (stress-activated protein kinases), and 
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the p38 MAP kinases (Morrison, 2012, Schaeffer and Weber, 1999). 
Generally, ERK 1 and ERK 2 are activated strongly by growth factors and are 
key transducers of proliferation signals. On the other hand, JNKs and p38 
MAPK/SAPKs are poorly activated by growth factors but are strongly 
activated by cellular stress inducers like inflammatory cytokines, DNA 
damaging agents, oxidative stress, UV irradiation and growth factor 
deprivation (Figure 4.10) (Krishna and Narang, 2008). 
  
 
Figure 4.10. Schematic overview of MAPK pathways. MAPK signalling pathways 
mediate intracellular signalling initiated by extracellular or intracellular stimuli. 
MAPKKKs, which are activated by MAPKKKKs or GTPases, phosphorylate and 
activate MAPKKs, which in turn phosphorylate and activate MAPKs. Phosphorylated 
MAPKs then phosphorylate various substrate proteins like transcription factors and 
cofactors. This process regulates a variety of cellular activities which include cell 
proliferation, differentiation, migration, inflammatory responses and death. In 
mammalian cells, the MAPK family comprises ERKs, JNKs and p38.  
 
 It is widely accepted that MAPK signalling pathways are closely 
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(Fang and Richardson, 2005, Slattery et al., 2012, Lascorz et al., 2010). In 
contrast, blockade of MAPK pathway in human colorectal cancer cells can 
exert an antiproliferative effect on tumour cells (Sebolt-Leopold et al., 1999, 
Hoshino et al., 2001, Wang et al., 2004, Yeh et al., 2007, Sakamoto et al., 
2013). 
 
 Studies showing viral activation of MAPK signalling pathways are 
accumulating. HBx, a 154-amino acid viral protein of 17 kDa encoded by 
hepatitis B virus, is a multifunctional regulator that is capable of modulating 
the cellular signal transduction pathways such as the Ras/Raf/MAPK pathway. 
Together with its role in upregulating proto-oncogenes like c-jun, c-fos and c-
myc, HBx plays a significant role in the development of hepatocarcinoma 
(Motavaf et al., 2013, Ng and Lee, 2011, Matsuda and Ichida, 2009). 
Similarly, the Epstein-Barr virus latent membrane protein, LMP1, is found to 
mediate the activation of Ras/MAPK-dependent pathway (Roberts and 
Cooper, 1998) and the JNK/AP-1 cascade (Kieser et al., 1997, Hatzivassiliou 
et al., 1998), demonstrating its transforming potential in cells. 
 
4.6.2.1  Possible involvement of MAPK (p42/44 or ERK1/2 and 
SAPK/JNK) in HERV-H mediated transformation process 
 Relatively lower expression of PIX2, MEF2C and MAP4K1 was found 
in LS174T:HERV-H_GFP cells when compared to LS174T:GFP. Our western 
blot finding also demonstrated a higher expression of phosphor-p42/44 and 
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 MAPK signalling has been closely linked to PIX2 in many studies 
(Basu and Roy, 2013, Sohn et al., 2009, Vadlamudi et al., 2005, Kioussi et al., 
2002). Studies have also shown that PIX2 is implicated in breast cancer 
(Maier et al., 2007), ovarian cancer (Fung et al., 2012), prostate cancer 
(Hampton, 2006) and colorectal cancer, where overexpression of PIX2 is 
intriguingly associated with improved survival in patients as a result of 
reduced proliferative activity and invasiveness (Hirose et al., 2011). The 
reduced PIX2 expression in LS174T:HERV-H_GFP cells corroboratres with 
the findings demonstrated by Hirose et al where LS174T:HERV-H_GFP cells 
are indeed possessing a higher proliferative activity, albeit weak invasiveness. 
 
4.6.2.1.2 MEF2C 
 Studies have shown that myocyte enhancer factor 2C (MEF2C) is 
closely associated with MAPK signalling pathway (Han et al., 1997, Wu et al., 
2010, Khiem et al., 2008, Black and Olson, 1998). In addition, the oncogenic 
potential of MEF2C has been demonstrated not only in hepatocellular 
carcinoma (Bai et al., 2008), ovarian carcinoma (Kim et al., 2010), acute 
myelogenous leukaemia (Schwieger et al., 2009), T cell acute lymphoblastic 
leukaemia (Homminga et al., 2011, Nagel et al., 2008), and chronic myeloid 
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leukaemia (Agatheeswaran et al., 2013), but also in colorectal cancers 
(Nagaraj and Reverter, 2011) and gastric cancers (Ohta et al., 2009). Hence, a 




 The reduced expression of mitogen-activated protein kinase kinase 
kinase kinase 1 (MAP4K1) in our study is consistent with the finding that 
human colorectal adenocarcinomas, when compared to adult normal colon, 
has lost MAP4K1 in a cDNA microarray analysis (Kaiser et al., 2007). 
MAP4K1, also known as hematopoietic progenitor kinase 1 (HPK1), is a 
kinase upstream of JNK (MAP1K) (Ma et al., 2001). As such, MAP4K1 
activates the JNK signalling pathway in a MAP4K1-TAK1-MKK4-JNK 
manner (Figure 4.6F) (Zhou et al., 1999). Specifically, MAP4K1 does not to 
implicate other MAPK signalling pathways like ERK and p38 signalling 
(Kiefer et al., 1996, Hu et al., 1996). While the signalling pathway of 
MAP4K1 has been mapped, its biological functions remain to be elucidated 
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4.6.3 Possible co-involvement of Wnt and MAPK signalling pathways in 
HERV-H mediated transformation process 
4.6.3.1  EGR1  
 Many previous studies have reported early growth response 1(EGR1) 
is regulated by the MAPK pathway (Grotegut et al., 2006, Tarcic et al., 2012, 
Xu et al., 2008, Lo et al., 2001, Saegusa et al., 2008). Hence, in our study, a 
high level of expressed EGR1 together with a high level of phosphor-p42/44 
and phosphor-SAPK/JNK (Western blot) in LS174T:HERV-H_GFP implies 
the involvement of a MAPK signalling pathway (Figure 4.6E & F).  
 
 Interestingly, EGR1 gene is a transcription factor that acts as both a 
tumour suppressor and a tumour promoter. As a tumour suppressor, EGR1 
binds to p53 for p53-mediated functions (Krones-Herzig et al., 2005). This 
mechanistic model, however, does not reconcile with our study.  
 
 On the other hand, the implication of EGR1 in the control of cell 
growth, survival and transformation emerged to be favourable (Thiel and 
Cibelli, 2002, Huang et al., 1998a). Specifically, the proliferative activity of 
EGR-1 was demonstrated in various human cancer models including prostate 
(Abdulkadir et al., 2001), skin (Riggs et al., 2000), and kidney(Scharnhorst et 
al., 2000). A variety of growth factors targeting at the EGR1 and mediating 
mitogenic signalling cascade were also identified in a microarray analysis 
(Svaren et al., 2000). More recently, it has been shown that in vitro EGR1-
induced overexpression of TCF4 (transcription factor 4) resulted in the 
stabilization of nuclear β-catenin (in Wnt signalling pathway) and that may 
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play a role in the induction and maintenance of trans-differentiation in 
endometrial carcinoma cells (Saegusa et al., 2008).  
  
 Interestingly, one study has reported that the upregulation of EGR1 
mRNA level was observed in the early-onset of colorectal cancers (Hong et 
al., 2007). As EGR1 is constitutively expressed in colon cancer cells, TRAIL-
mediated apoptosis is inhibited. The inhibition effect is thought to be driven 
by the constitutive expression of c-FLIP (Mahalingam et al., 2010). Hence, the 
upregulation of EGR1 promotes the development of colon cancers.  
 
 Assimilating these findings, the Wnt/MAPK pathway emerged as the 
implicated signalling pathway during the HERV-H mediated transforming 
process. 
  
4.6.4 The p53 signalling pathway 
 While p53 is described as the “guardian of the genome” (Lane, 1992) 
and the “cellular gatekeeper”  (Levine, 1997), it is also known as a short-lived 
key tumour suppressor transcription factor in the cell (Levine et al., 2004, 
Vousden and Lane, 2007). The p53 tumour suppressor (or TP53 gene) can be 
induced by a range of stresses including DNA damage, oncogene activation, 
or hypoxia (Horn and Vousden, 2007). Such p53 induction may lead to 
different biological outcomes such as apoptosis, cell-cycle arrest, senescence, 
or modulation of autophagy (Yee and Vousden, 2005, Riley et al., 2008, 
Chapter 4: Role of HERV-H in viral mediated signalling 
 
Page | 164  
 
Green and Kroemer, 2009, Jin and Levine, 2001). Among these, one of the 
most important functions will be innate tumour suppression (Meek, 2009).   
 
 The activation of the p53 protein in response to stresses is mediated 
and regulated by post-translational modifications which include 
phosphorylation, acetylation, methylation, ubiquitination or sumoylation. On 
the one hand, p53 can be activated by protein kinases, histone 
acetyltransferases, methylases, ubiquitin and sumo ligases; on the other hand, 
p53 can also be inactivated by phosphatases, histone deacetylases and 
ubiquitinases (Jin and Levine, 2001). 
 
 To exert its tumour suppressive properties, p53 mediates many 
biological effector functions (Figure 4.11). For instance, p53 is implicated in 
the cell cycle checkpoints, inducing G1 arrest mainly through the 
transactivation of p21 or inducing G2/M arrest mainly through the 
perturbation of the cyclin B1/cdc2 complex (Brugarolas et al., 1995, Deng et 
al., 1995). 
 
 p53 is also implicated in cellular senescence, in which p53 
transactivates p21 via the association of p14ARF and Mdm2, and p21 inhibits 
E2F (a potent inducer of cell proliferation) via the inhibition of cyclin-
dependent kinases upstream of the RB tumour suppressor. 
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 In addition, p53 is implicated in autophagy, activating the damage-
regulated autophagy modulator (DRAM) gene and inducing autophagy in a 
DRAM-dependent manner (Crighton et al., 2006). Similarly, p53 is implicated 
in apoptosis, either transactivating many genes involved in apoptosis, which 
include Bax, PIG3, Killer/DR5, CD95 (Fas), p53AIP1, Perp, and BH3-only 
proteins Noxa and PUMA (p53-up-regulated modulator of apoptosis) (Riley et 
al., 2008), and/or inducing mitochondrial outer membrane permeabilization 
(MOMP) as well as interacting with Bcl2, Bcl-XL, and Bak at the mitochondria 




Figure 4.11. The p53 functional circuit. The diversity of stress signals that activate 
the p53 protein contributes to the central role of p53 as a tumour suppressor. The 
downstream targets of p53 mediating the different biological outcomes like cell cycle 
arrest, apoptosis, senescence and DNA repair are shown. (Adapted from (Harris and 
Levine, 2005)  
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 More than 38% of almost all human cancers contain somatic TP53 
mutations (Olivier et al., 2010). Consequently, p53 function is often 
inactivated or suppressed in human cancers (Green and Kroemer, 2009). The 
inactivation of the p53 pathway by mutation of TP53 is one of the key genetic 
molecular aetiology in colorectal cancer (Markowitz and Bertagnolli, 2009). 
In many cases of inactivated TP53, the transition of large adenomas into 
invasive carcinomas is often encountered (Baker et al., 1990). 
 
 Of particular interest, various DNA viruses, such as simian virus 40 
(SV40), human papillomavirus (HPV), adenoviruses or Epstein-Barr virus 
(EBV), encode proteins that target the p53 protein for inactivation. For 
instance, SV40 encodes a large T-antigen (Tag) that binds to p53 and 
inactivates its effector functions via its blockade of p53 binding to the 
ribosomal gene cluster (RGC) site (Bargonetti et al., 1992).  
 
 On the other hand, the E6 proteins of HPV-16 and -18 bind to the p53 
protein and inactivate it by accelerating its proteolytic degradation via poly-
ubiquitination (Scheffner et al., 1990, Scheffner et al., 1993, Munger and 
Howley, 2002).  
 
 Likewise, the E1B55K and E4orf6 proteins of adenovirus are capable 
of forming a complex with the p53 protein, and thereby recruiting a Cullin-
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containing complex to direct the ubiquitin-mediated proteolysis of p53 
(Sarnow et al., 1982, Querido et al., 2001).  
 
 Similarly, the BZLF1 protein from EBV is capable of reconstituting a 
multiprotein ECS (Elongin B/C-Cul2/5-SOCS-box protein) complex with 
ubiquitin ligase activity, and this complex targets p53 for ubiquitination and 
degradation (Sato et al., 2009). Taken together, viral proteins are capable of 
undermining p53 functions and thus contribute to the progression of cancers 
(Table 4.6). 
 
Table 4.6. Viruses that act on p53 inactivation (Collot-Teixeira et al., 2004) 
Virus Associated human cancer p53 binding 
Adenovirus Not documented E1B55K/E4orf6 
SV40 Not documented Large T antigen 
JC and BK polyomaviruses Brain tumours Large T antigen 
EBV Burkitt’s lymphoma BZLF1 
HPV (16/18) Cervical carcinoma E6 
Each of the DNA tumour viruses encodes oncogene products that associate with p53 
for inactivation.  
 
4.6.4.1  Abrogation of p53 in HERV-H mediated transformation 
process 
 It is crucial to realise that it is the wildtype TP53, but not its mutant 
forms, is functioning as a tumour suppressor gene (Eliyahu et al., 1989, Finlay 
et al., 1989). Thus, the lowered TP53 expression found in LS174T:HERV-
H_GFP cells must be evaluated in consideration of TP53 sequences integrity. 
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Consistent with ATCC colon cancer p53 hotspot mutation cell panel (ATCC® 
TCP-2020) specifications, a previous study has shown that LS174T cell line 
possesses a wildtype TP53 (Liu and Bodmer, 2006). Given these information, 
a lowered expression of wildtype TP53 indicates a greater degree of 
tumorigenicity of LS174T:HERV-H_GFP colorectal cells (Figures 4.5 & 
4.7F). This finding corroborates with a recent study that demonstrates TP53 
mRNA expression was lower in tumours when compared to paired non-
neoplastic specimens (Calcagno et al., 2013). 
 
 A decreased expression of cell death-inducing p53 target 1 (CDIP) or 
C16orf5 was also found in LS174T:HERV-H_GFP cells. CDIP was 
previously demonstrated to be a novel p53 target that induced apoptosis via 
the intrinsic apoptotic pathway. As such, a reduced expression of CDIP 
indicates that there is a lowered inhibition of CDIP-mediated abrogation of 
p53-mediated apoptosis (Brown et al., 2007). 
 
 Comparatively low expression of v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene homolog (KIT) was likewise demonstrated in 
LS174T:HERV-H_GFP cells (Figure 4.7A). This finding corroborates with a 
previous study that shows c-Kit was suppressed in human colorectal cancer 
cells (Gavert et al., 2013). In addition, a more aggressive cancer phenotype 
resulting from the loss of c-Kit has also been demonstrated in many cancers 
(Maffini et al., 2008, Tsutsui et al., 2006, Tonary et al., 2000, Zakut et al., 
1993) , including melanoma, where c-Kit expression in a highly metastatic 
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cell line resulted in a reduction of tumorigenicity and metastatic capacity 
(Huang et al., 1998b). 
 
4.6.5 Inflammation: cytokines signalling 
 Inflammation is a physiological host response to tissue damage 
following microbial pathogen infection, chemical irritation, or physical insult 
(Sgambato and Cittadini, 2010). An inflammatory response can be acute or 
chronic.  
 
 Acute inflammation is a short-term response to the triggering stimuli 
and is characterized by leukocytes (neutrophils) infiltrating at the site of 
infection or injury with roles to remove obnoxious stimuli and carry out tissue 
repair (Ryan and Majno, 1977, Medzhitov, 2008). On the other hand, chronic 
inflammation is a prolonged and dysregulated response characterised by active 
inflammation, domination of macrophages, T lymphocytes and plasma cells, 
angiogenesis, tissue destruction and fibrosis (Kumar et al., 2009). Whereas 
acute inflammation normally impedes the development of cancer, chronic 
inflammation promotes cancer development (Coussens and Werb, 2002, Philip 
et al., 2004). 
  In fact, it was in 1863 that Rudolf Virchow put forward the idea that 
the origin of cancer was at sites of chronic inflammation (Balkwill and 
Mantovani, 2001). On the same note, it was postulated that within such a rich 
microenvironment of biological mediators like cytokines, chemokines,  
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interleukins, inducible cyclooxygenase (COX-2), inducible nitric oxide 
synthase (iNOS/NOS2), and matrix metalloproteinases (MMPs) (Aggarwal et 
al., 2006), this provides a good platform for the development of cancer as it 
encompasses multiple signalling pathways that corroborate with the hallmarks 
of cancer (Hanahan and Weinberg, 2011). To this end, the inflammatory 
microenvironment serves to provide an inflammatory cytokine network that 
modulates survival, growth, mutation, proliferation, differentiation and 
movement of both tumour and stromal cells (Balkwill and Mantovani, 2001), 
ssupporting the notion of cancer-related inflammation as the seventh hallmark 
of cancer in the past (Colotta et al., 2009). 
 
 The release of cytokines is in response to a wide range of cellular 
stresses. Consequently, normal physiological host responses to these released 
cytokines aid in containing the associated biological damages while promoting 
recovery. When such a homeostatic mechanism fails, persistent production of 
cytokines ensues. This leads to the dysregulation of cellular signalling and 
erroneously promotes neoplastic programming of the affected cells (Johansson 
et al., 2008).  
 
 The association between inflammation and cancer has been mapped as 
the convergence of two pathways: the extrinsic pathway which is driven by 
inflammatory conditions and the intrinsic pathway which is driven by 
activated oncogenic events (Figure 4.12) (Mantovani et al., 2008). The role of 
c 
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Figure 4.12. Pathways that link inflammation and cancer. A schematic 
view of the link between chronic inflammation and cancer via two pathways: 
the intrinsic pathway and the extrinsic pathway. The intrinsic pathway is 
driven by oncogenetic events like mutations that cause neoplasia. The 
extrinsic pathway is driven by inflammatory conditions and infections. 
Induced by inflammation, reactive oxygen species and nitrogen intermediates 
are capable of DNA damage. Activation of transcription factors, 
predominantly nuclear factor-κB (NF-κB), signal transducer and activator of 
transcription 3 (STAT3) and hypoxia-inducible factor (HIF), in tumour cells 
occurs after the two pathways converge. Resultant effects include the 
production of cytokines, chemokines and prostaglandins as well as the 
recruitment and activation of immune cells (chronic inflammation). Activated 
immune cells secrete more cytokines and provide an inflammatory 
microenvironment that has tumour-promoting effects. COX2: cyclooxygenase 
2, NOS2: inducible nitric oxide synthase, IL-1: interleukin 1, TNF: tumour 
necrosis factor, IL-6: interleukin 6, VEGF: vascular endothelial growth factor, 
CXCL8: CXC-chemokine ligand 8, CCL2: CC-chemokine ligand 2, MMP: 
matrix metalloproteinase, EMT: epithelial–mesenchymal transition. (Adapted 
from (Mantovani et al., 2008, Aggarwal et al., 2006)). 
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cytokines, chemokines and interleukins involved in the tumorigenesis is 
interestingly complex but has been summarized in Table 4.7.  In general, pro-
inflammatory cytokines are pro-apoptotic and anti-inflammatory cytokines are 
anti-apoptotic (Schuerwegh et al., 2003).  The role of immune cells in tumour-
promoting inflammation is presented in Table 4.8.  
 
Table 4.7. Role of cytokines and other molecular players in tumorigenesis 
 (Terzic et al., 2010, Lu et al., 2006, Aggarwal et al., 2006, Dranoff, 2004) 
Agent Mechanisms 
TNF Promote survival, activation, recruitment, 
growth. 
AP-1, MAPK and NF-B activation 
IL-6 Promote survival, growth,  
STAT3, ERK, and Akt activation 
IL-11 Promote survival, growth.  
STAT3, STAT1, ERK activation 
IL-23 T-cell differentiation (Th17) and 
interference with Tregs, production of 
IL-17 and IL-22 by immune cells. 
IL-15 Promotes proliferation, survival,  
prevents apoptosis 
IL-1, IL-1 Survival, growth, cytokines, chemokines, 
tumour invasion, angiogenesis.  
NF-B, MAPK activation 
IL-22 Survival, mucosal integrity, chemokines. 
STAT3 activation 
IL-17A,F Survival, chemokines, T-cell regulation, 
monocytes, and neutrophil recruitment. 
MAPK, NF-B activation 
IL-8 Promote tumour growth, angiogenesis 
IL-18 Metastasis 
Epidermal growth factor Survival, proliferation.  
MAPK, STAT3 activation 
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IL-10 Anti-inflammatory, Treg stimulation. 
STAT3, MAPK activation 
macrophage-migration inhibitory 
factor 
inhibits p53 tumour-suppressor functions 
Chemokines Promote tumor cell growth 
Facilitate invasion and metastasis by 
directing tumor cell migration and 
promoting basement membrane 
degradation 
NF-B Mediate inflammation progress, 
promoting chronic inflammation. 
Promote the production of mutagenic 
reactive oxygen species. 
Protect transformed cells from apoptosis. 
Promote tumor invasion and metastasis. 
Feedback loop between proinflammatory 
cytokines 
iNOS Downstream of NF-B and 
proinflammatory cytokines. 
Induce DNA damage and disrupt DNA 
damage response. 
Regulate angiogenesis and metastasis 
COX-2 Produce inflammation mediator 
prostaglandins. 
Promote cell proliferation, antiapoptotic 
activity, angiogenesis, and metastasis 
HIF-1 Promote chronic inflammation. 
Induced by proinflammatory cytokines 
through NF-B. 
Enhance the glycolytic activity of cancer 
cells. 
Contribute to angiogenesis, tumor 
invasion, and metastasis by 
transactivating VEGF 
STAT3 Activated by proinflammatory cytokines. 
Promote proliferation, apoptosis 
resistance, and immune tolerance 
Nrf2 Anti-inflammatory activity. 
Protect against DNA damage. 
NFAT Regulate proinflammatory cytokine 
expression. 
Required in cell transformation 
CXCR4 Metastasis, invasion and growth, 
proliferation 
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CCR6 Cell invasion 








Table 4.8. Role of immune cells in tumorigenesis (Grivennikov et al., 2010, Terzic 
et al., 2010) 
Cell types Tumour-promoting 
Macrophages, dendritic cells, 
myeloid-derived suppressor cells 
Immunosuppression; production of 
cytokines (IL-6, IL-1,VEGF, IL-
23,TNF), chemokines, proteases, growth 
factors and angiogenic factors 
Mast cells Production of cytokines 
B cells Production of cytokines and antibodies; 
activation of mast cells; 
immunosuppression 
CD8+ T cells Production of cytokines? 
CD4+ Th2 cells Education of macrophages; production of 
cytokines; B cell activation 
CD4+ Th1 cells Production of cytokines 
CD4+ Th17 cells Production of cytokines 
CD4+ Treg cells Immunosuppression;  
production of cytokines (IL-10, TGF-) 
Suppress inflammation 
Neutrophils Production of cytokines, proteases, and 
ROS 
NK cells Production of cytokine production (IFN, 
IL-22, IL-17) 
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 Chronic viral infection is gradually being recognised as a leading cause 
of cancer worldwide (Parkin, 2006, Zur Hausen, 2009, de Martel et al., 2012). 
With HPV, HBV, EBV, HTLV-1, HCV, KSHV implicated in the process of 
tumorigenesis (Mattock, 2012), chronic inflammation associated with chronic 
viral infection has provided a strong link to viral mediated carcinogenesis 
(McLaughlin-Drubin and Munger, 2008, Zhang et al., 2013b, Butel, 2000) . In 
such viral-mediated carcinogenesis, signalling pathways involving NF-B, 
STAT3 and hypoxia-inducible factors (HIFs) are often implicated (Mantovani 
et al., 2008) (Figure 4.12). 
 
4.6.5.1  Possible involvement of inflammation-associated cytokine 
signalling in HERV-H mediated transformation process 
 LS174T:HERV-H_GFP colorectal cells showed relatively higher 
expression in interleukin 1B (IL1B), interleukin 1 receptor, type I (IL1R1) and 
caspase 1 (CASP1) when compared to LS174T:GFP.  
 
4.6.5.1.1 IL1B 
 IL1B is a highly active proinflammatory cytokine that has a pivotal 
role in autoinflammatory diseases, a diverse group of disorders characterised 
by abnormal activation of the innate immune system and chronic 
inflammation with high levels of acute-phase reactants (Ozen and Bilginer, 
2013). Together with its angiogenic capability (Voronov et al., 2003) and 
ability to recruit immune cells (Rider et al., 2011), IL1B is found to play a role 
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in tumour metastasis (Dinarello, 2009).  In certain cancers like melanoma (Li 
et al., 2009), acute myelogenous leukemia (Giavazzi et al., 1995) and multiple 
myeloma(Lust and Donovan, 1999), IL1B is expressed as part of their 
oncogenic nature. In line with previous studies, higher expression of IL1B was 
observed in LS174T:HERV-H_GFP cells when compared with LS174T:GFP 
cells.  
 
4.6.5.1.2 IL1B, CASP1 and IL1R1 
 Caspase-1 is an enzyme that is involved in the processing of pro-IL1B 
to active, secreted IL1B. Thus, the consequence of caspase-1 activation is the 
secretion of IL1B. Furthermore, IL1B regulates its own production and 
processing (Denes et al., 2012). This suggests that the concordance rise in 
IL1B and CASP1 expression in LS174T:HERV-H_GFP might well 
correspond to the inflammatory state that the transfected cells was in, given 
that HERV-H is after all a viral peptide (Figure 4.6A & 4.7A).  
 
 On the same note, the surface expression of IL1R1 is promoted by the 
inflammatory mediators like prostaglandin E2, epidermal growth factor, IL-2 
and IL-4 (Dinarello, 2009).  As LS174T:HERV-H_GFP cells might well be in 
an inflammatory microenvironment, the existence of a myriad of cytokines 
may collectively enhance the expression of IL1R1.  
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4.6.5.1.3 IL-16 
 Compared to LS174T:GFP cells, interleukin 16 (IL-16) was found to 
be upregulated in LS174T:HERV-H_GFP cells. IL-16, originally identified as 
a lymphocyte chemoattractant factor in 1982 (Center and Cruikshank, 1982), 
is currently regarded as a proinflammatory cytokine (Cruikshank et al., 2000), 
although it does not induce detectable apoptotic cell death (Krautwald, 1998). 
Previous study has shown that the surface expression of IL-2R and IL-2R 
was increased following IL-16 stimulation.  However, there was no increase in 
IL-2R expression (Parada et al., 1998). In contrast to this finding, our data 
showed increased expression of IL-2R (Figure 4.5), suggesting that the effect 
of IL-16 might be cell specific (CD4+ T cells versus colorectal cells). 
Nevertheless, IL-16 is an activator of the SAPK signalling pathway (Figure 
4.7E) (Krautwald, 1998). While the correlation between IL-16 and tumour 
growth is limited by available literature, studies have shown that IL-16 was 
lower in treated non-Hodgkin lymphomas patients (Passam et al., 2008), and 
higher in astrocytic brain tumours (Liebrich et al., 2007) and multiple 
myeloma (Liebrich et al., 2007). In addition, increased IL-16 mRNA 
expression was also found in cutaneous T cell lymphoma (Blaschke et al., 
1999).   
 
4.6.6 Concluding remarks 
 Taken together, HERV-H transfected LS174T cells may represent a 
feasible in vitro model to study the signalling pathways involved in 
endogenous viral-mediated carcinogenesis. Our data has shown that pathways 
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involving p42/44 MAPK, SAPK/JNK as well as p53 may be implicated in 
HERV-H-mediated oncogenic mechanism. These findings have important 
implications for the development of rationale therapeutics, as it raises the 
possibility to target signalling pathways that are highly active specifically in 
colorectal cancer cells.  
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CHAPTER 5 
GENERAL DISCUSSION AND CONCLUSION 
5.1 Viral-mediated carcinogenesis 
 The concept of viral mediated carcinogenesis has been well established 
(Haverkos, 2004, Butel, 2000, Carrillo-Infante et al., 2007, McLaughlin-
Drubin and Munger, 2008, Zhang et al., 2013b). A comprehensive account of 
the diverse aspects of viral carcinogenesis is intricately arduous. Thus, only 
six oncogenic viruses that are classified by IARC as “carcinogenic to humans” 
(Group I) will be briefly discussed. As previously mentioned in Chapter 1, 
these six oncogenic viruses include four DNA viruses – EBV, HBV, HPV and 
KSHV and two RNA viruses – HCV and HTLV-1.  
 
 All tumour viruses are capable of modulating signalling pathways via 
their oncogene products to regulate cellular proliferation, migration, apoptosis, 
differentiation and recognition by the immune system. An overview of the 
viral oncoproteins together with their associated cellular targets and 
deregulated signalling pathways is presented in Table 5.1. In addition, a 
KEGG pathway map depicting the viral carcinogenesis (Kanehisa, 2013, 
Kanehisa et al., 2012) is illustrated in Figure 5.1. All these findings illuminate 
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Table 5.1. Oncogenic virus and associated cell-signalling molecules (Adapted 















DNA Yes, usually E6 p53, p73, E6AP, 
CBP/p300, c-Myc 
p53, cell-cycle 
E7 pRb, pRb pocket 
proteins, p21CIP1, 
p27KIP1, IRF-1, Cyclin 
A and E 
pRb, cell-cycle, ub-
proteasome 




EBNA3C p53, Mdm2, pRb, p300, 
RBP-Jκ, Chk2, Nm23-
H1, c-Myc, HDAC1, 
SUMO-1, SUMO-3, 
SCFSkp2-complex, 
DDX20, SMN, CtBP, 






EBV DNA - LMP1 TRAFs 1, 2, 3 and 5, 







LMP2 TNFR associated 
factors, RAS, JAK 
Apoptosis, metastasis, 
MAPK, PI3K/Akt, 
JAK/STAT, TNF, BCR 
signalling 
KSHV DNA - LANA p53, pRb, c-Myc, 
GSK3β, MAPK2, 
FADD, core histones, 
Transcriptional 
activators- Brd2, Brd4, 
Sp1, AP-1, and CBP 
and transcriptional 







vFLIP TRAF2 Apoptosis, NFκB, 
JNK/AP1 
HBV DNA Yes, usually HBx NFκB, p53, c-jun, c-







HCV RNA No NS3 p53, Arginine 
methyltransferase 1, 
PKA, H2B, H4 
PKC, inflammation 
NS5A p53, Bax, IFN-induced 
dsRNA activated 
protein kinase (PKR), 
growth factor receptor- 
binding protein 2 
(Grb2), PI3K p85 
subunit, TRADD, 
CDK1, TRAF2, TBP 
Cell-cycle, apoptosis, 
Ras-Erk MAPK pathway, 
PI3K, NFκB 
HTLV-1 RNA Yes, as 
provirus 
Tax Cyclic AMP, 
p300/CBP, MAD-1, 
MAD-2, cyclin D1, 
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Figure 5.1. KEGG pathway map showing the deregulated pathways in viral 
carcinogenesis. Viral carcinogenesis  involving (A) hepatitis B virus, hepatitis C 
virus; (B) human T lymphotropic virus type 1, Kaposi’s sarcoma-associated 
herpesvirus; (C) Epstein-Barr virus and human papilloma virus. (Figure was adapted 
with permission from http://www.genome.jp/kegg-bin/show_pathway?hsa05203 
(Kanehisa, 2013)) 
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5.2 Colorectal carcinogenesis 
 The molecular pathogenesis of colorectal cancer has been mapped out 
and has been focusing on the molecular players like APC, K-ras, TP53, DCC, 
SMAD2 and SMAD4 (Fearon and Vogelstein, 1990, Arnold et al., 2005, 
Fearon, 2011, Kheirelseid et al., 2013, Remo et al., 2012). Nevertheless, there 
is also literature indicating that chronic inflammation plays a role in colorectal 
carcinogenesis (Balkwill and Mantovani, 2001, Coussens and Werb, 2002, 
Koehne and Dubois, 2004, Galon et al., 2006, Mantovani et al., 2008, Kamp et 
al., 2011, Vendramini-Costa and Carvalho, 2012, Itzkowitz and Yio, 2004, 
Greten et al., 2004). Interestingly, viral-mediated colorectal carcinogenesis has 
been proposed (Enam et al., 2002, Niv et al., 2005, Collins et al., 2011) and 
many studies have been conducted to demonstrate the pathological association 
(Chiaravalli et al., 2013, Mou et al., 2012, Vilkin and Niv, 2011, Niv et al., 
2010, Lin et al., 2008, Theodoropoulos et al., 2005).  
 
Figure 5.2. A proposed relationship of HERVs in colorectal carcinogenesis. 
Ancient germ cell infections by exogenous retroviruses has led to the families of 
HERVs been integrated into the human genome. The integration of retroviral 
sequences has resulted in insertional polymorphisms (and/or mutagenesis). 
Hypomethylation of endogenous long terminal repeat (LTR) was recently 
demonstrated to play a contributory role in carcinogenesis. The Gag, Pol and Env 
proteins of HERVs are antigenic, and are capable of inducing immune responses. 
With persistent expression, chronic inflammation may ensue. Given that HERVs are 
of viral origin and are capable of mediating genetic alterations and chronic 
inflammation, HERVs present themselves as a putative player in colorectal 
carcinogenesis. 
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 Taking all into account, the human endogenous retroviruses (HERVs) 
present themselves as a likely player in the development of colorectal cancer 
(Figure 5.2), given that HERVs are of viral origin, and have been associated 
with numerous cancers (Mullins and Linnebacher, 2012, Cegolon et al., 2013) 
and inflammatory conditions (Reynier et al., 2009, Manghera and Douville, 
2013).  
 
5.3 The causal role of HERV-H in colorectal carcinogenesis 
 As previously mentioned in the preceding chapters, the 
aetiopathogenic role of HERVs in cancer development is not well understood. 
Although many studies have detected increased HERV expression in cancers 
(Dolei, 2006, Cegolon et al., 2013), only HERV-K viral proteins Rec and Np9 
have been proven to be oncogenic via the derepression of c-myc (Denne et al., 
2007). Clinical findings have shown that HERV-H is preferentially expressed 
in colorectal cancer but not in normal tissue (Liang et al., 2007b, Alves et al., 
2008, Wentzensen et al., 2007, Liang et al., 2009). This has led to the current 
study which aims to unravel the role of HERV-H  in colorectal carcinogenesis 
as colorectal cancer is the most common cancer in both men and women in 
Singapore (Wong and Eu, 2007, Teo and Soo, 2013).  Here, for the first time, 
our study has demonstrated the oncogenic involvement of HERV-H in 
colorectal cancer cells. A high distribution frequency (89.9%) of HERV-H in 
sampled Singapore population is concordant with a high age-standardized 
incidence rate of colorectal cancer in males (39.9 per 100 000) and females 
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(28.3 per 100 000), suggesting a role of HERV-H in colorectal cancer in 
Singapore.   
 
 The effects of HERV-H overexpression on colorectal cancer cells were 
evaluated using established in vitro models. Elevated HERV-H expression 
resulted in the augmentation of proliferative activity, migratory capacity, 
ability to form cancer stem cell-like colonospheres, and expression levels of 
cancer stem cell markers, CD133 and CD44. In addition, the gain of decreased 
serum dependence was most noticeable. Furthermore, it was shown that 
knock-down of HERV-H significantly lowered cancer cell proliferation, 
substantiating the oncogenic role of HERV-H in the transforming process 
(Chapter 3). Interestingly, results from real-time PCR array revealed the 
involvement of MAPK, Wnt and p53 signalling pathways (Chapter 4). 
 
 Clearly, the oncogenic role of HERV-H was illuminated with reference 
to the hallmarks of cancer (Hanahan and Weinberg, 2000), namely, (i) 
limitless replicative potential, (ii) tissue invasion & metastasis, (iii) self-
sufficiency in growth signals and (iv) the deregulation of cellular energetic in 
Chapter 3. In addition, the signalling pathways that were implicated in HERV-
H-mediated transforming process were also consistent with the hallmarks of 
cancer, such as (i) sustaining proliferative signalling and (ii) tumour-
promoting inflammation (Hanahan and Weinberg, 2011) (Chapter 4). In this 
chapter, in addition to the hallmarks of cancer, the role of HERV-H in the 
development of colorectal cancer will be further discussed with reference to a 
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distinct subclass of neoplastic cells – cancer stem cells (Lobo et al., 2007), 
which are known to play a contributory role in the next generation of cancer 
hallmarks (Hanahan and Weinberg, 2011). 
 
5.3.1 Endowment of cancer stem cell potency 
 The recent reports of a link between increased HERV expressions and 
stem cell potency are particularly interesting. Studies have shown that the 
transcriptional activity of endogenous retroviral elements is able to regulate 
the stem cell potency in mouse embryonic stem cells (Macfarlan et al., 2012), 
and the expression of HERV-H is able to contribute to the pluripotency in 
human embryonic stem cells (Santoni et al., 2012). A more recent study 
reported that HERV-K (HML-2) RNA and protein is a marker for human 
embryonic and induced pluripotent stem cells (Fuchs et al., 2013). In line with 
these findings, our finding showed HERV-H up-regulation is capable of 
endowing colorectal cancer cells with cancer stem cell-like characteristics like 
increased expression of CD133 and CD44 (markers of cancer stem cells) and 
the ability to form cancer stem cell-like colonospheres (Figures 3.7, 3.14, 
3.15, 3.17 and 3.18).  
 
 
5.3.2 Activated Wnt signalling linked to CD133 in cancer stem cells  
 CD133 is a widely used marker of cancer stem cells (O'Brien et al., 
2007) and it is also regarded as a target gene of the Wnt/β-catenin signalling 
pathway (Horst et al., 2009a, Katoh and Katoh, 2007). A previous report has 
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illustrated this by demonstrating the finding of higher Wnt activity in CD133-
positive DLD1 cells when compared to CD133-negative DLD1 cells (Deng et 
al., 2010). In addition, Wnt/β-catenin signalling plays a pivotal role in the 
growth and maintenance of colonospheres (Kanwar et al., 2010). In line with 
colonospheres displaying the characteristics of a cancer stem cell, our study 
demonstrated that HERV-H transfectants showed higher expression of CD133 
and Wnt, as well as the ability to form colonospheres when compared to their 
control cells (Figures 3.7, 3.14, 3.17 and 4.3). 
   
 Viewing from another perspective, there are also numerous studies 
showing the role of Wnt signalling in the preservation of stem cell 
proliferation and pluripotency (Schepers and Clevers, 2012, Vijayaragavan et 
al., 2009). Interestingly, signalling pathways that are known to be tumour-
promoting, like the Wnt, Notch and Sonic Hedgehog signalling pathways, are 
also implicated in normal stem cell self-renewal in the same tissue (Cheng et 
al., 2011). This implies that Wnt signalling is also playing an important role in 
the malignancy transformation of embryonic stem cells. In line with these 
findings, our finding has showed that as HERV-H transfected colorectal 
cancer cells were endowed with cancer stem cells characteristics, Wnt 
signalling pathway was implicated (Figures 3.7, 3.14, 3.17 and 4.3). 
  
 It is relevant to note that the activation of Wnt pathway can result in 
the elevation of DKK1 (inhibitor) expression via its negative feedback 
regulation (Niida et al., 2004). This cause and effect phenomenon was 
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observed in our study, indicating that the activated Wnt pathway had indeed 
upregulated the expression of DKK1 (Figure 4.3).  
 
 
5.3.3 Activated MAPK/ERK signalling linked to CD133 and CD44 
 CD133 and CD44 are widely used marker of cancer stem cells 
(O'Brien et al., 2007, Dalerba et al., 2007). CD133 was found to significantly 
activate MAPK/ERK pathway in U87MG human glioblastoma cells (Dong et 
al., 2010) and CD133 positive primary colon cancer cells (Wang et al., 2010). 
Upregulation of CD44 variants was also shown to be linked to MAPK/ERK 
pathway in primary T cells (Weg-Remers et al., 2001, Herishanu et al., 2011). 
Additionally, the MAPK/ERK and p38 pathway had also been shown to 
increase CD44 RNA and CD44 alternate splicing, respectively, in prostate 
cancer cells (Robbins et al., 2008). The activated ERK pathway was also 
found to induce the upregulation CD44 in fibrosarcoma, bladder carcinoma 
and rhabdomyosarcoma (Tanimura et al., 2003).  Consistent with these 
findings, our study demonstrated that HERV-H up-regulation is capable of 
increasing the expression levels of CD133 and CD44 while activating the 
MAPK/ERK signalling pathway (Figures 3.14, 3.15, 3.17, 3.18, 4.3 and 4.8). 
 
5.3.4  EGR1 dictates cellular migratory capability 
 It appears that EGR1 plays a central role in the HERV-H mediated 
transforming process (Figure 5.3). EGR1, a nuclear phosphoprotein 
(Milbrandt, 1987) that is inducible by cytokines, growth factors, and stresses 
like radiation, injury or mechanical stress (Liu et al., 1998, O'Donovan et al., 
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1999, Gashler and Sukhatme, 1995), has been shown previously to associate 
closely with the MAPK signalling pathway. Specifically, increased 
transcription of EGR1 is mediated by the MAPK signalling pathway, of which 
all 3 families, p42/44 MAPK, JNK/SAPK and p38 MAPK are involved 
(Cohen et al., 1996, Harada et al., 1996, Hipskind et al., 1994, Hodge et al., 
1998, Lim et al., 1998, Rolli et al., 1999). Given that EGR1 is able to regulate 
the transcription of heparanase, an endoglycosidase that degrades key 
components of the extracellular matrix and basement membranes (de Mestre 
et al., 2005) and that it is also able to serve as a positive regulator of EGF-
induced cell migration (Tarcic et al., 2012), EGR1 is playing a part in the 
regulation of cell migration. The augmented migratory capability and 
increased expression of EGR1 in HERV-H transfected colorectal cancer cells 
when compared to control cells is consistent with these previous findings 
(Figures 3.6 and 4.3). 
 
Figure 5.3. Putative central role of EGR1 in HERV-H mediating transforming 
process. 
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5.3.5 EGR1 and CD133: direct correlationship 
 CD133 is a widely used marker of cancer stem cells (O'Brien et al., 
2007) . Previous data has shown that EGR1 is highly correlated to CD133 
expression (Spearman r = 0.625; P = 0.022; (Ernst et al., 2011)). Consistent 
with these data, our study demonstrated the concordant expression of CD133 
and EGR1 in LS174T:HERV-H_GFP cells (Figures 3.17 and 4.3). 
 
  
5.3.6 Involvement of EGR1, CD133 and LGR5 
 In the past 5-6 years, a number of studies had shown that EGR1 may 
act as a regulator of TCF4 (transcription factor 4) which then acts on LGR5 (a 
stem cell marker) (Hirsch et al., 2013) via the Wnt/-catenin pathway 
(Saegusa et al., 2008, Barker et al., 2009, Barker et al., 2007). Furthermore, it 
was also demonstrated that aberrant activation of the Wnt pathway increases 
the LGR5+ stem cell numbers when stimulated by Wnt agonist (Kim et al., 
2005). Taken together, this suggests that HERV-H may play a role in the 
EGR1/CD133/LGR5 network via the Wnt pathway. While this offers a 
plausible link when cells are endowed with stem cell potency, further studies 
are needed to determine this network. 
 
5.3.7 Consistency test: role of EGR1 and p53 in proliferation 
 A concept of two-pulse “consistency test”, which involves EGR1 and 
p53, was recently proposed (Zwang et al., 2012). The consistency test was put 
forward to account for the ability of cells to disregard sporadic signals in a 
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plethora of biological signalling molecules within a cell microenvironment. 
Specifically, the test requires two consecutive pulses of signalling for 
mitogenesis. However, it is the second pulse of signalling that instructs cell 
proliferation, since the second pulse simultaneously downregulates p53-
mediated functions which are upregulated by the first pulse of signalling 
(Figure 5.4) (Zwang et al., 2011). This implies that with the loss of p53 
functions, a characteristic of many human cancers, tumour cells would be 
more responsive to stimulation by very short exposures to proliferative 
signals. Our finding of increased expression of EGR1 and reduced expression 
of TP53 aligns with this novel concept.  
 
 
Figure 5.4. Schematic representation of the proposed consistency test of the cell 
cycle. The first pulse of EGF (epidermal growth factor; a mitogenic signal) enhances 
lipid metabolism and induces p53 activation. Activation of p53 induces the 
expression of antiproliferation genes. The second pulse of EGF (mitogenic signal) 
enhances the activation of ERK/EGR1 and induces PI3K/AKT signalling. This 
results in a suppressed expression of antiproliferative genes and allows cells to cross 
the restriction point (R) and enter the S phase (Adapted from (Zwang et al., 2011)). 
Chapter 5: General Discussion and Conclusion 
 
Page | 194  
 
5.3.8 Activated Wnt activity linked to proliferative and migratory 
capability  
 Wnt activity in colorectal cancer stem cells is well established (de 
Sousa et al., 2011, Vermeulen et al., 2010). Similarly, CD44 is a widely used 
marker of cancer stem cells (Dalerba et al., 2007). When compared to control 
cells, HERV-H transfected colorectal cancer cells demonstrated augmented 
proliferative and migratory capability, and increased expression of CD44 and 
Wnt11. This is consistent with a previous study that has shown Wnt11 
significantly increases the proliferation, migration and invasion activities as 
well as enhances the expression levels of CD44 in HCT-116 colorectal cancer 
cells (Nishioka et al., 2013). Interestingly, down-regulation of MAP4K1 is 
associated with suppressed invasive ability of RKO colon cancer cells (Yang 
et al., 2006). The decreased expression of MAP4K1 and the lack of gain-of-
invasive ability in LS174T:HERV-H_GFP colorectal cancer cells when 
compared to their control cells are in line with these previous findings.  
 
5.3.9 Conferment of reduced serum dependence and colonospheres-
forming ability  
 The observations of reduced serum dependence and gain of 
colonospheres-forming ability following HERV-H transduction warrant future 
investigations. Cancer stem cells, which is considered a principal driving force 
of tumorigenesis and the initiation of metastases, play an important role in 
tumour relapse (Nguyen et al., 2012). With phenotypic epithelial-
mesenchymal transition (EMT), cancer stem cells metastasize to a distant site 
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and seed a new tumour, a clinical situation that is associated with poor 
prognosis. Nevertheless, the key to successful initiation of a new tumour 
depends not only on the replicative capability of the cancer stem cells but also 
on the microenvironment of the targeted tissues and the immune system 
(Medema, 2013). However, should the cancer stem cells be endowed with 
characteristic like reduced serum dependence, the consequences will be 
undesirably augmented and unfavourable, since they are able to survive in 
nutrients-poor sites. In this respect, patients with cancer cachexia may not be 
spared from tumour relapse if cancer stem cells possess both self-renewal 
ability and reduced serum dependence characteristic. It is currently not clear 
what the link between cancer stem cells and the Warburg effect is (Chapter 3). 
In addition,  the link between cancer stem cells quiescence and reduced serum 
dependence is also unknown, although quiescent cancer stem stems are known 
to be resistant to cytotoxic chemotherapy and have slow cell cycling states (Li 
et al., 2008). Further studies are needed to elucidate these relationships. 
 
5.4 Criteria for HERV pathogenicity 
 First set in 1890, Robert Koch’s postulates are widely regarded as the 
gold standard for establishing the microbiological aetiology of infection and 
disease (Table 5.2) (Walker et al., 2006). Two centuries later, in a period of 
time when advances in biotechnology are making impactful contributions to 
medical knowledge, a broader framework is necessary to identify a pathogenic 
agent in an intricate host-pathogen relationship (Nelson et al., 2012, 
Fredericks and Relman, 1996, Segre, 2013). A set of nine criteria were first 
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proposed by Austin Bradford Hill and put forward to evaluate a putative factor 
for causality (Table 5.3) (Hill, 1965). While this set of criteria is now widely 
accepted (Sarid and Gao, 2011), a simplified version had been recently 
suggested to consider the potential role of HERV in disease (Young et al., 




Table 5.2. Koch’s postulates  (Walker et al., 2006) 
1 
The organism must be shown to be invariably present in characteristic form and 
arrangement in the diseased tissue. 
2 
The organism, which from its relationship to the diseased tissue appears to be 
responsible for the disease, must be isolated and grown in pure culture. 
3 The pure culture must be shown to induce the disease experimentally. 




Table 5.3. Hill's criteria for causation (Hill, 1965, Sarid and Gao, 2011, Carrillo-
Infante et al., 2007, Voisset et al., 2008) 
Criteria Description 
1 Strength of association Association between an agent and disease 
2 Consistency  Consistency of disease association, i.e. consistent 
findings across studies 
3 Specificity Specificity of the association, i.e. infection is unique 
to exposure of agent 
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4 Temporality Infection precedes disease onset 
5 Biological gradient Dose-response, i.e. an increased dose of agent 
induces more rapid onset or more severe conditions 
6 Biological plausibility Does the causal relationship seem reasonable when 
related to current knowledge? 
7 Coherence Is the relationship in line with present knowledge of 
the disease? 





 Using Young’s HERV criteria for causation, our studies showed that 
HERV-H is almost able to satisfying all four prescribed criteria (Table 5.4), 
indicating a close fit to the definition of HERV pathogenicity in colorectal 
carcinogenesis. Briefly, the four met criteria are (1) the discovery of selective 
HERV-H expression in colorectal cancers but not in normal colonic tissues, 
(2) the identification of HERV-H being the individual provirus involved in 
colorectal cancers, (3) the description of a constructed model for HERV-H 
involvement, in this case the HERV-H transfected colorectal cancer cell lines, 
and lastly (4) the validation carried out for testing the role of HERV-H in 
colorectal carcinogenesis, which demonstrated the tumorigenic effects of 
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Table 5.4. Four phases of HERV pathogenicity for deliberation. HERV-H is put 
to assessment using these recent HERV-specific criteria for causality (Young et al., 
2013). 
Phases Description 
In this study and 
available literatures 
A Discovery Detection of HERV expression in 
disease consistently 
Yes, HERV-H transcripts 
were detected (Wentzensen 
et al., 2004, Liang et al., 
2007b, Wentzensen et al., 
2007, Alves et al., 2008, 
Liang et al., 2009). 
 
B Identification Definition of individual proviruses 
involved 
Yes, specifically HERV-H 
is involved. High 
prevalence rate of HERV-
H in sampled Singapore 
population is concordant 
with high incidence rate of 
colorectal cancer in 
Singapore.   
(Results in Chapter 2) 
 
C Description Construction of a specific model 
for HERV involvement 
Yes. Construction of 
HERV-H transfected 
colorectal cancer cell lines 
done. 
(Results in Chapter 3) 
 
D Validation Testing to prove/disprove model Yes. HERV-H transfected 
colorectal cancer cell lines 
showed oncogenic 
potential of HERV-H 
peptide. Implicated 
signalling pathways were 
made known by real time 
PCR array results.  





5.5  Conclusion             
 An aetiopathogenic role of HERVs in cancer development has long 
been postulated, but direct molecular evidence of their involvement in disease 
has been incomplete.  The studies reported in this thesis demonstrated that 
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HERV-H is highly prevalent (89.3%) in the sampled population of Singapore 
where its incidence rate of colorectal cancer remains consistently high. Given 
the findings that HERV-H overexpression endowed colorectal cancer cells 
with greater cell proliferation, motility, ability to form cancer stem cell-like 
colonospheres and expression of  stem cell markers (CD133 and CD44), as 
well as reduced serum dependence,  it is reasonable to ascribe the oncogenic 
potential of HERV-H for colorectal carcinogenesis. An additional level of 
evidence would come from the finding that knock-down of HERV-H 
significantly reduced cancer cell proliferation.  Using real-time PCR array, 
mitogen-activated protein kinases (MAPK), Wnt and p53 pathways were all 
found to be implicated in HERV-H-mediated oncogenic signalling. This 
information provided an invaluable resource for rationalizing the therapeutic 
approach to treat colorectal cancers. Together with previous clinical reports, 
our data demonstrates the tumorigenic role of HERV-H in colorectal cancer 
and highlights the molecular basis underlying its involvement. Importantly, 
the work described in this thesis fits into the Young’s four-phase framework 
of HERV pathogenicity, illuminating the causality of HERV-H in 
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6.1 Proposed future areas of work 
 This study has provided numerous insights into the possible role of 
HERV-H in the pathogenesis of colorectal cancer. The present findings, which 
probe into HERV-H oncogenic characteristics and implicated signalling 
pathways, is to our knowledge without precedence. The unravelling of 
signalling pathways that involved Wnt, MAPK and p53 open up therapeutic 
vistas for HERV-H implicated colorectal cancers.  
 However, further works are necessary to probe for the precise 
molecular target in the light of different signalling pathways are involved. In 
addition, it is also helpful to determine the consequences of HERV-H 
expression in colorectal cancer. This may aid in the selection of aggressive 
versus conventional therapeutic interventions in different clinical settings. 
Hence, the future areas of research would be to further identify molecular 
events that are important to HERV-H mediating transformation process as 
well as to demonstrate the prognostic value of HERV-H expression in 
colorectal cancer. Scope for future works includes the following: 
 
6.1.1  Characterisation of aberrant initiating points in signalling 
pathways 
 In this study, it was found that Wnt, MAPK and p53 signalling 
pathways are involved in the HERV-H mediating transformation process. To 
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enhance the translational value of this knowledge, it is worthwhile to 
investigate the precise molecular target in the implicated signalling pathways. 
This can be done using a specific inhibitor of the pathway or inhibitors of each 
individual pathway at various intermediate steps. The resultant information 
will provide invaluable resources for the development of novel molecular 
therapeutic interventions. In addition, the interacting partner(s) of HERV-H 
can be identified by pull-down assay, co-immunoprecipitation (Co-IP) or yeast 
two hybrid screening. With proteomic identification of the interacting partner 
proteins, the role of HERV-H in colorectal carcinogenesis can be further 
defined and better molecular targeted cancer therapeutic drugs can be devised. 
 
6.1.2  In vivo discovery of HERV-H tumorigenicity  
 The tumorigenicity of HERV-H transfected colorectal cancer cells can 
be examined by using animal models, for instance, the use of nude mice 
(Sharkey and Fogh, 1984). Mice with HERV-H transfected tumours can also 
be further employed in another setting where they can be treated with different 
pharmacological agents to evaluate how these tumours regress. With this 
testing system, the tumour-killing efficiency of various pharmacological 
agents can be exploited efficiently.  
  
6.1.3  Implications of HERV-H sequence homology  
 A high level of HERV-H sequence conservation was observed in this 
study (Chapter 2). A thorough evaluation of the biological significance of this 
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evolutionarily conserved region is warranted as highly conserved DNA 
sequences are conventionally thought to possess functional value. Using a 
variety of bioinformatics resources, studies may involve functional in silico 
analysis of conserved gene segment (Nimrod et al., 2005), assignment of 
function to conserved noncoding sequences (Meisler, 2001) and comparative 
analysis of noncoding regions across vertebrate genomes (Venkatesh et al., 
2006, Woolfe et al., 2005).  
 
6.1.4 The significance of reduced serum dependence 
 The discovery of reduced serum dependence following HERV-H 
transduction is remarkably intriguing as it suggests cancer resilience that 
associates well with poor clinical outcome. However, the molecular 
mechanism underlying this characteristic remains to be elucidated.  
 It is suggested that an altered metabolism of cancer cells, the Warburg 
effect, is conducive to cell proliferation (Vander Heiden et al., 2009). The link 
between reduced serum dependence and the Warburg effect is unknown, 
although both are enabling cancer cells to adapt well in a nutrients-deficient 
environment. Thus, it is interesting to examine the effect of HERV-H up-
regulation on the Warburg effect in colorectal cancer cells.  In addition, the 
clinical implications of reduced serum dependence can be tested out using 
animal models. It is anticipated that the effect of reduced serum dependence 
will associate with acute fulminant metastases and poor survival rate.  
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6.1.5 The role of HERV-H in the EGR1/CD133/LGR5 network 
 Heightened expression of EGR1 and CD133 is associated with cancer 
stem cells potency (Ernst et al., 2011). LGR5 is another stem cell marker 
which is used in colorectal cancer studies (Hirsch et al., 2013, Barker et al., 
2007) and is implicated in the EGR1/CD133/LGR5 network (Figure 5.3) 
(Ernst et al., 2011) . Our study has shown that HERV-H overexpression 
endows colorectal cancer cells with cancer stem cell-like characteristics like 
increased expression of EGR1 and CD133, as well as colonospheres-forming 
ability. It is interesting to know whether LGR5 is also implicated in the 
HERV-H mediated transformation process. Further studies involving 
overexpression and knockdown assays of EGR1 and LGR5 will provide 
insights into the molecular mechanisms underlying this pathway. In addition, 
to examine how HERV-H mediated transformation process is intertwined with 
stem cell pluripotency, the expression profile of embryonic stem cells markers 
like SOX2, OCT4 and Nanog (Mitsui et al., 2003, Pan and Thomson, 2007, 
Okumura-Nakanishi et al., 2005, Niwa et al., 2000) can be determined.  
 
6.1.6 Evaluation of prognostic value of HERV-H in Singapore cohort of 
colorectal cancer patients  
 Clinical studies demonstrating HERV-H expression in colorectal 
cancers are already available (Liang et al., 2007b, Alves et al., 2008, 
Wentzensen et al., 2007, Liang et al., 2009). To demonstrate the significance 
of HERV-H expression in the Singapore cohort of colorectal cancer patients, a 
prospective cohort study or a retrospective case-control study can be initiated. 
Chapter 6: Future directions 
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A large-scale study is needed for clinical relevance. Sampling should include 
cohorts of colorectal cancer patients and healthy individuals. A clearly defined 
biomarker derived from this large-scale cohort study would serve well as a 
stratification factor for clinical outcome.  This will aid in predicting 
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